Original Article
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
N Engl J Med 2001; 344:1038-1042April 5, 2001
- Abstract
Background
BCR-ABL, a constitutively activated tyrosine kinase, is the product of the Philadelphia (Ph) chromosome. This enzyme is present in virtually all cases of chronic myeloid leukemia (CML) throughout the course of the disease, and in 20 percent of cases of acute lymphoblastic leukemia (ALL). On the basis of the substantial activity of the inhibitor in patients in the chronic phase, we evaluated STI571 (formerly known as CGP 57148B), a specific inhibitor of the BCR-ABL tyrosine kinase, in patients who had CML in blast crisis and in patients with Ph-chromosome–positive ALL.
Methods
In this dose-escalating pilot study, 58 patients were treated with STI571; 38 patients had myeloid blast crisis and 20 had ALL or lymphoid blast crisis. Treatment was given orally at daily doses ranging from 300 to 1000 mg.
Results
Responses occurred in 21 of 38 patients (55 percent) with a myeloid-blast-crisis phenotype; 4 of these 21 patients had a complete hematologic response. Of 20 patients with lymphoid blast crisis or ALL, 14 (70 percent) had a response, including 4 who had complete responses. Seven patients with myeloid blast crisis continue to receive treatment and remain in remission from 101 to 349 days after starting the treatment. All but one patient with lymphoid blast crisis or ALL has relapsed. The most frequent adverse effects were nausea, vomiting, edema, thrombocytopenia, and neutropenia.
Conclusions
The BCR-ABL tyrosine kinase inhibitor STI571 is well tolerated and has substantial activity in the blast crises of CML and in Ph-chromosome–positive ALL.
Media in This Article
Figure 2
Time to Relapse in Patients with Myeloid or Lymphoid Blast Crisis Who Had a Response to STI571.Figure 1
Kinetics of Complete Response in a Patient with Myeloid Blast Crisis Treated with 400 mg per Day of STI571.Article Activity
- Article
The BCR-ABL tyrosine kinase, the product of the chimeric gene produced by the Philadelphia (Ph) chromosome, is the molecular abnormality that causes chronic myeloid leukemia (CML). During the chronic phase of the disease, there is massive clonal expansion of myeloid cells, which retain the ability to differentiate. Over time, however, the leukemic clone loses this ability, and the disease inevitably progresses to an acute leukemia known as blast crisis.1,2 In two thirds of patients the blasts are myeloid, and in one third they are lymphoid. Up to 20 percent of adults and 5 percent of children with acute lymphoblastic leukemia (ALL) have the BCR-ABL fusion protein.1 In virtually all patients with CML, including those with blast crisis, the BCR-ABL protein has a molecular mass of 210 kd, whereas in 50 percent of adults and 80 percent of children with ALL the BCR-ABL protein is smaller, with a molecular mass of 185 or 190 kd.1,2
The blast crisis is highly refractory to treatment. The rate of response to standard induction chemotherapy in patients with myeloid blast crisis is approximately 20 percent, and the rate of complete remission is less than 10 percent. In patients with lymphoid blast crisis, the rate of response is approximately 50 percent, but remissions are short-lived.3-5 After allogeneic stem-cell transplantation during blast crisis, the five-year survival rate is only 6 percent6,7; Ph-chromosome–positive ALL also has a poor prognosis.8-10
STI571 (4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate; Glivec, Novartis, Basel, Switzerland) is a potent and selective inhibitor of the tyrosine kinase activity of BCR-ABL.11,12 In a phase 1 trial of STI571 in patients with CML in the chronic phase, reported elsewhere in this issue of the Journal, those treated with daily doses of 300 mg or more had a high rate of response and minimal adverse effects.13 Disease progression to blast crisis is associated with genetic instability and numerous molecular abnormalities. Thus, it is possible that other oncogenic abnormalities replace the need for BCR-ABL tyrosine kinase activity for cellular survival of leukemic blasts. In this study, we evaluated the effects of STI571 in the treatment of CML in blast crisis and Ph-chromosome–positive ALL.
Methods
Patients
Patients with CML were eligible if they tested positive for the Ph chromosome, were at least 18 years of age, and were in blast crisis (with more than 30 percent blasts in the peripheral blood or bone marrow), irrespective of prior therapy. Patients with Ph-chromosome–positive ALL were eligible if they had not had a response to standard induction or consolidation chemotherapy or had had a relapse after such therapy. Treatment with STI571 was not initiated until at least 24 hours after treatment with hydroxyurea ended and until at least four weeks after treatment with standard induction or consolidation therapy ended. Adequate renal, hepatic, and cardiac function and performance status were required. Written informed consent was obtained from all patients before they entered the study.
Study Design
This pilot dose-escalation study was designed to assess the antileukemic activity and safety of STI571 in patients with CML in blast crisis or Ph-chromosome–positive ALL. Patients were assigned to successive dose cohorts of STI571 ranging from 300 to 1000 mg. The starting dose of 300 mg per day was selected on the basis of its efficacy in a parallel phase 1 study in patients with CML in the chronic phase.13 To dissociate the confounding role of underlying illness in acutely ill patients from drug-related toxicity, decisions about dose escalation were based on findings from the phase 1 study, which was conducted simultaneously. Six to eight patients were assigned to each dose; STI571 was administered orally once daily, except for the 800-mg and 1000-mg doses, which were administered twice daily in 400-mg and 500-mg doses, respectively. Patients received continuous therapy unless unacceptable adverse effects or disease progression occurred. Therapy with hydroxyurea was permitted after the initiation of treatment for a maximum of seven days during the first four weeks as required to maintain acceptable blood counts. No other anticancer agents were allowed during treatment, and no dose modifications were allowed for hematologic toxicity during the first 14 days of therapy. All patients received allopurinol for 48 hours before the initiation of treatment with STI571.
Complete blood counts were obtained three times weekly. Assessments of bone marrow, including cytogenetic assessments, were performed once every 6 weeks during the first 12 weeks of treatment and then once every 12 weeks. If grade 4 neutropenia, defined as an absolute neutrophil count of less than 500 per cubic millimeter, occurred on or after 14 days of treatment with STI571, bone marrow aspiration and biopsy were performed. If marrow cellularity was less than 10 percent, treatment with STI571 was interrupted until the absolute neutrophil count rose to more than 1000 per cubic millimeter. If neutropenia recurred, treatment with STI571 was again interrupted until the absolute neutrophil count was more than 1000 per cubic millimeter and then resumed at the dose level of the previous cohort. If marrow cellularity was more than 10 percent, contained more than 30 percent blasts, or both, treatment with STI571 was continued. There were no dose modifications for thrombocytopenia.
Assessment of Toxicity and Response
Safety assessments included the evaluation of adverse events and vital signs, hematologic tests, biochemical tests, urinalysis, and physical examination. Toxicity was graded in accordance with the Common Toxicity Criteria of the National Cancer Institute.14
We used standard criteria to define a complete hematologic response4: a decrease in marrow blasts to 5 percent or less of total cellularity, a disappearance of blasts from the peripheral blood, an absolute neutrophil count of more than 1000 per cubic millimeter, and a platelet count of more than 100,000 per cubic millimeter. In patients who did not have a complete hematologic response, a marrow response was defined as a decrease in marrow blasts to either no more than 5 percent or between 5 and 15 percent, regardless of the peripheral-blood cell counts. A relapse was defined as either disease progression (an increase in marrow blasts to more than 15 percent, in peripheral-blood blasts to more than 5 percent, or in white cells to more than 20,000 per cubic millimeter) or death. The time to relapse was calculated from the first dose of STI571. Cytogenetic responses were classified as previously described.4
Results
Accrual of Patients
From April 1999 through March 2000, 58 patients were enrolled; their characteristics are summarized in Table 1Table 1
Characteristics of the 58 Patients.. Patients with lymphoid blast crisis and Ph-chromosome–positive ALL are grouped together. The phenotype of the blasts in the 58 patients was myeloid in 38 and lymphoid in 20; these 20 included 10 patients with Ph-chromosome–positive ALL. One patient was enrolled as an exception, on the basis of lymphoid blasts in the breast that were detected during the course of CML. Sixteen patients with myeloid blast crisis and seven with lymphoid blast crisis had received previous therapy for the blast crises. The study required that all patients with Ph-chromosome–positive ALL had received prior chemotherapy. The study is ongoing, and the results reported here represent an interim analysis of the data.Safety Profile
STI571 was generally well tolerated (Table 2Table 2
Drug-Related Adverse Effects.). The most frequent adverse effects were nausea (in 55 percent of patients), vomiting (41 percent), and edema (41 percent); most of these were grade 1 (mild) or grade 2 (moderate). Patients treated with higher doses of STI571 were more likely to have grade 1 or 2 nausea, edema, or diarrhea than patients given lower doses of the drug. Grade 4 neutropenia and thrombocytopenia occurred in 40 percent and 33 percent of patients, respectively (Table 3Table 3
Hematologic Toxicity.). Elevations in liver-enzyme levels of grade 3 or 4 were reported in eight patients (14 percent) a median of 16 days after the initiation of treatment (range, 7 to 194), without evidence of a dose relation. Treatment with STI571 was discontinued because of these abnormalities in only one patient; four of the eight patients had grade 1 elevations in liver-enzyme levels at base line.There were 16 deaths due to disease progression. No deaths were considered to be related to treatment with STI571. The following serious adverse events in 13 patients were possibly related to STI571: nausea and vomiting in 4 patients, febrile neutropenia in 3 patients, and elevated liver-enzyme levels, exfoliative dermatitis, gastric hemorrhage, renal failure, pancytopenia, and congestive heart failure in 1 patient each. These events occurred more frequently in patients treated with 800 or 1000 mg of STI571 per day.
Hematologic and Bone Marrow Response
In the intention-to-treat analysis of response rates, all patients in the study were included whether or not the response could be properly evaluated. There was a decrease of 50 percent or more in peripheral-blood blasts in 46 of the 58 patients (79 percent). According to the criteria for responses described in the Methods section, the overall rates of response were 55 percent and 70 percent among patients with myeloid and lymphoid blast crises, respectively (Table 4Table 4
Responses in Patients with a Myeloid Phenotype. and Table 5Table 5
Responses in Patients with a Lymphoid Phenotype.). Of the 38 patients with myeloid blast crisis, 4 had a complete hematologic remission and 17 had a decrease in blasts in the marrow to 15 percent or less (8 of these had a decrease to 5 percent or less). Of the 20 patients with lymphoid blast crisis and Ph-chromosome–positive ALL, 4 had a complete hematologic remission and 10 had a marrow response. In the small groups we studied, there was no relation between the dose of STI571 and the proportion of patients with hematologic responses. In patients who had a response to the drug, the reduction in peripheral blasts typically occurred within one week after the initiation of therapy (Figure 1Figure 1Kinetics of Complete Response in a Patient with Myeloid Blast Crisis Treated with 400 mg per Day of STI571.).The median duration of therapy was 74 days (range, 1 to 349). Of the 21 patients with myeloid blast crisis who had a response to STI571, 9 subsequently relapsed between 42 and 194 days (median, 84) after the initiation of treatment. Seven of the 21 patients with myeloid blast crisis continue to receive therapy and are in remission, with a follow-up of 101 to 349 days. The other five patients were removed from the study: one for hematopoietic stem-cell transplantation, one because of poor compliance with therapy, and three because of adverse events.
Of the 14 patients with lymphoid blast crisis who had a response to STI571, 12 relapsed a median of 58 days after the initiation of treatment (range, 42 to 123), 1 underwent hematopoietic stem-cell transplantation, and the data on 1 who was in remission at day 58 have been censored because of the short length of follow-up (Figure 2Figure 2
Time to Relapse in Patients with Myeloid or Lymphoid Blast Crisis Who Had a Response to STI571.). The patient with extramedullary disease had a complete response at the extramedullary site and remains in remission at day 243.All patients who relapsed remained Ph-chromosome–positive. Major cytogenetic responses were observed in 7 of the 58 patients (12 percent). Of these responses, five were complete (three in patients with myeloid and two in patients with lymphoid blast crises) and two were partial, defined as less than 35 percent Ph-chromosome–positive cells (one in a patient with lymphoid and one in a patient with myeloid blast crisis).
Discussion
This study demonstrates that STI571 as a single agent is well tolerated and has substantial activity against acute leukemias characterized by the BCR-ABL fusion protein. The overall response rate in the myeloid blast crisis of CML was 55 percent, and the rate of complete remission was 11 percent. Leukemic blasts in the marrow were reduced to 5 percent or less in 12 patients (32 percent). Of these 12 patients with myeloid blast crisis who initially had a response to STI571, 7 are still in remission after 101 to 349 days of follow-up.
There was no obvious difference in response rates or the durability of responses between patients with lymphoid blast crisis and those with Ph-chromosome–positive ALL. The overall response rate in patients with lymphoid blast crisis or Ph-chromosome–positive ALL was 70 percent, and 20 percent had complete remissions. A decrease in bone marrow blasts to 5 percent or less occurred in 11 patients (55 percent). However, all but one patient who had only extramedullary disease relapsed. With standard therapy, patients with lymphoid blast crisis have higher rates and greater durability of response than those with myeloid blast crisis. However, in this study, there was a trend toward a more durable response in the group of patients with myeloid blast crisis.
Since the outcome of hematopoietic stem-cell transplantation is better in patients with blast crisis who are first returned to the chronic phase of CML than in patients who undergo transplantation during blast crisis,15 the reduction in the proportion of blasts in the marrow of patients with blast crisis suggests that STI571 may be a useful bridge to transplantation. Combinations of STI571 with standard antileukemic agents may also improve the outcome for patients with blast crisis.16,17 In the patients with blast crisis we treated, STI571 had relatively few adverse effects, the most frequent of which were nausea, vomiting, and edema. There was some evidence of an increased incidence of toxic effects at the higher doses of STI571, especially at 800 to 1000 mg per day. Myelosuppression of grade 3 or 4 was more frequent in these patients with blast crisis than in patients with CML in the chronic phase who were treated with STI571 in a parallel phase 1 study.13 This difference may reflect the severely compromised bone marrow function in patients in blast crisis and the fact that severe myelosuppression was allowed in this study because of the life-threatening nature of the illness, but not in the trial involving patients with CML in the chronic phase.
Rapid response is also a feature of therapy with STI571 (Figure 1); despite this, the tumor lysis syndrome developed in only one patient. Preliminary data suggest that cells from treated patients undergo rapid apoptosis (data not shown). Although STI571 can be given to outpatients, careful monitoring during the initiation of therapy, vigorous hydration, and administration of allopurinol are recommended.
The mechanism of resistance to STI571 or relapse during treatment with the drug is a subject of intense interest. Analyses of blast-crisis CML cell lines that have acquired resistance to STI571 after prolonged culture in doses below the threshold for inhibition of growth18-20 have shown amplification of the BCR-ABL gene, increased expression of the BCR-ABL protein without amplification of the gene, and increased expression of the multidrug-resistance protein (MDR1).18-20 Preliminary analyses have shown that leukemic cells in patients who relapse retain the Ph chromosome and that serum levels of STI571 are unchanged at the time of relapse. These data are consistent with the in vitro data that implicate drug efflux or amplification of the BCR-ABL gene in resistance to STI571, but other mechanisms are also possible.18-20
This study clearly demonstrates that in the majority of patients with CML in blast crisis and Ph-chromosome–positive ALL, the leukemic clone remains at least partially dependent on BCR-ABL for survival. We also show that targeting a critical molecular abnormality, even in advanced stages of disease, is a useful strategy; however, in these cases it is likely that this agent will need to be combined with other therapies to achieve maximal therapeutic benefits.
Supported by grants from the National Cancer Institute (CA65823, to Dr. Druker, and CA32737, to Dr. Sawyers) and by Novartis Pharmaceuticals. Dr. Druker is the recipient of a Translational Research Award from the Leukemia and Lymphoma Society, and Dr. Sawyers is a Scholar of the Leukemia and Lymphoma Society.
Drs. Druker, Sawyers, and Talpaz served as consultants to Novartis Pharmaceuticals during the design of this study.
We are indebted to the following people for their assistance with various aspects of this study: Alex Matter, Juerg Zimmerman, John Goldman, Gregory Burke, David Parkinson, Michael Hayes, Ulrike Zoellner, William Palo, Marianne Rosamilia, Carolyn Blasdel, Virginia Naessig, Sheila Broussard, Mary Beth Rios, Ronald Paquette, Kathryn Kolibaba, Richard Maziarz, Peter Graf, and Hans Michael Buerger.
Source Information
From the Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland (B.J.D.); the Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles (C.L.S.); the Departments of Leukemia (H.K.) and Bioimmunotherapy (M.T.), University of Texas M.D. Anderson Cancer Center, Houston; and the Department of Oncology Clinical Research, Novartis Pharmaceuticals, East Hanover, N.J. (D.R.J.), and Basel, Switzerland (S.F.R., J.M.F., R.C.).
Address reprint requests to Dr. Druker at Oregon Health Sciences University, L592, 3181 SW Sam Jackson Park Rd., Portland, OR 97201, or at drukerb@ohsu.edu.
- References
References
1
Faderl S ,Talpaz M ,Estrov Z ,O'Brien S ,Kurzrock R ,Kantarjian HM . The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-172
Full Text | Web of Science | Medline2
Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999;340:1330-1340
Full Text | Web of Science | Medline3
Kantarjian HM ,Talpaz M ,Keating MJ , et al. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 1991;68:1201-1207
CrossRef | Web of Science | Medline4
Sacchi S ,Kantarjian HM ,O'Brien S , et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999;86:2632-2641
CrossRef | Web of Science | Medline5
Walters RS ,Kantarjian HM ,Keating MJ , et al. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. Cancer 1987;60:1708-1712
CrossRef | Web of Science | Medline6
Gratwohl A ,Hermans J . Allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1996;17:Suppl 3:S7-S9
Web of Science | Medline7
Clift RA ,Storb R . Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant 1996;17:Suppl 3:S1-S3
Web of Science | Medline8
Copelan EA ,McGuire EA . The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995;85:1151-1168
Web of Science | Medline9
Westbrook CA ,Hooberman AL ,Spino C , et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992;80:2983-2990
Web of Science | Medline10
Arico M ,Valsecchi MG ,Camitta B , et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006
Full Text | Web of Science | Medline11
Buchdunger E ,Zimmerman J ,Mett H , et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-104
Web of Science | Medline12
Druker BJ ,Tamura S ,Buchdunger E , et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566
CrossRef | Web of Science | Medline13
Druker BJ ,Talpaz M ,Resta DJ , et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037
Full Text | Web of Science | Medline14
Cancer Therapy Evaluation Program. Common toxicity criteria, version 2.0. Bethesda, Md.: National Cancer Institute, March 1998.
15
Spencer A ,O'Brien SG ,Goldman JM . Options for therapy in chronic myeloid leukaemia. Br J Haematol 1995;91:2-7
CrossRef | Web of Science | Medline16
Thiesing JT ,Ohno-Jones S ,Kolibaba KS ,Druker BJ . Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000;96:3195-3199
Web of Science | Medline17
Fang G ,Kim CN ,Perkins CL , et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000;96:2246-2253
Web of Science | Medline18
Mahon FX ,Deininger MWN ,Schultheis B , et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070-1079
Web of Science | Medline19
Weisberg E ,Griffin JD . Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498-3505
Web of Science | Medline20
le Coutre P ,Tassi E ,Varella-Garcia M , et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758-1766
Web of Science | Medline
- Citing Articles (874)
Citing Articles
1
Simone Cardaci, Enrico Desideri, Maria Rosa Ciriolo. (2012) Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug. Journal of Bioenergetics and Biomembranes
CrossRef2
Vladimir Ratushny, Michael D. Gober, Ryan Hick, Todd W. Ridky, John T. Seykora. (2012) From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. Journal of Clinical Investigation 122:2, 464-472
CrossRef3
Bill H. Chang, Stephanie G. Willis, Linda Stork, Stephen P. Hunger, William L. Carroll, Bruce M. Camitta, Naomi J. Winick, Brian J. Druker, Kirk R. Schultz. (2012) Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ALL: a Children's Oncology Group (COG) study. British Journal of Haematologyn/a-n/a
CrossRef4
B. H. Srinivas, T. Roshni Paul, Shantveer G. Uppin, Megha S. Uppin, Rachel T. Jacob, D. Raghunadharao. (2012) Morphologic Changes in the Bone Marrow in Patients of Chronic Myeloid Leukemia (CML) Treated with ImatinibMesylate. Indian Journal of Hematology and Blood Transfusion
CrossRef5
O. Weigert, A. A. Lane, L. Bird, N. Kopp, B. Chapuy, D. van Bodegom, A. V. Toms, S. Marubayashi, A. L. Christie, M. McKeown, R. M. Paranal, J. E. Bradner, A. Yoda, C. Gaul, E. Vangrevelinghe, V. Romanet, M. Murakami, R. Tiedt, N. Ebel, E. Evrot, A. De Pover, C. H. Regnier, D. Erdmann, F. Hofmann, M. J. Eck, S. E. Sallan, R. L. Levine, A. L. Kung, F. Baffert, T. Radimerski, D. M. Weinstock. (2012) Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. Journal of Experimental Medicine
CrossRef6
Sabine Tschiedel, Enrica Bach, Annette Jilo, Song-Yau Wang, Thoralf Lange, Haifa-Kathrin Al-Ali, Vladan Vucinic, Dietger Niederwiese, Michael Cross. (2012) Bcr-Abl dependent post transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia. Leukemia & Lymphoma1-22
CrossRef7
J. M. Drake, N. A. Graham, T. Stoyanova, A. Sedghi, A. S. Goldstein, H. Cai, D. A. Smith, H. Zhang, E. Komisopoulou, J. Huang, T. G. Graeber, O. N. Witte. (2012) Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proceedings of the National Academy of Sciences
CrossRef8
Rosalie Fisher, James Larkin, Charles Swanton. (2011) Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. The EPMA Journal
CrossRef9
A. Hamilton, G. V. Helgason, M. Schemionek, B. Zhang, S. Myssina, E. K. Allan, F. E. Nicolini, C. Muller-Tidow, R. Bhatia, V. G. Brunton, S. Koschmieder, T. L. Holyoake. (2011) Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood
CrossRef10
Muhammad Mansoor Alam, Moshe Talpaz. 2011. Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. .
CrossRef11
Christine H. Chung, Paula R. Pohlmann, Mace L. Rothenberg, Brian B. Burkey, Joel Parker, Kevin Palka, Joseph Aulino, Igor Puzanov, Barbara Murphy, Eben L. Rosenthal. (2011) Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head & Neck 33:12, 1804-1808
CrossRef12
Wei-Gang Tong, Zeev Estrov, Yongtao Wang, Susan O’Brien, Stefan Faderl, David M. Harris, Quin Pham, Inbal Hazan-Halevy, Zhiming Liu, Patricia Koch, Hagop Kantarjian, Michael J. Keating, Alessandra Ferrajoli. (2011) The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Investigational New Drugs 29:6, 1206-1212
CrossRef13
David P. Steensma. (2011) Oddballs: Acute Leukemias of Mixed Phenotype and Ambiguous Origin. Hematology/Oncology Clinics of North America 25:6, 1235-1253
CrossRef14
S. P. Hunger. (2011) Tyrosine Kinase Inhibitor Use in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Anemia. Hematology 2011:1, 361-365
CrossRef15
A. Kumari, C. Brendel, A. Hochhaus, A. Neubauer, A. Burchert. (2011) Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood
CrossRef16
L. V. Sequist, R. S. Heist, A. T. Shaw, P. Fidias, R. Rosovsky, J. S. Temel, I. T. Lennes, S. Digumarthy, B. A. Waltman, E. Bast, S. Tammireddy, L. Morrissey, A. Muzikansky, S. B. Goldberg, J. Gainor, C. L. Channick, J. C. Wain, H. Gaissert, D. M. Donahue, A. Muniappan, C. Wright, H. Willers, D. J. Mathisen, N. C. Choi, J. Baselga, T. J. Lynch, L. W. Ellisen, M. Mino-Kenudson, M. Lanuti, D. R. Borger, A. J. Iafrate, J. A. Engelman, D. Dias-Santagata. (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology
CrossRef17
Noriaki Kawano, Shinya Okuda, Shuro Yoshida, Hiroko Kugimiya, Masaki Ito, Nagako Horikawa, Nobuaki Chosa, Tomoko Hisakata, Tomoko Fukudome, Ryoko Sakurai, Kiyoshi Yamashita, Akira Ueda, Yoshinobu Kanda. (2011) Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation. International Journal of Hematology
CrossRef18
Hui-Jen Tsai, Seiichiro Kobayashi, Kiyoko Izawa, Takaomi Ishida, Toshiki Watanabe, Kazuo Umezawa, Sheng-Fung Lin, Arinobu Tojo. (2011) Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment. Cancer Science 102:11, 2014-2021
CrossRef19
Jung-min Lee, Jasmine J. Han, Gary Altwerger, Elise C. Kohn. (2011) Proteomics and biomarkers in clinical trials for drug development. Journal of Proteomics 74:12, 2632-2641
CrossRef20
Davide Torti, Livio Trusolino. (2011) Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Molecular Medicine 3:11, 623-636
CrossRef21
Julie A. Keating, Rob Striker. (2011) Phosphorylation events during viral infections provide potential therapeutic targets. Reviews in Medical Virologyn/a-n/a
CrossRef22
C. Hurtz, K. Hatzi, L. Cerchietti, M. Braig, E. Park, Y.-m. Kim, S. Herzog, P. Ramezani-Rad, H. Jumaa, M. C. Muller, W.-K. Hofmann, A. Hochhaus, B. H. Ye, A. Agarwal, B. J. Druker, N. P. Shah, A. M. Melnick, M. Muschen. (2011) BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. Journal of Experimental Medicine 208:11, 2163-2174
CrossRef23
David B. Jackson, Anil K. Sood. (2011) Personalized cancer medicine—advances and socio-economic challenges. Nature Reviews Clinical Oncology
CrossRef24
Yukako Fukushi, Masaharu Hazawa, Kenji Takahashi, Atsushi Yoshizawa, Ikuo Kashiwakura. (2011) Liquid crystal-related compound-induced cell growth suppression and apoptosis in the chronic myelogenous leukemia K562 cell line. Investigational New Drugs 29:5, 827-832
CrossRef25
ZiJie Liu, Xia Wu, Yong Duan, YuMing wang, Bin Shan, JinXing Kong, XiaoBo Ma, YuXia Bao. (2011) AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib. Leukemia Research 35:10, 1355-1359
CrossRef26
Franca Fagioli, Marco Zecca, Carla Rognoni, Edoardo Lanino, Adriana Balduzzi, Massimo Berger, Chiara Messina, Claudio Favre, Marco Rabusin, Luca Lo Nigro, Riccardo Masetti, Arcangelo Prete, Franco Locatelli. (2011) Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia-Positive Acute Lymphoblastic Leukemia in Children and Adolescents: A Retrospective Multicenter Study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Biology of Blood and Marrow Transplantation
CrossRef27
Thomas Delomas, Christian Darné, Caroline Besson. (2011) Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib. Leukemia & Lymphoma1-2
CrossRef28
N. Ilic, T. Utermark, H. R. Widlund, T. M. Roberts. (2011) PNAS Plus: PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proceedings of the National Academy of Sciences 108:37, E699-E708
CrossRef29
Masaru Shibata, Sachiko Ezoe, Kenji Oritani, Keiko Matsui, Masahiro Tokunaga, Natsuko Fujita, Yuri Saito, Takayuki Takahashi, Masayuki Hino, Itaru Matsumura, Yuzuru Kanakura. (2011) Predictability of the response to tyrosine kinase inhibitors via in vitro analysis of Bcr-Abl phosphorylation. Leukemia Research 35:9, 1205-1211
CrossRef30
Raghuveer Singh Mali, Baskar Ramdas, Peilin Ma, Jianjian Shi, Veerendra Munugalavadla, Emily Sims, Lei Wei, Sasidhar Vemula, Sarah C. Nabinger, Charles B. Goodwin, Rebecca J. Chan, Fabiola Traina, Valeria Visconte, Ramon V. Tiu, Timothy A. Lewis, Andrew M. Stern, Qiang Wen, John D. Crispino, H. Scott Boswell, Reuben Kapur. (2011) Rho Kinase Regulates the Survival and Transformation of Cells Bearing Oncogenic Forms of KIT, FLT3, and BCR-ABL. Cancer Cell 20:3, 357-369
CrossRef31
M. S. Marcolino, E. Boersma, N. C. D. Clementino, A. V. Macedo, A. D. Marx-Neto, M. H. C. R. Silva, T. van Gelder, K. M. Akkerhuis, A. L. Ribeiro. (2011) Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Annals of Oncology 22:9, 2073-2079
CrossRef32
Rashmita Sahoo, Vidya Harini V, V. Chitti Babu, Geeta V. Patil Okaly, Smitha Rao, Ashwini Nargund, E. Venkataswamy, Raghavendra Rao, B.S. Ajai Kumar. (2011) Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 73:3, 316-319
CrossRef33
Milena S. Marcolino, Eric Boersma, Nelma C.D. Clementino, Maria do Carmo P. Nunes, Márcia M. Barbosa, Maria Helena C.R. Silva, Marcel L. Geleijnse, Antonio L. Ribeiro. (2011) The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients. Hematological Oncology 29:3, 124-130
CrossRef34
Paola Di Gion, Friederike Kanefendt, Andreas Lindauer, Matthias Scheffler, Oxana Doroshyenko, Uwe Fuhr, Jürgen Wolf , Ulrich Jaehde. (2011) Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics 50:9, 551-603
CrossRef35
Carol Beadling, Michael C. Heinrich, Andrea Warrick, Erin M. Forbes, Dylan Nelson, Emily Justusson, Judith Levine, Tanaya L. Neff, Janice Patterson, Ajia Presnell, Arin McKinley, Laura J. Winter, Christie Dewey, Amy Harlow, Oscar Barney, Brian J. Druker, Kathryn G. Schuff, Christopher L. Corless. (2011) Multiplex Mutation Screening by Mass Spectrometry. The Journal of Molecular Diagnostics 13:5, 504-513
CrossRef36
Tariq I. Mughal, Jerald P. Radich, Richard A. Van Etten, Alfonso Quintás-Cardama, Tomasz Skorski, Farhad Ravandi, Daniel J. DeAngelo, Carlo Gambacorti-Passerini, Giovanni Martinelli, Ayalew Tefferi. (2011) Chronic myeloid leukemia 2011: Successes, challenges, and strategies-Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. American Journal of Hematology 86:9, 811-819
CrossRef37
Michael S. Mathisen, Susan O’Brien, Deborah Thomas, Jorge Cortes, Hagop Kantarjian, Farhad Ravandi. (2011) Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports 6:3, 187-194
CrossRef38
Marta Świtalska, Anna Nasulewicz-Goldeman, Aleksandra Opolska, Magdalena Maciejewska, Andrzej Kutner, Joanna Wietrzyk. (2011) The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells. Anti-Cancer Drugs1
CrossRef39
Mark-Alexander Schwarzbich, Michael Gutknecht, Julia Salih, Helmut R. Salih, Peter Brossart, Susanne M. Rittig, Frank Grünebach. (2011) The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors. Cancer Immunology, Immunotherapy
CrossRef40
Ignacio Garrido-Laguna, Manuel Hidalgo, Razelle Kurzrock. (2011) The inverted pyramid of biomarker-driven trials. Nature Reviews Clinical Oncology 8:9, 562-566
CrossRef41
Jean-Yves Blay. (2011) A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. Cancer Treatment Reviews 37:5, 373-384
CrossRef42
João Agostinho Machado-Neto, Patricia Favaro, Mariana Lazarini, Fernando Ferreira Costa, Sara T. Olalla Saad, Fabiola Traina. (2011) Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1813:8, 1404-1411
CrossRef43
Partow Kebriaei, Rima Saliba, Gabriela Rondon, Alexandre Chiattone, Rajyalakshmi Luthra, Paolo Anderlini, Borje Andersson, Elizabeth Shpall, Uday Popat, Roy Jones, Laura Worth, Farhad Ravandi, Deborah Thomas, Susan O’Brien, Hagop Kantarjian, Marcos de Lima, Sergio Giralt, Richard Champlin. (2011) Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes. Biology of Blood and Marrow Transplantation
CrossRef44
R Parameswaran, M Yu, M Lim, J Groffen, N Heisterkamp. (2011) Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 25:8, 1314-1323
CrossRef45
Richard A. Van Etten. (2011) BCL6: A Novel Target for Therapy of Ph+ B Cell Acute Lymphoblastic Leukemia. Cancer Cell 20:1, 3-5
CrossRef46
Marina Pajic, Christopher J. Scarlett, David K. Chang, Robert L. Sutherland, Andrew V. Biankin. (2011) Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Human Genetics 130:1, 93-101
CrossRef47
Osamu Yamada, Kohji Ozaki, Thoru Furukawa, Mitsuyo Machida, Yan-Hua Wang, Toshiko Motoji, Tsuyoshi Mitsuishi, Masaharu Akiyama, Hisashi Yamada, Kiyotaka Kawauchi, Rumiko Matsuoka. (2011) Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cellular Signalling 23:7, 1119-1127
CrossRef48
Liang Cheng, Riley Alexander, Shaobo Zhang, Chong-Xian Pan, Gregory T MacLennan, Antonio Lopez-Beltran, Rodolfo Montironi. (2011) The clinical and therapeutic implications of cancer stem cell biology. Expert Review of Anticancer Therapy 11:7, 1133-1145
CrossRef49
Xiaochun Zhang, Takeshi Inukai, Koshi Akahane, Kinuko Hirose, Itaru Kuroda, Hiroko Honna, Kumiko Goi, Keiko Kagami, Tetsuzo Tauchi, Hideo Yagita, Kanji Sugita. (2011) Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosome-positive leukemia cells to TRAIL-mediated apoptosis. Leukemia Research 35:7, 940-949
CrossRef50
Amy C. Anderson, Michael P. Pollastri, Celia A. Schiffer, Norton P. Peet. (2011) The challenge of developing robust drugs to overcome resistance. Drug Discovery Today
CrossRef51
M. Levis. (2011) FLT3/ITD AML and the law of unintended consequences. Blood 117:26, 6987-6990
CrossRef52
P. Nair. (2011) Profile of Charles L. Sawyers. Proceedings of the National Academy of Sciences 108:25, 10033-10035
CrossRef53
S.-J. Chen, G.-B. Zhou, X.-W. Zhang, J.-H. Mao, H. de The, Z. Chen. (2011) From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 117:24, 6425-6437
CrossRef54
Yukio Kobayashi, Hisashi Sakamaki, Shin Fujisawa, Kiyoshi Ando, Kazuhito Yamamoto, Masaya Okada, Kenichi Ishizawa, Tadashi Nagai, Syuichi Miyawaki, Toshiko Motoji, Noriko Usui, Shinsuke Iida, Masafumi Taniwaki, Nobuhiko Uoshima, Taku Seriu, Ryuzo Ohno. (2011) Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis. International Journal of Hematology 93:6, 745-749
CrossRef55
P. Bose, O. Qubaiah. (2011) A review of tumour lysis syndrome with targeted therapies and the role of rasburicase. Journal of Clinical Pharmacy and Therapeutics 36:3, 299-326
CrossRef56
N. Suwaki, E. Vanhecke, K. M. Atkins, M. Graf, K. Swabey, P. Huang, P. Schraml, H. Moch, A. M. Cassidy, D. Brewer, B. Al-Lazikani, P. Workman, J. De-Bono, S. B. Kaye, J. Larkin, M. E. Gore, C. L. Sawyers, P. Nelson, T. M. Beer, H. Geng, L. Gao, D. Z. Qian, J. J. Alumkal, G. Thomas, G. V. Thomas. (2011) A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma. Science Translational Medicine 3:85, 85ra47-85ra47
CrossRef57
Bénédicte Deau, Franck E. Nicolini, Joelle Guilhot, Françoise Huguet, Agnès Guerci, Laurence Legros, Cécile Pautas, Christian Berthou, Denis Guyotat, Pascale Cony-Makhoul, Martine Gardembas, Mauricette Michallet, Sandrine Hayette, Jean Michel Cayuela, Isabelle Radford Weiss, Delphine Réa, Sylvie Castaigne, François-Xavier Mahon, François Guilhot, Philippe Rousselot. (2011) The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leukemia Research 35:6, 777-782
CrossRef58
Stephen P. Hunger, Elizabeth A. Raetz, Mignon L. Loh, Charles G. Mullighan. (2011) Improving outcomes for high-risk ALL: Translating new discoveries into clinical care. Pediatric Blood & Cancer 56:6, 984-993
CrossRef59
Cihangir Duy, Christian Hurtz, Seyedmehdi Shojaee, Leandro Cerchietti, Huimin Geng, Srividya Swaminathan, Lars Klemm, Soo-mi Kweon, Rahul Nahar, Melanie Braig, Eugene Park, Yong-mi Kim, Wolf-Karsten Hofmann, Sebastian Herzog, Hassan Jumaa, H. Phillip Koeffler, J. Jessica Yu, Nora Heisterkamp, Thomas G. Graeber, Hong Wu, B. Hilda Ye, Ari Melnick, Markus Müschen. (2011) BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition. Nature 473:7347, 384-388
CrossRef60
Thomas J. Hudson. (2011) Cancer genome variation in children, adolescents, and young adults. Cancer 117:S10, 2262-2267
CrossRef61
Jon O. Wee, Yolonda L. Colson. (2011) Invited Commentary. The Annals of Thoracic Surgery 91:5, 1538
CrossRef62
Stefania Paolini, Anna Gazzola, Elena Sabattini, Francesco Bacci, Stefano Pileri, Pier Paolo Piccaluga. (2011) Pathobiology of acute lymphoblastic leukemia. Seminars in Diagnostic Pathology 28:2, 124-134
CrossRef63
T. Zander, M. Hallek. (2011) Thyrosinkinaseinhibitoren in der Onkologie. Der Internist 52:5, 595-600
CrossRef64
J. Chad Brenner, Bushra Ateeq, Yong Li, Anastasia K. Yocum, Qi Cao, Irfan A. Asangani, Sonam Patel, Xiaoju Wang, Hallie Liang, Jindan Yu, Nallasivam Palanisamy, Javed Siddiqui, Wei Yan, Xuhong Cao, Rohit Mehra, Aaron Sabolch, Venkatesha Basrur, Robert J. Lonigro, Jun Yang, Scott A. Tomlins, Christopher A. Maher, Kojo S.J. Elenitoba-Johnson, Maha Hussain, Nora M. Navone, Kenneth J. Pienta, Sooryanarayana Varambally, Felix Y. Feng, Arul M. Chinnaiyan. (2011) Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. Cancer Cell 19:5, 664-678
CrossRef65
Alexandra Böhm, Harald Herrmann, Gerlinde Mitterbauer-Hohendanner, Alexander W Hauswirth, Werner Rabitsch, Margit Mitterbauer, Wolfgang R Sperr, Peter Kalhs, Ulrich Jäger, Peter Valent. (2011) Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet ‘pre-leukemic’ stem cells?. Leukemia & Lymphoma 52:5, 842-848
CrossRef66
Yutaka Ueda, Tatsu Shimoyama, Haruyasu Murakami, Noboru Yamamoto, Yasuhide Yamada, Hitoshi Arioka, Tomohide Tamura. (2011) Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 67:5, 1101-1109
CrossRef67
Hun J. Lee, James E. Thompson, Eunice S. Wang, Meir Wetzler. (2011) Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 117:8, 1583-1594
CrossRef68
Eidarus Salah, Emilie Ugochukwu, Alastair J. Barr, Frank von Delft, Stefan Knapp, Jonathan M. Elkins. (2011) Crystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide Class. Journal of Medicinal Chemistry 54:7, 2359-2367
CrossRef69
Joon Ho Moon, Sang Kyun Sohn, Shi Nae Kim, Seon Yang Park, Sung Soo Yoon, In ho Kim, Hyeoung Joon Kim, Yeo Kyeoung Kim, Yoo Hong Min, June Won Cheong, Jin Seok Kim, Chul Won Jung, Dong Hwan Kim. (2011) Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Medical Oncology
CrossRef70
Brianna Backlund, Rachel E. Cianciolo, Audrey K. Cook, Fred J. Clubb, George E. Lees. (2011) Minimal change glomerulopathy in a cat. Journal of Feline Medicine & Surgery 13:4, 291-295
CrossRef71
Roberta Maggio, Nadia Peragine, Maria Stefania Propris, Antonella Vitale, Loredana Elia, Elisabetta Calabrese, Irene Della Starza, Stefania Intoppa, Maria Laura Milani, Anna Guarini, Robin Foà. (2011) Immunocompetent cell functions in Ph+ acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment. Cancer Immunology, Immunotherapy 60:4, 599-607
CrossRef72
Leisl Packer, Richard Marais. (2011) Unswitch-ABL Drugs Overcome Resistance in Chronic Myeloid Leukemia. Cancer Cell 19:4, 435-437
CrossRef73
Sami Joha, Véronique Dauphin, Frédéric Leprêtre, Sélim Corm, Franck E. Nicolini, Christophe Roumier, Olivier Nibourel, Nathalie Grardel, Véronique Maguer-Satta, Thierry Idziorek, Martin Figeac, Jean-Luc Laï, Bruno Quesnel, Gabriel Etienne, François Guilhot, Eric Lippert, Claude Preudhomme, Catherine Roche-Lestienne. (2011) Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. Leukemia Research 35:4, 448-458
CrossRef74
Q. Jiang, L.-P. Xu, D.-H. Liu, K.-Y. Liu, S.-S. Chen, B. Jiang, H. Jiang, H. Chen, Y.-H. Chen, W. Han, X.-H. Zhang, Y. Wang, Y.-Z. Qin, Y.-R. Liu, Y.-Y. Lai, X.-J. Huang. (2011) Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 117:11, 3032-3040
CrossRef75
Elizabeth S. Yeh, Thomas W. Yang, Jason J. Jung, Heather P. Gardner, Robert D. Cardiff, Lewis A. Chodosh. (2011) Hunk is required for HER2/neu-induced mammary tumorigenesis. Journal of Clinical Investigation 121:3, 866-879
CrossRef76
Qi-fa Liu, Xiao-jun Xu, Yin-kui Chen, Jing Sun, Yu Zhang, Zhi-ping Fan, Dan Xu, Qian-li Jiang, Yong-qiang Wei, Fen Huang, Ru Feng, Xiao-li Liu, Bing Xu, Fan-Yi Meng. (2011) Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China. Annals of Hematology 90:3, 331-341
CrossRef77
Eric D. Green, Mark S. Guyer, Eric D. Green, Mark S. Guyer, Teri A. Manolio, Jane L. Peterson. (2011) Charting a course for genomic medicine from base pairs to bedside. Nature 470:7333, 204-213
CrossRef78
Amber Fullmer, Hagop Kantarjian, Jorge Cortes, Elias Jabbour. (2011) New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leukemia & Lymphoma 52:S1, 81-91
CrossRef79
H. M. Kantarjian, F. J. Giles, K. N. Bhalla, J. Pinilla-Ibarz, R. A. Larson, N. Gattermann, O. G. Ottmann, A. Hochhaus, J. P. Radich, G. Saglio, T. P. Hughes, G. Martinelli, D.-W. Kim, Y. Shou, N. J. Gallagher, R. Blakesley, M. Baccarani, J. Cortes, P. D. le Coutre. (2011) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117:4, 1141-1145
CrossRef80
Hong Hoe Koo. (2011) Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Childhood. Korean Journal of Pediatrics 54:3, 106
CrossRef81
A. Borriello, I. Caldarelli, D. Bencivenga, V. Cucciolla, A. Oliva, E. Usala, P. Danise, L. Ronzoni, S. Perrotta, F. Della Ragione. (2011) p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells. Carcinogenesis 32:1, 10-18
CrossRef82
Hong Hoe Koo. (2011) Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Childhood. Korean Journal of Pediatrics 54:3, 105
CrossRef83
Ye Hu, Yang Peng, Kevin Lin, Haifa Shen, Louis C. Brousseau III, Jason Sakamoto, Tong Sun, Mauro Ferrari. (2011) Surface engineering on mesoporous silica chips for enriching low molecular weight phosphorylated proteins. Nanoscale 3:2, 421
CrossRef84
Yaoyu Chen. (2011) Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?. Leukemia Research 35:1, 27-29
CrossRef85
Fabio P. S. Santos, Hagop Kantarjian, Alfonso Quintás-Cardama, Jorge Cortes. (2011) Evolution of Therapies for Chronic Myelogenous Leukemia. The Cancer Journal 17:6, 465-476
CrossRef86
Azusa Hoshino-Yoshino, Motohiro Kato, Kohnosuke Nakano, Masaki Ishigai, Toshiyuki Kudo, Kiyomi Ito. (2011) Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/toxicodynamics. Drug Metabolism and Pharmacokinetics
CrossRef87
Ah Young Cho, Dae Hun Kim, Myung Im, Young Lee, Young Joon Seo, Jeung Hoon Lee. (2011) Pityriasis rosea -like Drug Eruption Induced by Imatinib Mesylate (Gleevec™). Annals of Dermatology 23:Suppl 3, S360
CrossRef88
Don L. Gibbons, Sabrina Pricl, Hagop Kantarjian, Jorge Cortes, Alfonso Quintás-Cardama. (2011) The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancern/a-n/a
CrossRef89
E. Jabbour, J. Cortes, F. P. S. Santos, D. Jones, S. O'Brien, G. Rondon, U. Popat, S. Giralt, P. Kebriaei, H. Kantarjian, R. Champlin, M. De Lima. (2010) Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood
CrossRef90
Jason S. Griffith, Peter A. Binkley, Namir B. Kirma, Robert S. Schenken, Craig A. Witz, Rajeshwar R. Tekmal. (2010) Imatinib decreases endometrial stromal cell transmesothial migration and proliferation in the extracellular matrix of modeled peritoneum. Fertility and Sterility 94:7, 2531-2535
CrossRef91
Partow Kebriaei. 2010. The Role of Hematopoietic Stem-Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. , 250-258.
CrossRef92
Andreas Hochhaus. 2010. Therapy of Newly Diagnosed and Chronic-Phase Chronic Myeloid Leukemia. , 271-280.
CrossRef93
Olga Sala-Torra, Jerald P. Radich. 2010. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Current Treatment Status and Perspectives. , 228-243.
CrossRef94
Baijun Fang, Ning Li, Yongping Song, Qin Han, Robert Chunhua Zhao. (2010) Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib. Annals of Hematology 89:11, 1099-1105
CrossRef95
D Sears, P Luong, M Yuan, G Nteliopoulos, Y K S Man, J V Melo, S Basu. (2010) Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia. Cell Death and Disease 1:11, e93
CrossRef96
R. A. J. Signer, E. Montecino-Rodriguez, O. N. Witte, K. Dorshkind. (2010) Immature B-cell progenitors survive oncogenic stress and efficiently initiate Ph+ B-acute lymphoblastic leukemia. Blood 116:14, 2522-2530
CrossRef97
Thomas E. Merchant, Richard J. Gilbertson. 2010. Ependymoma. , 24-33.
CrossRef98
Wolfram E. Samlowski, James Moon, Ralph J. Tuthill, Michael C. Heinrich, Naomi S. Balzer-Haas, Stuart A. Merl, Ronald C. DeConti, John A. Thompson, Merle T. Witter, Lawrence E. Flaherty, Vernon K. Sondak. (2010) A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin). American Journal of Clinical Oncology 33:5, 495-499
CrossRef99
Stefan Schmidt, Dominik Wolf, Josef Thaler, Sonja Burgstaller, Wolfgang Linkesch, Andreas Petzer, Michael Fridrik, Alois Lang, Hermine Agis, Peter Valent, Otto Krieger, Alois Walder, Markus Korger, Ernst Schlögl, Tamer Sliwa, Ernst Wöll, Manfred Mitterer, Wolfgang Eisterer, Michael Pober, Günther Gastl. (2010) First annual report of the Austrian CML registry. Wiener klinische Wochenschrift 122:19-20, 558-566
CrossRef100
Lynette M. Sholl, Janina Longtine. 2010. Molecular Analysis of Gene Rearrangements and Mutations in Acute Leukemias and Myeloproliferative Neoplasms. .
CrossRef101
Itsuro Jinnai, Tohru Sakura, Motohiro Tsuzuki, Yasuhiro Maeda, Noriko Usui, Masayuki Kato, Hirokazu Okumura, Taiichi Kyo, Yasunori Ueda, Yuji Kishimoto, Fumiharu Yagasaki, Kosuke Tsuboi, Shigeo Horiike, Jin Takeuchi, Masako Iwanaga, Yasushi Miyazaki, Shuichi Miyawaki, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno. (2010) Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study. International Journal of Hematology 92:3, 490-502
CrossRef102
Miguel Quintela-Fandino, Antonio González-Martín, Ramon Colomer. (2010) Targeting cytoskeleton reorganisation as antimetastatic treatment. Clinical and Translational Oncology 12:10, 662-669
CrossRef103
Emilie Dehours, Béatrice Riu, Baptiste Valle, Etienne Chatelut, Christian Recher, Olivier Fourcade, Françoise Huguet. (2010) Overdose with 16,000mg of imatinib mesylate. Leukemia Research 34:10, e286-e287
CrossRef104
Peter Valent. (2010) Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?. European Journal of Clinical Investigation 40:10, 918-931
CrossRef105
Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes. (2010) Third-Generation Tyrosine Kinase Inhibitors and Beyond. Seminars in Hematology 47:4, 371-380
CrossRef106
R. Tanaka, M. S. Squires, S. Kimura, A. Yokota, R. Nagao, T. Yamauchi, M. Takeuchi, H. Yao, M. Reule, T. Smyth, J. F. Lyons, N. T. Thompson, E. Ashihara, O. G. Ottmann, T. Maekawa. (2010) Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood 116:12, 2089-2095
CrossRef107
Y Chen, C Peng, C Sullivan, D Li, S Li. (2010) Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia 24:9, 1545-1554
CrossRef108
Yasuko Rikihisa, Mingqun Lin, Hua Niu. (2010) Microreview: Type IV secretion in the obligatory intracellular bacterium Anaplasma phagocytophilum. Cellular Microbiology 12:9, 1213-1221
CrossRef109
Janice P. Dutcher, Evelyn L. Morris, Bruce Gaynor, Elisabeth Paietta, Peter H. Wiernik. (2010) A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia. Medical Oncology 27:3, 728-735
CrossRef110
Elisabeth Paietta. (2010) Surrogate marker profiles for genetic lesions in acute leukemias. Best Practice & Research Clinical Haematology 23:3, 359-368
CrossRef111
Hui-Ping Liu, Hong-Dar Isaac Wu, John Wen-Cheng Chang, Yi-Cheng Wu, Hsin-Yi Yang, Ya-Ting Chen, Wen-You Hsieh, Ying-Tsong Chen, Yi-Rong Chen, Shiu-Feng Huang. (2010) Prognostic Implications of Epidermal Growth Factor Receptor and KRAS Gene Mutations and Epidermal Growth Factor Receptor Gene Copy Numbers in Patients with Surgically Resectable Non-small Cell Lung Cancer in Taiwan. Journal of Thoracic Oncology 5:8, 1175-1184
CrossRef112
R. Katherine Hyde, P. Paul Liu. (2010) RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1). Journal of Cellular Biochemistry 110:5, 1039-1045
CrossRef113
Ying-Chun Shen, Chiun Hsu, Ann-Lii Cheng. (2010) Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. Journal of Gastroenterology 45:8, 794-807
CrossRef114
Melanie R. Bui, Victoria Hodson, Tom King, Derek Leopold, Shaodong Dai, Valerie Fiolkoski, Sarah Oakes, Richard Duke, David Apelian, Alex Franzusoff, James DeGregori. (2010) Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model. Vaccine 28:37, 6028-6035
CrossRef115
Charles L. Wiggins, Linda C. Harlan, Harold E. Nelson, Jennifer L. Stevens, Cheryl L. Willman, Edward N. Libby, Robert A. Hromas. (2010) Age Disparity in the Dissemination of Imatinib for Treating Chronic Myeloid Leukemia. The American Journal of Medicine 123:8, 764.e1-764.e9
CrossRef116
P.J. Schuler, S. Heikaus, U. Friebe-Hoffmann, T.K. Hoffmann, J. Greve, T. Klenzner, J. Schipper, K. Scheckenbach. (2010) Mammakarzinommetastasen im Kopf-Hals-Bereich. HNO 58:8, 859-865
CrossRef117
Hyun Pyo Kim, Arthur E. Frankel, Donna E. Hogge. (2010) A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leukemia Research 34:8, 1035-1042
CrossRef118
Monica Messina, Sabina Chiaretti, Simona Tavolaro, Nadia Peragine, Antonella Vitale, Loredana Elia, Simona Sica, Alessandro Levis, Anna Guarini, Robin Foà. (2010) Protein kinase gene expression profiling and in vitro functional experiments identify novel potential therapeutic targets in adult acute lymphoblastic leukemia. Cancer 116:14, 3426-3437
CrossRef119
Friedrich Stölzel, Christine Steudel, Uta Oelschlägel, Brigitte Mohr, Sina Koch, Gerhard Ehninger, Christian Thiede. (2010) Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. Annals of Hematology 89:7, 653-662
CrossRef120
Pratibha Sharma, Sujata Mohanty, Vinod Kochupillai, Lalit Kumar. (2010) Mutations in ABL kinase domain are associated with inferior progression-free survival. Leukemia & Lymphoma 51:6, 1072-1078
CrossRef121
J Boultwood, J Perry, R Zaman, C Fernandez-Santamaria, T Littlewood, R Kusec, A Pellagatti, L Wang, R E Clark, J S Wainscoat. (2010) High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia 24:6, 1139-1145
CrossRef122
Min Sung Kim, Soo Young Hur, Nam Jin Yoo, Sug Hyung Lee. (2010) Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. The Journal of Pathology 221:2, 147-152
CrossRef123
Ana Lucia Abujamra, Michel Pinheiro dos Santos, Rafael Roesler, Gilberto Schwartsmann, Algemir Lunardi Brunetto. (2010) Histone deacetylase inhibitors: A new perspective for the treatment of leukemia. Leukemia Research 34:6, 687-695
CrossRef124
Ruth March. (2010) Delivering on the promise of personalized healthcare. Personalized Medicine 7:3, 327-337
CrossRef125
Andre Luiz Mencalha, B. Du Rocher, D. Salles, R. Binato, E. Abdelhay. (2010) LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. Cancer Chemotherapy and Pharmacology 65:6, 1039-1046
CrossRef126
Sara M Tinsley. (2010) Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Journal of Clinical Nursing 19:9-10, 1207-1218
CrossRef127
Reza Serizawa, Per Guldberg. 2010. DNA Biomarkers in the Diagnosis and Management of Cancer. , 165-184.
CrossRef128
D Ercan, K Zejnullahu, K Yonesaka, Y Xiao, M Capelletti, A Rogers, E Lifshits, A Brown, C Lee, J G Christensen, D J Kwiatkowski, J A Engelman, P A Jänne. (2010) Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29:16, 2346-2356
CrossRef129
Thomas J. Hudson (Chairperson), Warwick Anderson, Axel Aretz, Anna D. Barker, Cindy Bell, Rosa R. Bernabé, M. K. Bhan, Fabien Calvo, Iiro Eerola, Daniela S. Gerhard, Alan Guttmacher, Mark Guyer, Fiona M. Hemsley, Jennifer L. Jennings, David Kerr, Peter Klatt, Patrik Kolar, Jun Kusuda, David P. Lane, Frank Laplace, Youyong Lu, Gerd Nettekoven, Brad Ozenberger, Jane Peterson, T.S. Rao, Jacques Remacle, Alan J. Schafer, Tatsuhiro Shibata, Michael R. Stratton, Joseph G. Vockley, Koichi Watanabe, Huanming Yang, Matthew M. F. Yuen, Bartha M. Knoppers (Leader), Martin Bobrow, Anne Cambon-Thomsen, Lynn G. Dressler, Stephanie O. M. Dyke, Yann Joly, Kazuto Kato, Karen L. Kennedy, Pilar Nicolás, Michael J. Parker, Emmanuelle Rial-Sebbag, Carlos M. Romeo-Casabona, Kenna M. Shaw, Susan Wallace, Georgia L. Wiesner, Nikolajs Zeps, Peter Lichter (Leader), Andrew V. Biankin, Christian Chabannon, Lynda Chin, Bruno Clément, Enrique de Alava, Françoise Degos, Martin L. Ferguson, Peter Geary, D. Neil Hayes, Thomas J. Hudson, Amber L. Johns, Arek Kasprzyk, Hidewaki Nakagawa, Robert Penny, Miguel A. Piris, Rajiv Sarin, Aldo Scarpa, Tatsuhiro Shibata, Marc van de Vijver, P. Andrew Futreal (Leader), Hiroyuki Aburatani, Mónica Bayés, David D.L. Bowtell, Peter J. Campbell, Xavier Estivill, Daniela S. Gerhard, Sean M. Grimmond, Ivo Gut, Martin Hirst, Carlos López-Otín, Partha Majumder, Marco Marra, John D. McPherson, Hidewaki Nakagawa, Zemin Ning, Xose S. Puente, Yijun Ruan, Tatsuhiro Shibata, Michael R. Stratton, Hendrik G. Stunnenberg, Harold Swerdlow, Victor E. Velculescu, Richard K. Wilson, Hong H. Xue, Liu Yang, Paul T. Spellman (Leader), Gary D. Bader, Paul C. Boutros, Peter J. Campbell, Paul Flicek, Gad Getz, Roderic Guigó, Guangwu Guo, David Haussler, Simon Heath, Tim J. Hubbard, Tao Jiang, Steven M. Jones, Qibin Li, Nuria López-Bigas, Ruibang Luo, Lakshmi Muthuswamy, B. F. Francis Ouellette, John V. Pearson, Xose S. Puente, Victor Quesada, Benjamin J. Raphael, Chris Sander, Tatsuhiro Shibata, Terence P. Speed, Lincoln D. Stein, Joshua M. Stuart, Jon W. Teague, Yasushi Totoki, Tatsuhiko Tsunoda, Alfonso Valencia, David A. Wheeler, Honglong Wu, Shancen Zhao, Guangyu Zhou, Lincoln D. Stein (Leader), Roderic Guigó, Tim J. Hubbard, Yann Joly, Steven M. Jones, Arek Kasprzyk, Mark Lathrop, Nuria López-Bigas, B. F. Francis Ouellette, Paul T. Spellman, Jon W. Teague, Gilles Thomas, Alfonso Valencia, Teruhiko Yoshida, Karen L. Kennedy (Leader), Myles Axton, Stephanie O. M. Dyke, P. Andrew Futreal, Daniela S. Gerhard, Chris Gunter, Mark Guyer, Thomas J. Hudson, John D. McPherson, Linda J. Miller, Brad Ozenberger, Kenna M. Shaw, Arek Kasprzyk (Leader), Lincoln D. Stein (Leader), Junjun Zhang, Syed A. Haider, Jianxin Wang, Christina K. Yung, Anthony Cross, Yong Liang, Saravanamuttu Gnaneshan, Jonathan Guberman, Jack Hsu, Martin Bobrow (Leader), Don R. C. Chalmers, Karl W. Hasel, Yann Joly, Terry S. H. Kaan, Karen L. Kennedy, Bartha M. Knoppers, William W. Lowrance, Tohru Masui, Pilar Nicolás, Emmanuelle Rial-Sebbag, Laura Lyman Rodriguez, Catherine Vergely, Teruhiko Yoshida, Sean M. Grimmond (Leader), Andrew V. Biankin, David D. L. Bowtell, Nicole Cloonan, Anna deFazio, James R. Eshleman, Dariush Etemadmoghadam, Brooke A. Gardiner, James G. Kench, Aldo Scarpa, Robert L. Sutherland, Margaret A. Tempero, Nicola J. Waddell, Peter J. Wilson, John D. McPherson (Leader), Steve Gallinger, Ming-Sound Tsao, Patricia A. Shaw, Gloria M. Petersen, Debabrata Mukhopadhyay, Lynda Chin, Ronald A. DePinho, Sarah Thayer, Lakshmi Muthuswamy, Kamran Shazand, Timothy Beck, Michelle Sam, Lee Timms, Vanessa Ballin, Youyong Lu (Leader), Jiafu Ji, Xiuqing Zhang, Feng Chen, Xueda Hu, Guangyu Zhou, Qi Yang, Geng Tian, Lianhai Zhang, Xiaofang Xing, Xianghong Li, Zhenggang Zhu, Yingyan Yu, Jun Yu, Huanming Yang, Mark Lathrop (Leader), Jörg Tost, Paul Brennan, Ivana Holcatova, David Zaridze, Alvis Brazma, Lars Egevad, Egor Prokhortchouk, Rosamonde Elizabeth Banks, Mathias Uhlén, Anne Cambon-Thomsen, Juris Viksna, Fredrik Ponten, Konstantin Skryabin, Michael R. Stratton (Leader), P. Andrew Futreal, Ewan Birney, Ake Borg, Anne-Lise Børresen-Dale, Carlos Caldas, John A. Foekens, Sancha Martin, Jorge S. Reis-Filho, Andrea L. Richardson, Christos Sotiriou, Hendrik G. Stunnenberg, Gilles Thomas, Marc van de Vijver, Laura van’t Veer, Fabien Calvo (Leader), Daniel Birnbaum, Hélène Blanche, Pascal Boucher, Sandrine Boyault, Christian Chabannon, Ivo Gut, Jocelyne D. Masson-Jacquemier, Mark Lathrop, Iris Pauporté, Xavier Pivot, Anne Vincent-Salomon, Eric Tabone, Charles Theillet, Gilles Thomas, Jörg Tost, Isabelle Treilleux, Fabien Calvo (Leader), Paulette Bioulac-Sage, Bruno Clément, Thomas Decaens, Françoise Degos, Dominique Franco, Ivo Gut, Marta Gut, Simon Heath, Mark Lathrop, Didier Samuel, Gilles Thomas, Jessica Zucman-Rossi, Peter Lichter (Leader), Roland Eils (Leader), Benedikt Brors, Jan O. Korbel, Andrey Korshunov, Pablo Landgraf, Hans Lehrach, Stefan Pfister, Bernhard Radlwimmer, Guido Reifenberger, Michael D. Taylor, Christof von Kalle, Partha P. Majumder (Leader), Rajiv Sarin, T. S. Rao, M. K. Bhan, Aldo Scarpa (Leader), Paolo Pederzoli, Rita T. Lawlor, Massimo Delledonne, Alberto Bardelli, Andrew V. Biankin, Sean M. Grimmond, Thomas Gress, David Klimstra, Giuseppe Zamboni, Tatsuhiro Shibata (Leader), Yusuke Nakamura, Hidewaki Nakagawa, Jun Kusuda, Tatsuhiko Tsunoda, Satoru Miyano, Hiroyuki Aburatani, Kazuto Kato, Akihiro Fujimoto, Teruhiko Yoshida, Elias Campo (Leader), Carlos López-Otín, Xavier Estivill, Roderic Guigó, Silvia de Sanjosé, Miguel A. Piris, Emili Montserrat, Marcos González-Díaz, Xose S. Puente, Pedro Jares, Alfonso Valencia, Heinz Himmelbaue, Victor Quesada, Silvia Bea, Michael R. Stratton (Leader), P. Andrew Futreal, Peter J. Campbell, Anne Vincent-Salomon, Andrea L. Richardson, Jorge S. Reis-Filho, Marc van de Vijver, Gilles Thomas, Jocelyne D. Masson-Jacquemier, Samuel Aparicio, Ake Borg, Anne-Lise Børresen-Dale, Carlos Caldas, John A. Foekens, Hendrik G. Stunnenberg, Laura van’t Veer, Douglas F. Easton, Paul T. Spellman, Sancha Martin, Anna D. Barker, Lynda Chin, Francis S. Collins, Carolyn C. Compton, Martin L. Ferguson, Daniela S. Gerhard, Gad Getz, Chris Gunter, Alan Guttmacher, Mark Guyer, D. Neil Hayes, Eric S. Lander, Brad Ozenberger, Robert Penny, Jane Peterson, Chris Sander, Kenna M. Shaw, Terence P. Speed, Paul T. Spellman, Joseph G. Vockley, David A. Wheeler, Richard K. Wilson, Thomas J. Hudson (Chairperson), Lynda Chin, Bartha M. Knoppers, Eric S. Lander, Peter Lichter, Lincoln D. Stein, Michael R. Stratton, Warwick Anderson, Anna D. Barker, Cindy Bell, Martin Bobrow, Wylie Burke, Francis S. Collins, Carolyn C. Compton, Ronald A. DePinho, Douglas F. Easton, P. Andrew Futreal, Daniela S. Gerhard, Anthony R. Green, Mark Guyer, Stanley R. Hamilton, Tim J. Hubbard, Olli P. Kallioniemi, Karen L. Kennedy, Timothy J. Ley, Edison T. Liu, Youyong Lu, Partha Majumder, Marco Marra, Brad Ozenberger, Jane Peterson, Alan J. Schafer, Paul T. Spellman, Hendrik G. Stunnenberg, Brandon J. Wainwright, Richard K. Wilson, Huanming Yang. (2010) International network of cancer genome projects. Nature 464:7291, 993-998
CrossRef130
E. Chankiewitz, G.A. Scholz, B.M. Spriewald, A. Mackensen, A. Bergua. (2010) Fundus leucaemicus als Erstmanifestation einer chronischen myeloischen Leukämie. Der Ophthalmologe 107:4, 359-362
CrossRef131
Amber Fullmer, Jorge Cortes, Hagop Kantarjian, Elias Jabbour. (2010) ASH 2009 meeting report-Top 10 clinically oriented abstracts in acute leukemia. American Journal of Hematology 85:4, 277-280
CrossRef132
Hagop M. Kantarjian, Jorge Cortes, Paul La Rosée, Andreas Hochhaus. (2010) Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer 116:6, 1419-1430
CrossRef133
M.V. Ramana Reddy, Venkat R. Pallela, Stephen C. Cosenza, Muralidhar R. Mallireddigari, Revathi Patti, Marie Bonagura, May Truongcao, Balaiah Akula, Shashidhar S. Jatiani, E. Premkumar Reddy. (2010) Design, synthesis and evaluation of (E)-α-benzylthio chalcones as novel inhibitors of BCR-ABL kinase. Bioorganic & Medicinal Chemistry 18:6, 2317-2326
CrossRef134
Vladimír Vonka. (2010) Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy 2:2, 227-241
CrossRef135
Yenan Li, Dehui Zou, Yaozhong Zhao, Yingchang Mi, Jianxiang Wang, Lugui Qiu. (2010) Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China. Leukemia & Lymphoma 51:3, 488-496
CrossRef136
Andrea Hoelbl, Christian Schuster, Boris Kovacic, Bingmei Zhu, Mark Wickre, Maria A. Hoelzl, Sabine Fajmann, Florian Grebien, Wolfgang Warsch, Gabriele Stengl, Lothar Hennighausen, Valeria Poli, Hartmut Beug, Richard Moriggl, Veronika Sexl. (2010) Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Molecular Medicine 2:3, 98-110
CrossRef137
Momoko Suzuki, Akihiro Abe, Shizuka Imagama, Yuka Nomura, Ryohei Tanizaki, Yosuke Minami, Fumihiko Hayakawa, Yoshie Ito, Akira Katsumi, Kazuhito Yamamoto, Nobuhiko Emi, Hitoshi Kiyoi, Tomoki Naoe. (2010) BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. European Journal of Haematology 84:3, 229-238
CrossRef138
P. C. De Witt Hamer. (2010) Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro-Oncology 12:3, 304-316
CrossRef139
Jerry P. Jasinski, Ray J. Butcher, Q. N. M. Hakim Al-Arique, H. S. Yathirajan, B. Narayana. (2010) N -(5-Amino-2-methylphenyl)-4-(3-pyridyl)pyrimidin-2-amine. Acta Crystallographica Section E Structure Reports Online 66:2, o349-o349
CrossRef140
Gaurav D. Shah, Nick Loizos, Hagop Youssoufian, Jonathan D. Schwartz, Eric K. Rowinsky. (2010) Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor α. Cancer 116:S4, 1018-1026
CrossRef141
Olivia Roth, Odile Spreux-Varoquaux, Stephane Bouchet, Philippe Rousselot, Sylvie Castaigne, Sophie Rigaudeau, Victoria Raggueneau, Patrice Therond, Philippe Devillier, Mathieu Molimard, Benjamin Maneglier. (2010) Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS. Clinica Chimica Acta 411:3-4, 140-146
CrossRef142
Naoto Hoshi, Lorene K. Langeberg, Christine M. Gould, Alexandra C. Newton, John D. Scott. (2010) Interaction with AKAP79 Modifies the Cellular Pharmacology of PKC. Molecular Cell 37:4, 541-550
CrossRef143
Liliane Goetsch, Véronique Caussanel. (2010) Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers. Biomarkers in Medicine 4:1, 149-170
CrossRef144
Wendy Stock. (2010) Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia & Lymphoma 51:2, 188-198
CrossRef145
Katari Naresh Kumar, Kintali Sreeramamurthy, Sadananda Palle, Khagga Mukkanti, Parthasarathi Das. (2010) Dithiocarbamate and DBU-promoted amide bond formation under microwave condition. Tetrahedron Letters 51:6, 899-902
CrossRef146
Konstantinos Skobridis, Maria Kinigopoulou, Vassiliki Theodorou, Emilia Giannousi, Alison Russell, Rakhee Chauhan, Roberta Sala, Nicola Brownlow, Serafim Kiriakidis, Jan Domin, AndreasâG. Tzakos, NickâJ. Dibb. (2010) Novel Imatinib Derivatives with Altered Specificity between BcrâAbl and FMS, KIT, and PDGF Receptors. ChemMedChem 5:1, 130-139
CrossRef147
Alexa B. Turke, Kreshnik Zejnullahu, Yi-Long Wu, Youngchul Song, Dora Dias-Santagata, Eugene Lifshits, Luca Toschi, Andrew Rogers, Tony Mok, Lecia Sequist, Neal I. Lindeman, Carly Murphy, Sara Akhavanfard, Beow Y. Yeap, Yun Xiao, Marzia Capelletti, A. John Iafrate, Charles Lee, James G. Christensen, Jeffrey A. Engelman, Pasi A. Jänne. (2010) Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC. Cancer Cell 17:1, 77-88
CrossRef148
Masafumi Minoshima, James C. Chou, Sophie Lefebvre, Toshikazu Bando, Ken-ichi Shinohara, Joel M. Gottesfeld, Hiroshi Sugiyama. (2010) Potent activity against K562 cells by polyamide–seco-CBI conjugates targeting histone H4 genes. Bioorganic & Medicinal Chemistry 18:1, 168-174
CrossRef149
Anat Gafter-Gvili, Ron Ram, Uzi Gafter, Ofer Shpilberg, Pia Raanani. (2010) Renal failure associated with tyrosine kinase inhibitors—Case report and review of the literature. Leukemia Research 34:1, 123-127
CrossRef150
Amber Fullmer, Elias Jabbour. (2010) Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?. American Journal of HematologyNA-NA
CrossRef151
Wai Kit Chia, Noor Akmal Sharifah, Rahayu Md Zin Reena, Zakaria Zubaidah, Ching Huat Clarence-Ko, Muhammad Rohaizak, Ibrahim Naqiyah, Das Srijit, Abdullah Nor Hisham, Arbi Asmiati, Md Kaslan Rafie. (2010) Fluorescence in situ hybridization analysis using PAX8- and PPARG-specific probes reveals the presence of PAX8-PPARG translocation and 3p25 aneusomy in follicular thyroid neoplasms. Cancer Genetics and Cytogenetics 196:1, 7-13
CrossRef152
Mantej K Chhina, Weir Nargues, Geraldine M Grant, Steven D Nathan. (2010) Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. Future Cardiology 6:1, 19-35
CrossRef153
Ronald D. Barr. (2010) Imatinib mesylate in children and adolescents with cancer. Pediatric Blood & Cancern/a-n/a
CrossRef154
Michael A. Tainsky. 2009. Oncology Biomarkers. .
CrossRef155
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning, Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, 6-22
CrossRef156
Alfonso Quintás-Cardama, Jorge E. Cortés. (2009) The Next Generation of Therapies for Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia 9:0, S395-S403
CrossRef157
Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes. (2009) Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 115:23, 5382-5393
CrossRef158
Michael A. Tainsky. (2009) Genomic and proteomic biomarkers for cancer: A multitude of opportunities. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1796:2, 176-193
CrossRef159
Nielka P. van Erp, Hans Gelderblom, Henk-Jan Guchelaar. (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treatment Reviews 35:8, 692-706
CrossRef160
Macoura Gadji, Ana-Maria Tsanaclis Crous, David Fortin, Jerry Krcek, Mark Torchia, Sabine Mai, Regen Drouin, Thomas Klonisch. (2009) EGF receptor inhibitors in the treatment of glioblastoma multiform: Old clinical allies and newly emerging therapeutic concepts. European Journal of Pharmacology 625:1-3, 23-30
CrossRef161
J. Chad Brenner, Arul M. Chinnaiyan. (2009) Translocations in epithelial cancers. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1796:2, 201-215
CrossRef162
J. D. Scott, T. Pawson. (2009) Cell Signaling in Space and Time: Where Proteins Come Together and When They're Apart. Science 326:5957, 1220-1224
CrossRef163
Tsila Zuckerman, Jacob M Rowe. (2009) Hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia. Current Opinion in Hematology 16:6, 453-459
CrossRef164
Matthew J Walter, Timothy A Graubert, John F DiPersio, Elaine R Mardis, Richard K Wilson, Timothy J Ley. (2009) Next-generation sequencing of cancer genomes: back to the future. Personalized Medicine 6:6, 653-662
CrossRef165
Seung Hwan Oh, Tae Sung Park, Hye Ran Kim, Ja Young Lee, Jae Hyun Kim, Jeong Hwan Shin, Jeong Nyeo Lee. (2009) Chronic myelogenous leukemia showing biphenotypic blast crisis followed by lineage switch to B lymphoblastic leukemia. Leukemia Research 33:11, e195-e198
CrossRef166
Haizhen Zhong, Ly M. Tran, Jenna L. Stang. (2009) Induced-fit docking studies of the active and inactive states of protein tyrosine kinases. Journal of Molecular Graphics and Modelling 28:4, 336-346
CrossRef167
Jerry P. Jasinski, Ray J. Butcher, L. Mallesha, K. N. Mohana, H. S. Yathirajan, B. Narayana. (2009) Dual Chlorine-Bifurcated Acceptor Cl···H–(N,O) Hydrogen Bonds in 4-[(4-Methylpiperazin-1-yl) Methyl]benzoic Acid Dihydrochloride Hemihydrate. Journal of Chemical Crystallography 39:11, 773-776
CrossRef168
Farhad Ravandi, Partow Kebriaei. (2009) Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America 23:5, 1043-1063
CrossRef169
Syed A. Abutalib, Meir Wetzler, Wendy Stock. (2009) Looking Toward the Future: Novel Strategies Based on Molecular Pathogenesis of Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America 23:5, 1099-1119
CrossRef170
Jeroen J.W.M. Janssen, Henk W. Berendse, Gerrit-Jan Schuurhuis, Pauline A. Merle, Gert J. Ossenkoppele. (2009) A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment. American Journal of Hematology 84:10, 679-682
CrossRef171
A. Al-Kali, S. Farooq, A. Tfayli. (2009) Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. Journal of Clinical Pharmacy and Therapeutics 34:5, 607-610
CrossRef172
Brooke Grindlinger. (2009) Trio receives Lasker Foundation Clinical Award for breakthroughs in leukemia treatment. Journal of Clinical Investigation 119:10, 2863-2865
CrossRef173
Jennifer O. Lauchle, Doris Kim, Doan T. Le, Keiko Akagi, Michael Crone, Kimberly Krisman, Kegan Warner, Jeannette M. Bonifas, Qing Li, Kristen M. Coakley, Ernesto Diaz-Flores, Matthew Gorman, Sally Przybranowski, Mary Tran, Scott C. Kogan, Jeroen P. Roose, Neal G. Copeland, Nancy A. Jenkins, Luis Parada, Linda Wolff, Judith Sebolt-Leopold, Kevin Shannon. (2009) Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature 461:7262, 411-414
CrossRef174
O Martinho, A Longatto-Filho, M B K Lambros, A Martins, C Pinheiro, A Silva, F Pardal, J Amorim, A Mackay, F Milanezi, N Tamber, K Fenwick, A Ashworth, J S Reis-Filho, J M Lopes, R M Reis. (2009) Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. British Journal of Cancer 101:6, 973-982
CrossRef175
Daniela Cilloni, Giuseppe Saglio. (2009) CML: a model for targeted therapy. Best Practice & Research Clinical Haematology 22:3, 285-294
CrossRef176
Carolina Pavlovsky, Merrill J Egorin, Dhvani D Shah, Jan H Beumer, Silvia Rogel, Santiago Pavlovsky. (2009) Imatinib Mesylate Pharmacokinetics Before and After Sleeve Gastrectomy in a Morbidly Obese Patient with Chronic Myeloid Leukemia. Pharmacotherapy 29:9, 1152-1156
CrossRef177
G Visani, P Piccaluga, M Malagola, A Isidori. (2009) Efficacy of dasatinib in conjunction with α-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia. Leukemia 23:9, 1687-1688
CrossRef178
Alfonso Quintás-Cardama, Jorge Cortes. (2009) Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy?. Current Oncology Reports 11:5, 337-345
CrossRef179
Lars Klemm, Cihangir Duy, Ilaria Iacobucci, Stefan Kuchen, Gregor von Levetzow, Niklas Feldhahn, Nadine Henke, Zhiyu Li, Thomas K. Hoffmann, Yong-mi Kim, Wolf-Karsten Hofmann, Hassan Jumaa, John Groffen, Nora Heisterkamp, Giovanni Martinelli, Michael R. Lieber, Rafael Casellas, Markus Müschen. (2009) The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug Resistance in Chronic Myeloid Leukemia. Cancer Cell 16:3, 232-245
CrossRef180
Deepa Bhojwani, Scott C. Howard, Ching-Hon Pui. (2009) High-Risk Childhood Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma & Leukemia 9:0, S222-S230
CrossRef181
Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes. (2009) Imatinib and beyond—exploring the full potential of targeted therapy for CML. Nature Reviews Clinical Oncology 6:9, 535-543
CrossRef182
Merrill J. Egorin, Dhvani D. Shah, Susan M. Christner, Mara A. Yerk, Kristin A. Komazec, Leonard R. Appleman, Robert L. Redner, Brian M. Miller, Jan H. Beumer. (2009) Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. British Journal of Clinical Pharmacology 68:3, 370-374
CrossRef183
S. W. Lane, D. T. Scadden, D. G. Gilliland. (2009) The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 114:6, 1150-1157
CrossRef184
D A Irvine, J D Shepherd. (2009) Recurrence of lymphoid blast crisis over 20 years after successful sibling allo-SCT for CML: short lived complete cytogenetic response to imatinib. Bone Marrow Transplantation 44:4, 267-268
CrossRef185
John Anastasi. (2009) The Myeloproliferative Neoplasms: Insights into Molecular Pathogenesis and Changes in WHO Classification and Criteria for Diagnosis. Hematology/Oncology Clinics of North America 23:4, 693-708
CrossRef186
Y Chen, Y Hu, S Michaels, D Segal, D Brown, S Li. (2009) Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 23:8, 1446-1454
CrossRef187
Ali Torkamani, Gennady Verkhivker, Nicholas J. Schork. (2009) Cancer driver mutations in protein kinase genes. Cancer Letters 281:2, 117-127
CrossRef188
Keke Fan, Ernest Borden, Taolin Yi. (2009) Interferon-γ Is Induced in Human Peripheral Blood Immune Cells In Vitro by Sodium Stibogluconate/Interleukin-2 and Mediates Its Antitumor Activity In Vivo. Journal of Interferon & Cytokine Research 29:8, 451-459
CrossRef189
P Gamas, S Marchetti, A Puissant, S Grosso, A Jacquel, P Colosetti, J-M Pasquet, F-X Mahon, J-P Cassuto, P Auberger. (2009) Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells. Leukemia 23:8, 1500-1506
CrossRef190
Mi Ran Kang, Min Sung Kim, Ji Eun Oh, Yoo Ri Kim, Sang Yong Song, Seong Il Seo, Ji Youl Lee, Nam Jin Yoo, Sug Hyung Lee. (2009) Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. International Journal of Cancer 125:2, 353-355
CrossRef191
Roberto H. Nussenzveig, Jorge Cortes, Matjaz Sever, Alfonso Quintás-Cardama, Pat Ault, Taghi Manshouri, Carlos Bueso-Ramos, Josef T. Prchal, Hagop Kantarjian, Srdan Verstovsek. (2009) Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. International Journal of Hematology 90:1, 58-63
CrossRef192
Michael Darmon, Elie Azoulay. (2009) Critical care management of cancer patients: cause for optimism and need for objectivity. Current Opinion in Oncology 21:4, 318-326
CrossRef193
Yan-Lin Wei, Yun Liang, Lei Xu, Xiao-Ying Zhao. (2009) The Antiproliferation Effect of Berbamine on K562 Resistant Cells by Inhibiting NF-κB Pathway. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology 292:7, 945-950
CrossRef194
Robert A. Parise, Merrill J. Egorin, Susan M. Christner, Dhvani D. Shah, Wei Zhou, Jan H. Beumer. (2009) A high-performance liquid chromatography–mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum. Journal of Chromatography B 877:20-21, 1894-1900
CrossRef195
Thomas Armbrust, Michael Sobotta, Bastian Gunawan, Laszlo Füzesi, Claus Langer, Silke Cameron, Giuliano Ramadori. (2009) Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? – single center experience. European Journal of Gastroenterology & Hepatology 21:7, 819-823
CrossRef196
Nicola Gökbuget, B. Wassmann. (2009) New approaches to the treatment of adult acute lymphoblastic leukaemia. memo - Magazine of European Medical Oncology 2:2, 80-88
CrossRef197
James W. Watters, Pearl S. Huang. (2009) Can phenotypic pathway signatures improve the prediction of response to PI3K pathway inhibitors?. Drug Discovery Today: Therapeutic Strategies 6:2, 57-62
CrossRef198
Rüdiger Hehlmann. (2009) Leukemias. Onkopipeline 2:2, 53-58
CrossRef199
Franz Gruber, Satu Mustjoki, Kimmo Porkka. (2009) Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. British Journal of Haematology 145:5, 581-597
CrossRef200
Martin L. Sos, Kathrin Michel, Thomas Zander, Jonathan Weiss, Peter Frommolt, Martin Peifer, Danan Li, Roland Ullrich, Mirjam Koker, Florian Fischer, Takeshi Shimamura, Daniel Rauh, Craig Mermel, Stefanie Fischer, Isabel Stückrath, Stefanie Heynck, Rameen Beroukhim, William Lin, Wendy Winckler, Kinjal Shah, Thomas LaFramboise, Whei F. Moriarty, Megan Hanna, Laura Tolosi, Jörg Rahnenführer, Roel Verhaak, Derek Chiang, Gad Getz, Martin Hellmich, Jürgen Wolf, Luc Girard, Michael Peyton, Barbara A. Weir, Tzu-Hsiu Chen, Heidi Greulich, Jordi Barretina, Geoffrey I. Shapiro, Levi A. Garraway, Adi F. Gazdar, John D. Minna, Matthew Meyerson, Kwok-Kin Wong, Roman K. Thomas. (2009) Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions. Journal of Clinical Investigation 119:6, 1727-1740
CrossRef201
L. Noens, M.-A. van Lierde, R. De Bock, G. Verhoef, P. Zachee, Z. Berneman, P. Martiat, P. Mineur, K. Van Eygen, K. MacDonald, S. De Geest, T. Albrecht, I. Abraham. (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:22, 5401-5411
CrossRef202
D Mahalingam, R Swords, J S Carew, S T Nawrocki, K Bhalla, F J Giles. (2009) Targeting HSP90 for cancer therapy. British Journal of Cancer 100:10, 1523-1529
CrossRef203
Yi Le, Luhong Xu, Jiayun Lu, Jianpei Fang, Valentina Nardi, Li Chai, Leslie E. Silberstein. (2009) FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells. American Journal of Hematology 84:5, 273-278
CrossRef204
F. Castagnetti, F. Palandri, M. Amabile, N. Testoni, S. Luatti, S. Soverini, I. Iacobucci, M. Breccia, G. Rege Cambrin, F. Stagno, G. Specchia, P. Galieni, F. Iuliano, F. Pane, G. Saglio, G. Alimena, G. Martinelli, M. Baccarani, G. Rosti, . (2009) Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood 113:15, 3428-3434
CrossRef205
Andreas Peyrl, Amedeo Azizi, Thomas Czech, Mariella Gruber-Olipitz, Neil Jones, Christine Haberler, Daniela Prayer, Eva Autzinger, Irene Slavc. (2009) Tumor stabilization under treatment with imatinib in progressive hypothalamic-chiasmatic glioma. Pediatric Blood & Cancer 52:4, 476-480
CrossRef206
Patrick Brown, Steven P Hunger, Franklin O Smith, William L Carroll, Gregory H Reaman. (2009) Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Review of Hematology 2:2, 145-158
CrossRef207
Deborah L. White, Timothy P. Hughes. (2009) Predicting the response of CML patients to tyrosine kinase inhibitor therapy. Current Hematologic Malignancy Reports 4:2, 59-65
CrossRef208
Hisashi Sakamaki, Ken-ichi Ishizawa, Masafumi Taniwaki, Shin Fujisawa, Yasuo Morishima, Kensei Tobinai, Masaya Okada, Kiyoshi Ando, Noriko Usui, Shuichi Miyawaki, Atae Utsunomiya, Nobuhiko Uoshima, Tadashi Nagai, Tomoki Naoe, Toshiko Motoji, Itsuro Jinnai, Mitsune Tanimoto, Yasushi Miyazaki, Kazunori Ohnishi, Shinsuke Iida, Shinichiro Okamoto, Taku Seriu, Ryuzo Ohno. (2009) Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematology 89:3, 332-341
CrossRef209
Hongqi Li, Q. N. M. Hakim Al-arique, H. S. Yathirajan, B. Narayana, A. R. Ramesha. (2009) 4-(4-Carboxybenzyl)-1-methylpiperazin-1-ium picrate. Acta Crystallographica Section E Structure Reports Online 65:3, o518-o518
CrossRef210
Huei-Mei Huang, Juo-Chuan Liu. (2009) c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors. Journal of Cellular Physiology 218:3, 568-574
CrossRef211
Chikara Hirase, Yasuhiro Maeda, Shunsuke Takai, Akihisa Kanamaru. (2009) Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor. Leukemia Research 33:3, 450-459
CrossRef212
Jing Jin Gu, Jae Ryun Ryu, Ann Marie Pendergast. (2009) Abl tyrosine kinases in T-cell signaling. Immunological Reviews 228:1, 170-183
CrossRef213
A. Quintas-Cardama, J. Cortes. (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:8, 1619-1630
CrossRef214
S. Serdar Dogan, Bita Esmaeli. (2009) Ocular Side Effects Associated with Imatinib Mesylate and Perifosine for Gastrointestinal Stromal Tumor. Hematology/Oncology Clinics of North America 23:1, 109-114
CrossRef215
Karina Galoian, Sean Scully, Armen Galoyan. (2009) Myc-oncogene Inactivating Effect by Proline Rich Polypeptide (PRP-1) in Chondrosarcoma JJ012 Cells. Neurochemical Research 34:2, 379-385
CrossRef216
Brian A. Sparano, Merrill J. Egorin, Robert A. Parise, Jennifer Walters, Kristin A. Komazec, Robert L. Redner, Jan H. Beumer. (2009) Effect of antacid on imatinib absorption. Cancer Chemotherapy and Pharmacology 63:3, 525-528
CrossRef217
S. Haihua Chu, Donald Small. (2009) Mechanisms of resistance to FLT3 inhibitors. Drug Resistance Updates 12:1-2, 8-16
CrossRef218
Ayalew Tefferi. (2009) Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. Journal of Cellular and Molecular Medicine 13:2, 215-237
CrossRef219
Michael A. Teitell, Pier Paolo Pandolfi. (2009) Molecular Genetics of Acute Lymphoblastic Leukemia. Annual Review of Pathology: Mechanisms of Disease 4:1, 175-198
CrossRef220
T. Negri, G. M. Pavan, E. Virdis, A. Greco, M. Fermeglia, M. Sandri, S. Pricl, M. A. Pierotti, S. Pilotti, E. Tamborini. (2009) T670X KIT Mutations in Gastrointestinal Stromal Tumors: Making Sense of Missense. JNCI Journal of the National Cancer Institute 101:3, 194-204
CrossRef221
Sun Kyung Baek, Kyung Sam Cho, Byung Hyuk Yang, Si-Young Kim, Hwi-Joong Yoon, Kyunghwan Jeong, Chun Gyoo Ihm. (2009) Complete Hematologic Response and Cytogenetic Remission after Imatinib and Dexamethasone Treatment of a Ph+ Precursor B-cell Acute Lymphoblastic Leukemia in Renal Transplantation Patient. The Korean Journal of Hematology 44:1, 62
CrossRef222
Mario Tiribelli, Alessandra Sperotto, Anna Candoni, Erica Simeone, Silvia Buttignol, Renato Fanin. (2009) Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leukemia Research 33:1, 174-177
CrossRef223
Masamitsu Yanada, Ryuzo Ohno, Tomoki Naoe. (2009) Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematology 89:1, 3-13
CrossRef224
Sima Jeha. (2009) New Therapeutic Strategies in Acute Lymphoblastic Leukemia. Seminars in Hematology 46:1, 76-88
CrossRef225
Wan-Seok Kim, Dongho Kim, Dong-Wook Kim, Il-Young Kweon, Soo-Hyun Kim, Hyun-Gyung Goh, Sa-Hee Park, Jeong Lee. (2009) Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. Hematological Oncologyn/a-n/a
CrossRef226
Fabio P. S. Santos, Farhad Ravandi. (2009) Advances in treatment of chronic myelogenous leukemia – new treatment options with tyrosine kinase inhibitors. Leukemia & Lymphoma 50:s2, 16-26
CrossRef227
Ayalew Tefferi, Ross L. Levine, Hagop Kantarjian. (2009) Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation 15:1, 114-119
CrossRef228
Hideto KAMEDA. (2009) Imatinib. Japanese Journal of Clinical Immunology 32:2, 77-84
CrossRef229
Monika Conchon, Sabri S. Sanabani, Israel Bendit, Carla Luana Dinardo, Lucia Dias, Dalton de Alencar Fischer Chamone, Pedro Enrique Dorlhiac-Llacer, Frederico Luiz Dulley. (2009) The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation. Journal of Transplantation 2009, 1-4
CrossRef230
Mike G. Martin, John F. Dipersio, Geoffrey L. Uy. (2009) Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia & Lymphoma 50:1, 14-23
CrossRef231
Jorge H. Milone, Alicia Enrico. (2009) Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia & Lymphoma 50:s2, 9-15
CrossRef232
B. J. Druker. (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112:13, 4808-4817
CrossRef233
Zahra Ghiassi-Nejad, Scott L Friedman. (2008) Advances in antifibrotic therapy. Expert Review of Gastroenterology & Hepatology 2:6, 803-816
CrossRef234
Frank Neumann, Judith Markett, Roland Fenk, Monika Pooten, Anne Koch, Daniela Bruennert, Nadine Schimkus, Michael Wulfert, Brigitte Royer-Pokora, Ralf Kronenwett, Rainer Haas, Norbert Gattermann. (2008) Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study. Hematological Oncology 26:4, 213-218
CrossRef235
Scott L. Friedman. (2008) Hepatic fibrosis—Overview. Toxicology 254:3, 120-129
CrossRef236
T. P. Hughes, S. Branford, D. L. White, J. Reynolds, R. Koelmeyer, J. F. Seymour, K. Taylor, C. Arthur, A. Schwarer, J. Morton, J. Cooney, M. F. Leahy, P. Rowlings, J. Catalano, M. Hertzberg, R. Filshie, A. K. Mills, K. Fay, S. Durrant, H. Januszewicz, D. Joske, C. Underhill, S. Dunkley, K. Lynch, A. Grigg, . (2008) Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112:10, 3965-3973
CrossRef237
Peter Valent, Thomas Lion, Dominik Wolf, Christian Sillaber, Hermine Agis, Andreas Petzer, Alois Lang, Peter Kalhs, Dietmar Geissler, Richard Greil, Werner Linkesch, Sonja Burgstaller, Josef Thaler, Günther Gastl. (2008) Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Wiener klinische Wochenschrift 120:21-22, 697-709
CrossRef238
Y Kamitsuji, J Kuroda, S Kimura, S Toyokuni, K Watanabe, E Ashihara, H Tanaka, Y Yui, M Watanabe, H Matsubara, Y Mizushima, Y Hiraumi, E Kawata, T Yoshikawa, T Maekawa, T Nakahata, S Adachi. (2008) The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death and Differentiation 15:11, 1712-1722
CrossRef239
Hui Han, Yang-yang Yu, Yu-hong Wang. (2008) Imatinib mesylate–induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors. Journal of the American Academy of Dermatology 59:5, S80-S83
CrossRef240
Masahiro Kizaki, Shinichiro Okamoto, Tetsuzo Tauchi, Hideo Tanaka, Mitsune Tanimoto, Koiti Inokuchi, Tohru Murayama, Yoshio Saburi, Masayuki Hino, Mitsuru Tsudo, Taizo Shimomura, Yasushi Isobe, . (2008) Current and future perspectives on the TARGET system: the registration system for Glivec® established by the JSH. International Journal of Hematology 88:4, 409-417
CrossRef241
Asumi Yokota, Shinya Kimura. (2008) Novel agents to override imatinib resistance mechanisms. Drug Development Research 69:7, 398-406
CrossRef242
H Bittencourt, V Funke, L Fogliatto, S Magalhães, D Setubal, A Paz, A V Macedo, J Ruiz, A P Azambuja, L Silla, N Clementino, R Pasquini. (2008) Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplantation 42:9, 597-600
CrossRef243
Ju-Huei Chien, Jih-Luh Tang, Rong-Long Chen, Chi-Cheng Li, Chan Ping Lee. (2008) Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy. Leukemia Research 32:11, 1724-1734
CrossRef244
Makoto Yoshimitsu, Hiroshi Fujiwara, Atsuo Ozaki, Heiichiro Hamada, Kakushi Matsushita, Naomichi Arima, Chuwa Tei. (2008) Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions. International Journal of Hematology 88:3, 331-335
CrossRef245
Alfonso Quintás-Cardama, Jorge Cortes. (2008) Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncology 4:5, 611-621
CrossRef246
R. L. Levine, D. G. Gilliland. (2008) Myeloproliferative disorders. Blood 112:6, 2190-2198
CrossRef247
Yasser R. Abou Mourad, Hugo F. Fernandez, Mohamed A. Kharfan-Dabaja. (2008) Allogeneic Hematopoietic Cell Transplantation for Adult Philadelphia-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. Biology of Blood and Marrow Transplantation 14:9, 949-958
CrossRef248
Ryuzo Ohno. (2008) Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Current Oncology Reports 10:5, 379-387
CrossRef249
Thomas Force, Risto Kerkelä. (2008) Cardiotoxicity of the new cancer therapeutics – mechanisms of, and approaches to, the problem. Drug Discovery Today 13:17-18, 778-784
CrossRef250
Conrad Kunick, Anne-Marie Egert-Schmidt. (2008) Die kurze Geschichte der Proteinkinase-Inhibitoren. Jung, kompetitiv, erfolgreich. Pharmazie in unserer Zeit 37:5, 360-368
CrossRef251
Janusz Rak, Chloe Milsom, Joanne Yu. (2008) Tissue factor in cancer. Current Opinion in Hematology 15:5, 522-528
CrossRef252
Ruriko Tanaka, Shinya Kimura. (2008) Abl tyrosine kinase inhibitors for overriding Bcr–Abl/T315I: from the second to third generation. Expert Review of Anticancer Therapy 8:9, 1387-1398
CrossRef253
Daniela Matei, Robert E. Emerson, Jeanne Schilder, Nancy Menning, Lee Ann Baldridge, Cynthia S. Johnson, Tim Breen, John McClean, Doyle Stephens, Charles Whalen, Gregory Sutton. (2008) Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis. Cancer 113:4, 723-732
CrossRef254
A Koch, M Scherr, B Breyer, A Mancini, C Kardinal, K Battmer, M Eder, T Tamura. (2008) Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr–Abl transformed cells via the alteration of signaling complex and the receptor turnover. Oncogene 27:34, 4678-4689
CrossRef255
Lars Möllgård, Stefan Deneberg, Hareth Nahi, Sofia Bengtzen, Kerstin Jonsson-Videsäter, Thoas Fioretos, Anna Andersson, Christer Paul, Sören Lehmann. (2008) The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. Cancer Chemotherapy and Pharmacology 62:3, 439-448
CrossRef256
G. G. Laport, J. C. Alvarnas, J. M. Palmer, D. S. Snyder, M. L. Slovak, A. M. Cherry, R. M. Wong, R. S. Negrin, K. G. Blume, S. J. Forman. (2008) Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood 112:3, 903-909
CrossRef257
Carolyn Waugh Kinkade, Mireia Castillo-Martin, Anna Puzio-Kuter, Jun Yan, Thomas H. Foster, Hui Gao, Yvonne Sun, Xuesong Ouyang, William L. Gerald, Carlos Cordon-Cardo, Cory Abate-Shen. (2008) Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. Journal of Clinical Investigation
CrossRef258
Giovanni Tonon. (2008) From oncogene to network addiction: the new frontier of cancer genomics and therapeutics. Future Oncology 4:4, 569-577
CrossRef259
Peter Valent. (2008) Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. British Journal of Haematology 142:3, 361-378
CrossRef260
Sarah Larson, Wendy Stock. (2008) Progress in the treatment of adults with acute lymphoblastic leukemia. Current Opinion in Hematology 15:4, 400-407
CrossRef261
Joseph A. Ludwig. (2008) Personalized therapy of sarcomas: Integration of biomarkers for improved diagnosis, prognosis, and therapy selection. Current Oncology Reports 10:4, 329-337
CrossRef262
Chandan Kumar-Sinha, Scott A. Tomlins, Arul M. Chinnaiyan. (2008) Recurrent gene fusions in prostate cancer. Nature Reviews Cancer 8:7, 497-511
CrossRef263
Catherine E. Lewis, Michael W. Yeh. (2008) Inherited endocrinopathies: An update. Molecular Genetics and Metabolism 94:3, 271-282
CrossRef264
A Lakshmikuttyamma, E Pastural, N Takahashi, K Sawada, D P Sheridan, J F DeCoteau, C R Geyer. (2008) Bcr-Abl induces autocrine IGF-1 signaling. Oncogene 27:27, 3831-3844
CrossRef265
Simona Soverini, Giovanni Martinelli, Ilaria Iacobucci, Michele Baccarani. (2008) Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Review of Anticancer Therapy 8:6, 853-864
CrossRef266
Yuichi Takayama, Toshio Kokuryo, Yukihiro Yokoyama, Masato Nagino, Yuji Nimura, Takeshi Senga, Michinari Hamaguchi. (2008) MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth. Cancer Letters 264:2, 241-249
CrossRef267
Yuya Sugimoto, Satoki Nakamura, Keiji Okinaka, Isao Hirano, Takaaki Ono, Kazuyuki Shigeno, Kaori Shinjo, Kazunori Ohnishi. (2008) HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells. Leukemia Research 32:6, 962-971
CrossRef268
Taghi Manshouri, Alfonso Quintás-Cardama, Roberto H. Nussenzveig, Amos Gaikwad, Zeev Estrov, Josef Prchal, Jorge E. Cortes, Hagop M. Kantarjian, Srdan Verstovsek. (2008) The JAK kinase inhibitor CP-690,550 supresses the growth of human polycythemia vera cells carrying the JAK2 V617F mutation. Cancer Science 99:6, 1265-1273
CrossRef269
Daigo Akahane, Tetsuzo Tauchi, Seiichi Okabe, Kousuke Nunoda, Kazuma Ohyashiki. (2008) Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: In vitro and in vivo studies. Cancer Science 99:6, 1251-1257
CrossRef270
Thomas O'Hare, Christopher A Eide, Michael W Deininger. (2008) New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opinion on Investigational Drugs 17:6, 865-878
CrossRef271
Tadashi Nagai, Satoru Kikuchi, Ken Ohmine, Takuji Miyoshi, Makiko Nakamura, Takahito Kondo, Kazumichi Furuyama, Norio Komatsu, Keiya Ozawa. (2008) Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2. Journal of Cellular Biochemistry 104:2, 680-691
CrossRef272
M S Kim, E G Jeong, N J Yoo, S H Lee. (2008) Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. British Journal of Cancer 98:9, 1533-1535
CrossRef273
Cristina Montiel-Duarte, Lucia Cordeu, Xabier Agirre, José Román-Gómez, Antonio Jiménez-Velasco, Edurne San José-Eneriz, Leire Gárate, Enrique J. Andreu, Maria José Calasanz, Anabel Heiniger, Antonio Torres, Felipe Prósper. (2008) Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leukemia Research 32:5, 709-716
CrossRef274
Vasantha Thavaraj, Rachna Seth. (2008) Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate. World Journal of Pediatrics 4:2, 145-147
CrossRef275
Christopher Christophi, Nadia Harun, Theodora Fifis. (2008) Liver Regeneration and Tumor Stimulation—A Review of Cytokine and Angiogenic Factors. Journal of Gastrointestinal Surgery 12:5, 966-980
CrossRef276
Andreas Trumpp, Otmar D Wiestler. (2008) Mechanisms of Disease: cancer stem cells—targeting the evil twin. Nature Clinical Practice Oncology
CrossRef277
T. O'Hare, C. A. Eide, J. W. Tyner, A. S. Corbin, M. J. Wong, S. Buchanan, K. Holme, K. A. Jessen, C. Tang, H. A. Lewis, R. D. Romero, S. K. Burley, M. W. Deininger. (2008) SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proceedings of the National Academy of Sciences 105:14, 5507-5512
CrossRef278
J. G. Harb, B. I. Chyla, C. S. Huettner. (2008) Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis. Blood 111:7, 3760-3769
CrossRef279
Chie Hirayama, Hiroshi Watanabe, Reiko Nakashima, Takeru Nanbu, Akinobu Hamada, Akihiko Kuniyasu, Hitoshi Nakayama, Tatsuya Kawaguchi, Hideyuki Saito. (2008) Constitutive Overexpression of P-glycoprotein, Rather than Breast Cancer Resistance Protein or Organic Cation Transporter 1, Contributes to Acquisition of Imatinib-Resistance in K562 Cells. Pharmaceutical Research 25:4, 827-835
CrossRef280
Gerlinde Wernig, Michael G. Kharas, Rachel Okabe, Sandra A. Moore, Dena S. Leeman, Dana E. Cullen, Maricel Gozo, Elizabeth P. McDowell, Ross L. Levine, John Doukas, Chi Ching Mak, Glenn Noronha, Michael Martin, Yon D. Ko, Benjamin H. Lee, Richard M. Soll, Ayalew Tefferi, John D. Hood, D. Gary Gilliland. (2008) Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera. Cancer Cell 13:4, 311-320
CrossRef281
M. Copland, F. Pellicano, L. Richmond, E. K. Allan, A. Hamilton, F. Y. Lee, R. Weinmann, T. L. Holyoake. (2008) BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111:5, 2843-2853
CrossRef282
Ayalew Tefferi, Hagop Kantarjian. (2008) Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia—Remarkable activity with room for improvement. American Journal of Hematology 83:3, 175-177
CrossRef283
Georg Hess, Ralf G. Meyer, Brigitte Schuch, Katja Bechthold, Ilse El-Kholy, Christoph Huber. (2008) Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: A 5-year follow up. American Journal of Hematology 83:3, 178-184
CrossRef284
Falko Fend, Alexandar Tzankov, Karin Bink, Stefan Seidl, Leticia Quintanilla-Martinez, Marcus Kremer, Stephan Dirnhofer. (2008) Modern techniques for the diagnostic evaluation of the trephine bone marrow biopsy: Methodological aspects and applications. Progress in Histochemistry and Cytochemistry 42:4, 203-252
CrossRef285
Michela Palmisano, Tiziana Grafone, Matteo Renzulli, Emanuela Ottaviani, Nicoletta Testoni, Stefania Paolini, Cristina Papayannidis, Michele Baccarani, Giovanni Martinelli. (2008) Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. Hematology 13:1, 1-12
CrossRef286
Helene François, Paul Coppo, Jean-Philippe Hayman, Bruno Fouqueray, Béatrice Mougenot, Pierre Ronco. (2008) Partial Fanconi Syndrome Induced by Imatinib Therapy: A Novel Cause of Urinary Phosphate Loss. American Journal of Kidney Diseases 51:2, 298-301
CrossRef287
Lecia V. Sequist, Thomas J. Lynch. (2008) EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story. Annual Review of Medicine 59:1, 429-442
CrossRef288
Daniela D. Rosa, Gustavo Ismael, Lissandra Dal Lago, Ahmad Awada. (2008) Molecular-targeted therapies: Lessons from years of clinical development. Cancer Treatment Reviews 34:1, 61-80
CrossRef289
Mason Bond, Mark L. Bernstein, Alberto Pappo, Kirk R. Schultz, Mark Krailo, Susan M. Blaney, Peter C. Adamson. (2008) A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. Pediatric Blood & Cancer 50:2, 254-258
CrossRef290
Henry T. Lynch, Edibaldo Silva, Carrie Snyder, Jane F. Lynch. (2008) Hereditary Breast Cancer: Part I. Diagnosing Hereditary Breast Cancer Syndromes. The Breast Journal 14:1, 3-13
CrossRef291
Shigeki Yagyu, Akira Morimoto, Naoki Kakazu, Shinichi Tamura, Atsushi Fujiki, Yoko Nakase, Tomoko Iehara, Hajime Hosoi, Hiroshi Kuroda. (2008) Late appearance of a Philadelphia chromosome in a patient with therapy-related acute myeloid leukemia and high expression of EVI1. Cancer Genetics and Cytogenetics 180:2, 115-120
CrossRef292
C. Sillaber, M. Mayerhofer, A. Böhm, A. Vales, A. Gruze, K. J. Aichberger, H. Esterbauer, M. Pfeilstöcker, W. R. Sperr, W. F. Pickl, O. A. Haas, P. Valent. (2008) Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. European Journal of Clinical Investigation 38:1, 43-52
CrossRef293
Xavier Thomas, Hervé Dombret. (2008) Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leukemia & Lymphoma 49:7, 1246-1254
CrossRef294
Rowena S Lewis, Alister C Ward. (2008) Stat5 as a diagnostic marker for leukemia. Expert Review of Molecular Diagnostics 8:1, 73-82
CrossRef295
Karen R. Rabin, Judith Margolin, David G. Poplack. 2008. Molecular Genetics of ALL. , 361-370.
CrossRef296
Priya Koppikar, Ross L. Levine. (2008) JAK2 and MPL Mutations in Myeloproliferative Neoplasms. Acta Haematologica 119:4, 218-225
CrossRef297
A Tefferi. (2008) The history of myeloproliferative disorders: before and after Dameshek. Leukemia 22:1, 3-13
CrossRef298
R. L. Levine, M. Heaney. (2008) New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia. Hematology 2008:1, 76-82
CrossRef299
Lisa A. Hammond-Thelin. (2008) Cutaneous Reactions Related to Systemic Immunomodulators and Targeted Therapeutics. Dermatologic Clinics 26:1, 121-159
CrossRef300
Dragana Milojkovic, Jane Apperley. (2008) State-of-the-art in the treatment of chronic myeloid leukaemia. Current Opinion in Oncology 20:1, 112-121
CrossRef301
Johanna Buchstaller, Elsa Quintana, Sean J. Morrison. 2008. Cancer Stem Cells. , 141-154.
CrossRef302
Tomasz Skorski. (2008) BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts. Leukemia & Lymphoma 49:4, 610-614
CrossRef303
Alfonso Quintás-Cardama, Jorge Cortes, Hagop Kantarjian. 2008. Biology of Chronic and Acute Myeloid Leukemia. , 371-383.
CrossRef304
Shaoguang Li. (2008) Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leukemia & Lymphoma 49:1, 19-26
CrossRef305
Zainab Jagani, Amrik Singh, Roya Khosravi-Far. (2008) FoxO tumor suppressors and BCR–ABL-induced leukemia: A matter of evasion of apoptosis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1785:1, 63-84
CrossRef306
Pierre-Jean Saulnier, Florence Dalbiès, Christian Berthou, François Guilhot, Nicolas Bourmeyster, Jean-claude Chomel, Ali Thuran. (2008) Prolonged molecular remission in advanced phase of chronic myeloid leukemia using combination of imatinib and high-dose chemotherapy. Leukemia & Lymphoma 49:4, 815-816
CrossRef307
Christine Fernandez, Christine Fernandez, Véronique Leblond, Johnny Moretto. 2008. Traitement des leucémies. , 655-670.
CrossRef308
Xanthi N. Stahtea, Andeas E. Roussidis, Ioannis Kanakis, George N. Tzanakakis, George Chalkiadakis, Dimitris Mavroudis, Dimitris Kletsas, Nikos K. Karamanos. (2007) Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. International Journal of Cancer 121:12, 2808-2814
CrossRef309
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li, Yerong Hu, Zhiping Tan, Matthew Stokes, Laura Sullivan, Jeffrey Mitchell, Randy Wetzel, Joan MacNeill, Jian Min Ren, Jin Yuan, Corey E. Bakalarski, Judit Villen, Jon M. Kornhauser, Bradley Smith, Daiqiang Li, Xinmin Zhou, Steven P. Gygi, Ting-Lei Gu, Roberto D. Polakiewicz, John Rush, Michael J. Comb. (2007) Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer. Cell 131:6, 1190-1203
CrossRef310
Daniele Santini, Sara Galluzzo, Maria Elisabetta Fratto, Bruno Vincenzi, Silvia Angeletti, Giordano Dicuonzo, Gaia Schiavon, Giuseppe Tonini. (2007) Bisphosphonates: from preclinical evidence to survival data in the oncologic setting. Oncology Reviews 1:3, 141-151
CrossRef311
Shaoguang Li, Dongguang Li. (2007) Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors. Journal of Cellular and Molecular Medicine 11:6, 1251-1262
CrossRef312
Daniela S. Krause, Richard A. Van Etten. (2007) Right on target: eradicating leukemic stem cells. Trends in Molecular Medicine 13:11, 470-481
CrossRef313
Kimbach T Carpiuc, Jennifer M Stephens, Marc F Botteman, Weiwei Feng, Joel W Hay. (2007) A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy 8:16, 2775-2787
CrossRef314
Mingqun Lin, Amke den Dulk-Ras, Paul J. J. Hooykaas, Yasuko Rikihisa. (2007) Anaplasma phagocytophilum AnkA secreted by type IV secretion system is tyrosine phosphorylated by Abl-1 to facilitate infection. Cellular Microbiology 9:11, 2644-2657
CrossRef315
Robyn P. Araujo, Lance A. Liotta, Emanuel F. Petricoin. (2007) Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nature Reviews Drug Discovery 6:11, 871-880
CrossRef316
Gaurav D. Shah, Joel S. Silver, Steven S. Rosenfeld, Igor T. Gavrilovic, Lauren E. Abrey, Andrew B. Lassman. (2007) Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas. Journal of Neuro-Oncology 85:2, 217-222
CrossRef317
Steffen Koschmieder, Hubert L. Serve. 2007. Models for Human Leukaemias. .
CrossRef318
John G. Gribben. 2007. Management of Haematological Malignancies. .
CrossRef319
R A Van Etten. (2007) Aberrant cytokine signaling in leukemia. Oncogene 26:47, 6738-6749
CrossRef320
Lisa A. Kujawski, Moshe Talpaz. (2007) The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine & Growth Factor Reviews 18:5-6, 459-471
CrossRef321
Pierre J. Dilda, Philip J. Hogg. (2007) Arsenical-based cancer drugs. Cancer Treatment Reviews 33:6, 542-564
CrossRef322
Pier Paolo Piccaluga, Michela Rondoni, Stefania Paolini, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani. (2007) Imatinib mesylate in the treatment of hematologic malignancies. Expert Opinion on Biological Therapy 7:10, 1597-1611
CrossRef323
Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes. (2007) Flying under the radar: the new wave of BCR–ABL inhibitors. Nature Reviews Drug Discovery 6:10, 834-848
CrossRef324
Pier Paolo Piccaluga, Stefania Paolini, Giovanni Martinelli. (2007) Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 110:6, 1178-1186
CrossRef325
Paolo Neviani, Ramasamy Santhanam, Joshua J. Oaks, Anna M. Eiring, Mario Notari, Bradley W. Blaser, Shujun Liu, Rossana Trotta, Natarajan Muthusamy, Carlo Gambacorti-Passerini, Brian J. Druker, Jorge Cortes, Guido Marcucci, Ching-Shih Chen, Nicole M. Verrills, Denis C. Roy, Michael A. Caligiuri, Clara D. Bloomfield, John C. Byrd, Danilo Perrotti. (2007) FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia. Journal of Clinical Investigation 117:9, 2408-2421
CrossRef326
Steven Knapper. (2007) FLT3 inhibition in acute myeloid leukaemia. British Journal of Haematology 138:6, 687-699
CrossRef327
Guang-biao ZHOU, Guo LI, Sai-juan CHEN, Zhu CHEN. (2007) From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. Acta Pharmacologica Sinica 28:9, 1434-1449
CrossRef328
Jin DING, Yun FENG, Hong-yang WANG. (2007) From cell signaling to cancer therapy. Acta Pharmacologica Sinica 28:9, 1494-1498
CrossRef329
Ming Zhan. (2007) Deciphering modular and dynamic behaviors of transcriptional networks. Genomic Medicine 1:1-2, 19-28
CrossRef330
Daniel W. Sherbenou, Brian J. Druker. (2007) Applying the discovery of the Philadelphia chromosome. Journal of Clinical Investigation 117:8, 2067-2074
CrossRef331
Mirja Nurmio, Jorma Toppari, Farasat Zaman, Anna-Maria Andersson, Jorma Paranko, Olle Söder, Kirsi Jahnukainen. (2007) Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. International Journal of Andrology 30:4, 366-376
CrossRef332
Gary A. Koretzky. (2007) The legacy of the Philadelphia chromosome. Journal of Clinical Investigation 117:8, 2030-2032
CrossRef333
Rosângela Teixeira, Luis A. Marcos, Scott L. Friedman. (2007) Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. Hepatology Research 37:8, 579-595
CrossRef334
Tony Hunter. (2007) Treatment for chronic myelogenous leukemia: the long road to imatinib. Journal of Clinical Investigation 117:8, 2036-2043
CrossRef335
Andreas Burchert. (2007) Roots of imatinib resistance: A question of self-renewal?. Drug Resistance Updates 10:4-5, 152-161
CrossRef336
Baijun Fang, Yongping Song, Yanli Zhang, Quande Lin, Xudong Wei. (2007) Characterization of cancer stem-like cells in a novel STI571-resistant chronic myeloid leukemia cell line. The Chinese-German Journal of Clinical Oncology 6:4, 383-388
CrossRef337
Rüdiger Hehlmann, Andreas Hochhaus, Michele Baccarani. (2007) Chronic myeloid leukaemia. The Lancet 370:9584, 342-350
CrossRef338
Deborah A. Thomas, Susan O’Brien, Jorge Cortes, Hagop Kantarjian. (2007) New approaches to the management of Philadelphia chromosome-positive acute lymphocytic leukemia. Current Hematologic Malignancy Reports 2:3, 183-189
CrossRef339
Chikamasa Yoshida, Kenji Niiya, Masami Niiya, Misako Shibakura, Noboru Asaumi, Mitsune Tanimoto. (2007) Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells. Blood Coagulation & Fibrinolysis 18:5, 425-433
CrossRef340
H Menzel, N von Bubnoff, A Hochhaus, C Haferlach, C Peschel, J Duyster. (2007) Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib. Bone Marrow Transplantation 40:1, 83-84
CrossRef341
Sergio A. Giralt, Mukta Arora, John M. Goldman, Stephanie J. Lee, Richard T. Maziarz, Philip L. McCarthy, Kathleen A. Sobocinski, Mary M. Horowitz, . (2007) Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. British Journal of Haematology 137:5, 461-467
CrossRef342
L Alex Gaither. (2007) Chemogenomics approaches to novel target discovery. Expert Review of Proteomics 4:3, 411-419
CrossRef343
C Brendel, C Scharenberg, M Dohse, R W Robey, S E Bates, S Shukla, S V Ambudkar, Y Wang, G Wennemuth, A Burchert, U Boudriot, A Neubauer. (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21:6, 1267-1275
CrossRef344
S. Pursche, O.G. Ottmann, G. Ehninger, E. Schleyer. (2007) High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations. Journal of Chromatography B 852:1-2, 208-216
CrossRef345
G.M.T. Cheetham, P.A. Charlton, J.M.C. Golec, J.R. Pollard. (2007) Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Letters 251:2, 323-329
CrossRef346
Sung Hak Lee, Eun Goo Jeong, Suk Woo Nam, Jung Young Lee, Nam Jin Yoo, Sug Hyung Lee. (2007) Increased expression of Gab2, a scaffolding adaptor of the tyrosine kinase signalling, in gastric carcinomas. Pathology 39:3, 326-329
CrossRef347
R P Kuiper, E F P M Schoenmakers, S V van Reijmersdal, J Y Hehir-Kwa, A Geurts van Kessel, F N van Leeuwen, P M Hoogerbrugge. (2007) High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 21:6, 1258-1266
CrossRef348
G Iotti, G Ferrari-Amorotti, C Rosafio, F Corradini, M R Lidonnici, M Ronchetti, M Bardini, Y Zhang, R Martinez, F Blasi, B Calabretta. (2007) Expression of CCL9/MIP-1γ is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells. Oncogene 26:24, 3482-3491
CrossRef349
Oliver G. Ottmann, Barbara Wassmann, Heike Pfeifer, Aristoteles Giagounidis, Matthias Stelljes, Ulrich Dührsen, Marc Schmalzing, Lydia Wunderle, Anja Binckebanck, Dieter Hoelzer, . (2007) Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 109:10, 2068-2076
CrossRef350
Thomas Force, Daniela S. Krause, Richard A. Van Etten. (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer 7:5, 332-344
CrossRef351
Tatsuya Horio, Tomohiro Hamasaki, Toshihiko Inoue, Tatsushi Wakayama, Shinsaku Itou, Haruna Naito, Tetsuo Asaki, Hiroki Hayase, Tomoko Niwa. (2007) Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Bioorganic & Medicinal Chemistry Letters 17:10, 2712-2717
CrossRef352
Georg Häcker, Stefan A Paschen. (2007) Therapeutic targets in the mitochondrial apoptotic pathway. Expert Opinion on Therapeutic Targets 11:4, 515-526
CrossRef353
Torsten Haferlach, Ulrike Bacher, Wolfgang Kern, Susanne Schnittger, Claudia Haferlach. (2007) Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. Annals of Hematology 86:5, 311-327
CrossRef354
Zeba Aziz, Javaid Iqbal, Mohammad Akram, Sarah Saeed. (2007) Treatment of chronic myeloid leukemia in the imatinib era. Cancer 109:6, 1138-1145
CrossRef355
M Pérez-Caro, N Gutierrez-Cianca, I González-Herrero, I López-Hernández, T Flores, A Orfao, M Sánchez-Martín, A Gutiérrez-Adán, B Pintado, I Sánchez-García. (2007) Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice. Oncogene 26:12, 1702-1713
CrossRef356
F. Weissinger, D. Fabbro, H. Einsele. (2007) Signalübermittlungsinhibitoren. Der Onkologe 13:3, 213-226
CrossRef357
V Brazzelli, F Prestinari, T Barbagallo, C Rona, E Orlandi, F Passamonti, F Locatelli, M Zecca, S Villani, G Borroni. (2007) A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. Journal of the European Academy of Dermatology and Venereology 21:3, 384-387
CrossRef358
G. LeMarbre, C. Schinstock, R. Hoyer, J. Krook, A. Tefferi. (2007) Late onset aplastic anemia during treatment of chronic myeloid leukemia with imatinib mesylate. Leukemia Research 31:3, 414-415
CrossRef359
Yesid Alvarado, Effrosyni Apostolidou, Ronan Swords, Francis J Giles. (2007) Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia. Expert Opinion on Emerging Drugs 12:1, 165-179
CrossRef360
Suresh Ramalingam, Chandra P Belani. (2007) Recent advances in targeted therapy for non-small cell lung cancer. Expert Opinion on Therapeutic Targets 11:2, 245-257
CrossRef361
Ching-Hon Pui, Sima Jeha. (2007) New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nature Reviews Drug Discovery 6:2, 149-165
CrossRef362
Claudiu V. Cotta, Carlos E. Bueso-Ramos. (2007) New insights into the pathobiology and treatment of chronic myelogenous leukemia. Annals of Diagnostic Pathology 11:1, 68-78
CrossRef363
Sudhir Srivastava, Paul D Wagner. (2007) Risk-based and diagnostics-linked personalized medicine for cancer. Personalized Medicine 4:1, 33-43
CrossRef364
D. A. Thomas. (2007) Philadelphia Chromosome Positive Acute Lymphocytic Leukemia: A New Era of Challenges. Hematology 2007:1, 435-443
CrossRef365
Martin Weisser, Michael Schleuning, Claudia Haferlach, Rainer Schwerdtfeger, Hans Jochem Kolb. (2007) Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leukemia & Lymphoma 48:2, 295-301
CrossRef366
Hideto KAMEDA. (2007) Imatinib mesylate as a novel therapeutic drug for systemic rheumatic diseases. Japanese Journal of Clinical Immunology 30:3, 165-173
CrossRef367
Andreas Hochhaus, Philipp Erben, Thomas Ernst, Martin C. Mueller. (2007) Resistance to Targeted Therapy in Chronic Myelogenous Leukemia. Seminars in Hematology 44, 15-24
CrossRef368
S. Barete. (2007) Mastocitosis. EMC - Dermatolog??a 41:2, 1-17
CrossRef369
Thomas Force. (2007) In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nature Medicine 13:1, 15-16
CrossRef370
JONG WOO LEE, EUN GOO JEONG, SUNG HAK LEE, SUK WOO NAM, SANG HO KIM, JUNG YOUNG LEE, NAM JIN YOO, SUG HYUNG LEE. (2007) Mutational analysis of PTPRT phosphatase domains in common human cancers. APMIS 115:1, 47-51
CrossRef371
Steven J. Bark, Vivian Hook. (2007) The future of proteomic analysis in biological systems and molecular medicine. Molecular BioSystems 3:1, 14
CrossRef372
Sarah A Cross, Katherine A Lyseng-Williamson. (2007) Imatinib. Drugs 67:17, 2645-2654
CrossRef373
J. P. Radich. (2007) The Biology of CML Blast Crisis. Hematology 2007:1, 384-391
CrossRef374
Christine H. Chung, Shawn Levy, Pierre Chaurand, David P. Carbone. (2007) Genomics and proteomics: Emerging technologies in clinical cancer research. Critical Reviews in Oncology/Hematology 61:1, 1-25
CrossRef375
Michele Bianchini, Giovanni Martinelli, Matteo Renzulli, Marcela Gonzalez Cid, Irene Larripa. (2006) cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib. Cancer Chemotherapy and Pharmacology 59:3, 349-360
CrossRef376
Martin Weisser, Georg Ledderose, Hans Jochem Kolb. (2006) Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over the last decade. Annals of Hematology 86:2, 127-132
CrossRef377
Druker, Brian J., Guilhot, François, O'Brien, Stephen G., Gathmann, Insa, Kantarjian, Hagop, Gattermann, Norbert, Deininger, Michael W.N., Silver, Richard T., Goldman, John M., Stone, Richard M., Cervantes, Francisco, Hochhaus, Andreas, Powell, Bayard L., Gabrilove, Janice L., Rousselot, Philippe, Reiffers, Josy, Cornelissen, Jan J., Hughes, Timothy, Agis, Hermine, Fischer, Thomas, Verhoef, Gregor, Shepherd, John, Saglio, Giuseppe, Gratwohl, Alois, Nielsen, Johan L., Radich, Jerald P., Simonsson, Bengt, Taylor, Kerry, Baccarani, Michele, So, Charlene, Letvak, Laurie, Larson, Richard A., . (2006) Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. New England Journal of Medicine 355:23, 2408-2417
Full Text378
N Vey, X Thomas, C Picard, T Kovascovicz, C Charin, J M Cayuela, H Dombret, N Dastugue, F Huguet, C Bastard, A Stamatoulas, M Giollant, O Tournilhac, E Macintyre, A Buzyn, D Bories, M Kuentz, F Dreyfus, A Delannoy, S Raynaud, N Gratecos, D Bordessoule, S de Botton, C Preudhomme, O Reman, X Troussard, A Pigneux, C Bilhou, J P Vernant, C Boucheix, J Gabert. (2006) Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia 20:12, 2155-2161
CrossRef379
José Carlos Pascual, Jaime Matarredona, Julia Miralles, Venancio Conesa, Joaquín Borras-Blasco. (2006) Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases. International Journal of Dermatology 45:12, 1471-1473
CrossRef380
Axel Schulenburg, Herbert Ulrich-Pur, Dietmar Thurnher, Boban Erovic, Stefan Florian, Wolfgang R. Sperr, Peter Kalhs, Brigitte Marian, Friedrich Wrba, Christoph C. Zielinski, Peter Valent. (2006) Neoplastic stem cells: A novel therapeutic target in clinical oncology. Cancer 107:10, 2512-2520
CrossRef381
L H Abbott, F Michor. (2006) Mathematical models of targeted cancer therapy. British Journal of Cancer 95:9, 1136-1141
CrossRef382
JM Martín, E Jordá, C Monteagudo, V Alonso, L García, G Villalón. (2006) Follicular acneiform eruption induced by imatinib. Journal of the European Academy of Dermatology and Venereology 20:10, 1368-1370
CrossRef383
Thomas L-M. Sorensen, Katherine E. McAuley, Ralf Flaig, Elizabeth M.H. Duke. (2006) New light for science: synchrotron radiation in structural medicine. Trends in Biotechnology 24:11, 500-508
CrossRef384
Yeon Hee Park, Hae Jeong Park, Bong-Seog Kim, Eunyoung Ha, Kyung Hee Jung, Seo Hyun Yoon, Sung Vin Yim, Joo-Ho Chung. (2006) BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Letters 243:1, 16-22
CrossRef385
Monica Bocchia, Francesco Forconi, Francesco Lauria. (2006) Emerging drugs in chronic myelogenous leukaemia. Expert Opinion on Emerging Drugs 11:4, 651-664
CrossRef386
Shinya Kimura, Tomoko Niwa, Kazuko Hirabayashi, Taira Maekawa. (2006) Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor. Cancer Chemotherapy and Pharmacology 58:S1, 55-61
CrossRef387
Chandan Kumar-Sinha, Scott A. Tomlins, Arul M. Chinnaiyan. (2006) Evidence of recurrent gene fusions in common epithelial tumors. Trends in Molecular Medicine 12:11, 529-536
CrossRef388
Yuan Wei, Mats Hardling, Bob Olsson, Rahil Hezaveh, Anne Ricksten, Dick Stockelberg, Hans Wadenvik. (2006) Not all imatinib resistance in CML are BCR-ABL kinase domain mutations. Annals of Hematology 85:12, 841-847
CrossRef389
A Chizuka, M Suda, T Shibata, E Kusumi, A Hori, T Hamaki, Y Kodama, K Horigome, Y Kishi, K Kobayashi, T Matsumura, K Yuji, Y Tanaka, M Kami. (2006) Difference between hematological malignancy and Solid tumor research articles published in four major medical journals. Leukemia 20:10, 1655-1657
CrossRef390
Pier Paolo Piccaluga, Giovanni Martinelli, Michela Rondoni, Giuseppe Visani, Michele Baccarani. (2006) Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. Expert Opinion on Biological Therapy 6:10, 1011-1022
CrossRef391
Tibor Kovacsovics, Richard T. Maziarz. (2006) Philadelphia chromosome-positive acute lymphoblastic leukemia: Impact of imatinib treatment on remission induction and allogeneic stem cell transplantation. Current Oncology Reports 8:5, 343-351
CrossRef392
Mohammad Amin Moosavi, Razieh Yazdanparast, Abbas Lotfi. (2006) GTP Induces S-phase Cell-cycle Arrest and Inhibits DNA Synthesis in K562 Cells But Not in Normal Human Peripheral Lymphocytes. Journal of Biochemistry and molecular biology 39:5, 492-501
CrossRef393
Philip Dean, Paul Gane, Edward Zanders. 2006. Pharmacogenomics and Drug Design. .
CrossRef394
Ryuzo Ohno, . (2006) Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy. Current Hematologic Malignancy Reports 1:3, 180-187
CrossRef395
Jeffrey A. Zonder, Charles A. Schiffer. (2006) Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate. Current Hematologic Malignancy Reports 1:3, 141-151
CrossRef396
Meng-Heng Hsieh, Yueh-Fu Fang, Wen-Cheng Chang, Han-Pin Kuo, Shinn-Yn Lin, Hui-Ping Liu, Chih-Lin Liu, Hsiu-Chi Chen, Yuan-Chieh Ku, Ya-Ting Chen, Ya-Hui Chang, Ying-Tsong Chen, Bae-Li Hsi, Shih-Feng Tsai, Shiu-Feng Huang. (2006) Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer 53:3, 311-322
CrossRef397
Y-J Chung, T-M Kim, D-W Kim, H Namkoong, H K Kim, S-A Ha, S Kim, S M Shin, J-H Kim, Y-J Lee, H-M Kang, J W Kim. (2006) Gene expression signatures associated with the resistance to imatinib. Leukemia 20:9, 1542-1550
CrossRef398
Dariusz Pytel, Tomasz Wysocki, Ireneusz Majsterek. (2006) Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: Role of BCR/ABL in therapeutic resistance. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 144:1, 85-92
CrossRef399
Efsevia Albanis, Scott L. Friedman. (2006) Antifibrotic targets and therapy in HCV. Current Hepatitis Reports 5:3, 94-100
CrossRef400
John V Frangioni. (2006) Translating in vivo diagnostics into clinical reality. Nature Biotechnology 24:8, 909-913
CrossRef401
Robert P. Nelson, Kenneth Cornetta, Kelly E. Ward, Srinivasan Ramanuja, Chris Fausel, Larry D. Cripe. (2006) Desensitization to imatinib in patients with leukemia. Annals of Allergy, Asthma & Immunology 97:2, 216-222
CrossRef402
Hon Fong L. Mark, Robert A. Sokolic, Yvonne Mark. (2006) Conventional cytogenetics and FISH in the detection of BCR/ABL fusion in chronic myeloid leukemia (CML). Experimental and Molecular Pathology 81:1, 1-7
CrossRef403
Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein. (2006) The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nature Biotechnology 24:8, 985-995
CrossRef404
Ryuzo Ohno. (2006) Treatment of chronic myeloid leukemia with imatinib mesylate. International Journal of Clinical Oncology 11:3, 176-183
CrossRef405
Gerhard S. Mundinger, Virginia Espina, Lance A. Liotta, Emanuel F. Petricoin, Katherine R. Calvo. (2006) Clinical phosphoproteomic profiling for personalized targeted medicine using reverse phase protein microarray. Targeted Oncology 1:3, 151-167
CrossRef406
Luke A. J. O'Neill. (2006) Targeting signal transduction as a strategy to treat inflammatory diseases. Nature Reviews Drug Discovery 5:7, 549-563
CrossRef407
A. Ikeda, D.B. Shankar, M. Watanabe, F. Tamanoi, T.B. Moore, K.M. Sakamoto. (2006) Molecular targets and the treatment of myeloid leukemia. Molecular Genetics and Metabolism 88:3, 216-224
CrossRef408
Soo Kyung Kang, Jong Bae. Park, Seung Heun. Cha. (2006) Multipotent, Dedifferentiated Cancer Stem-like Cells from Brain Gliomas. Stem Cells and Development 15:3, 423-435
CrossRef409
Ryan P. Million. (2006) Impact of genetic diagnostics on drug development strategy. Nature Reviews Cancer 5:6, 459-462
CrossRef410
H. Agis, E. Jaeger, B. Doninger, C. Sillaber, C. Marosi, J. Drach, I. Schwarzinger, P. Valent, L. Oehler. (2006) In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. European Journal of Clinical Investigation 36:6, 402-408
CrossRef411
Daniele Santini, Michele Caraglia, Bruno Vincenzi, Ingunn Holen, Susanna Scarpa, Alfredo Budillon, Giuseppe Tonini. (2006) Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. Nature Clinical Practice Oncology 3:6, 325-338
CrossRef412
Yusuke Inoue, Arinobu Tojo, Rieko Sekine, Yasushi Soda, Seiichiro Kobayashi, Akiko Nomura, Kiyoko Izawa, Toshio Kitamura, Toshiyuki Okubo, Kuni Ohtomo. (2006) In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals. European Journal of Nuclear Medicine and Molecular Imaging 33:5, 557-565
CrossRef413
P. Workman, E. O. Aboagye, Y.-L. Chung, J. R. Griffiths, R. Hart, M. O. Leach, R. J. Maxwell, P. M. J. McSheehy, P. M. Price, J. Zweit. (2006) Minimally Invasive Pharmacokinetic and Pharmacodynamic Technologies in Hypothesis-Testing Clinical Trials of Innovative Therapies. JNCI Journal of the National Cancer Institute 98:9, 580-598
CrossRef414
Fionnuala B. Hickey, Thomas G. Cotter. (2006) Identification of transcriptional targets associated with the expression of p210 Bcr-Abl. European Journal of Haematology 76:5, 369-383
CrossRef415
Bertrand W. Parcells, Alan K. Ikeda, Tiffany Simms-Waldrip, Theodore B. Moore, Kathleen M. Sakamoto. (2006) FMS-Like Tyrosine Kinase 3 in Normal Hematopoiesis and Acute Myeloid Leukemia. Stem Cells 24:5, 1174-1184
CrossRef416
H. Kameda, H. Ishigami, M. Suzuki, T. Abe, T. Takeuchi. (2006) Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor. Clinical and Experimental Immunology 144:2, 335-341
CrossRef417
Merat Karbasian Esfahani, Evelyn L. Morris, Janice P. Dutcher, Peter H. Wiernik. (2006) Blastic phase of chronic myelogenous leukemia. Current Treatment Options in Oncology 7:3, 189-199
CrossRef418
Wenjuan Yu, Qing Rao, Min Wang, Zheng Tian, Dong Lin, Xiangrong Liu, Jianxiang Wang. (2006) The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level. Leukemia Research 30:5, 575-582
CrossRef419
Ken Wyman, Michael B. Atkins, Victor Prieto, Omar Eton, David F. McDermott, Francie Hubbard, Christine Byrnes, Kathleen Sanders, Jeffrey A. Sosman. (2006) Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma. Cancer 106:9, 2005-2011
CrossRef420
Robert L. Coleman, Russell R. Broaddus, Diane C. Bodurka, Judith K. Wolf, Thomas W. Burke, John J. Kavanagh, Charles F. Levenback, David M. Gershenson. (2006) Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecologic Oncology 101:1, 126-131
CrossRef421
C Miething, S Feihl, C Mugler, R Grundler, N von Bubnoff, F Lordick, C Peschel, J Duyster. (2006) The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia 20:4, 650-657
CrossRef422
Pier Paolo Piccaluga, Giovanni Martinelli, Michele Baccarani. (2006) Advances in the treatment for haematological malignancies. Expert Opinion on Pharmacotherapy 7:6, 721-732
CrossRef423
Richard A. Larson. (2006) Management of Acute Lymphoblastic Leukemia in Older Patients. Seminars in Hematology 43:2, 126-133
CrossRef424
Young Hwa Soung, Jong Woo Lee, Su Young Kim, Young Pil Wang, Keon Hyun Jo, Seok Whan Moon, Won Sang Park, Suk Woo Nam, Jung Young Lee, Nam Jin Yoo, Sug Hyung Lee. (2006) Somatic mutations of theERBB4 kinase domain in human cancers. International Journal of Cancer 118:6, 1426-1429
CrossRef425
J W Lee, Y G Kim, Y H Soung, K J Han,, S Y Kim, H S Rhim, W S Min, S W Nam, W S Park, J Y Lee, N J Yoo, S H Lee. (2006) The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 25:9, 1434-1436
CrossRef426
Juan-José Ventura, Ángel R. Nebreda. (2006) Protein kinases and phosphatases as therapeutic targets in cancer. Clinical and Translational Oncology 8:3, 153-160
CrossRef427
D Rea, L Legros, E Raffoux, X Thomas, P Turlure, S Maury, B Dupriez, A Pigneux, B Choufi, O Reman, D Stéphane, B Royer, M Vigier, M Ojeda-Uribe, C Recher, H Dombret, F Huguet, P Rousselot. (2006) High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 20:3, 400-403
CrossRef428
Valeria Brazzelli, Elena Roveda, Francesca Prestinari, Tania Barbagallo, Eleonora Bellani, Valentina Trevisan, Claudia Rona, Franco Locatelli, Marco Zecca, Giovanni Borroni. (2006) Vitiligo-Like Lesions and Diffuse Lightening of the Skin in a Pediatric Patient Treated with Imatinib Mesylate: A Noninvasive Colorimetric Assessment. Pediatric Dermatology 23:2, 175-178
CrossRef429
Tetsuo Asaki, Yukiteru Sugiyama, Taisuke Hamamoto, Masaya Higashioka, Masato Umehara, Haruna Naito, Tomoko Niwa. (2006) Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 16:5, 1421-1425
CrossRef430
Ian M. Adcock, K. Fan Chung, Gaetano Caramori, Kazuhiro Ito. (2006) Kinase inhibitors and airway inflammation. European Journal of Pharmacology 533:1-3, 118-132
CrossRef431
M. J. Mauro, R. T. Maziarz. (2006) Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia: When Should It Be Used?. Mayo Clinic Proceedings 81:3, 404-416
CrossRef432
Mark A Guthridge, Jason A Powell, Emma F Barry, Frank C Stomski, Barbara J McClure, Hayley Ramshaw, Fernando A Felquer, Mara Dottore, Daniel T Thomas, Bik To, C Glenn Begley, Angel F Lopez. (2006) Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. The EMBO Journal 25:3, 479-485
CrossRef433
Ting Chen, Jessica A. George, Christopher C. Taylor. (2006) Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?. Anti-Cancer Drugs 17:2, 123-131
CrossRef434
Konstantinos T. Papazisis, Theodora G. Kalemi, Dimitra Zambouli, George D. Geromichalos, Alexandros F. Lambropoulos, Alexandros Kotsis, Lazaros L. Boutis, Alexandros H. Kortsaris. (2006) Synergistic effects of protein tyrosine kinase inhibitor genistein with camptothecins against three cell lines in vitro. Cancer Letters 233:2, 255-264
CrossRef435
Livio Pagano, Morena Caira, Luana Fianchi, Giuseppe Leone. (2006) Acute lymphoblastic leukemia in elderly patients: clinical characteristics, treatment and outcome. Aging Health 2:1, 123-133
CrossRef436
Aimee S. Payne, William D. James, Raymond B. Weiss. (2006) Dermatologic Toxicity of Chemotherapeutic Agents. Seminars in Oncology 33:1, 86-97
CrossRef437
Letizia Venturini, Matthias Eder, Michaela Scherr. (2006) RNA-Mediated Gene Silencing in Hematopoietic Cells. Journal of Biomedicine and Biotechnology 2006, 1-14
CrossRef438
Martin Bornhauser, Nicolaus Kroger, Rainer Schwerdtfeger, Karin Schafer-Eckart, Herbert G. Sayer, Christoph Scheid, Mattias Stelljes, Joachim Kienast, Peter Mundhenk, Stefan Fruehauf, Michael G. Kiehl, Hannes Wandt, Catrin Theuser, Gerhard Ehninger, Axel R. Zander, . (2006) Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. European Journal of Haematology 76:1, 9-17
CrossRef439
Ireneusz Majsterek, Tomasz Sliwinski, Tomasz Poplawski, Dariusz Pytel, Michal Kowalski, Artur Slupianek, Tomasz Skorski, Janusz Blasiak. (2006) Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 603:1, 74-82
CrossRef440
Deborah A. Thomas, Andreas H. Sarris, Jorge Cortes, Stefan Faderl, Susan O'Brien, Francis J. Giles, Guillermo Garcia-Manero, Maria A. Rodriguez, Fernando Cabanillas, Hagop Kantarjian. (2006) Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 106:1, 120-127
CrossRef441
D Cilloni, F Messa, F Arruga, I Defilippi, A Morotti, E Messa, S Carturan, E Giugliano, M Pautasso, E Bracco, V Rosso, A Sen, G Martinelli, M Baccarani, G Saglio. (2006) The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance. Leukemia 20:1, 61-67
CrossRef442
Rongzhen Xu, Qinghua Dong, Yingzi Yu, Xiaoying Zhao, Xiaoxian Gan, Dong Wu, Qinghua Lu, Xiaohua Xu, Xiao-Fang Yu. (2006) Berbamine: A novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leukemia Research 30:1, 17-23
CrossRef443
Claus Langer. 2006. Gastrointestinale Stromatumoren (GIST). , 523-531.
CrossRef444
Jan A. Burger, Annette Schmitt-Gräff, Andrea Bürkle, Lysann Seiler, Jürgen Finke. (2006) Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia. Leukemia & Lymphoma 47:11, 2427-2430
CrossRef445
E. Albanis, S. L. Friedman. (2006) Antifibrotic Agents for Liver Disease. American Journal of Transplantation 6:1, 12-19
CrossRef446
H. Li, M. Zhan. (2006) Systematic intervention of transcription for identifying network response to disease and cellular phenotypes. Bioinformatics 22:1, 96-102
CrossRef447
Shuichi Ota, Manabu Musashi, Keiichi Kondo, Nobuyasu Toyoshima, Tomomi Toubai, Masahiro Onozawa, Akio Mori, Satoshi Hashino, Junji Tanaka, Kazuhiko Matsuno, Masahiro Imamura, Masahiro Asaka. (2006) Effect of Imatinib Mesylate Combined with Granulocyte Colony-Stimulating Factor on Leukaemic Blast Cells Derived from Advanced-Stage Chronic Myelogenous Leukaemia Patients. Acta Haematologica 116:1, 8-18
CrossRef448
Razelle Kurzrock, Moshe Talpaz, Lan Li, Zeev Estrov. (2006) Distinct biological impact of dephosphorylation vs. downregulation of p210 Bcr-Abl : Implications for imatinib mesylate response and resistance. Leukemia & Lymphoma 47:8, 1651-1664
CrossRef449
Rie Yamazaki, Shinichiro Okamoto, Chien-Kang Chen, Shinichiro Tada, Hidetane Saito, Rie Shibata, Michiie Sakamoto, Takehiko Mori, Yasuo Ikeda. (2006) Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase. Leukemia & Lymphoma 47:7, 1427-1430
CrossRef450
Masamitsu Yanada, Tomoki Naoe. (2006) Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: Major challenges in current practice. Leukemia & Lymphoma 47:9, 1747-1753
CrossRef451
Keren Paz, Zhenping Zhu. (2005) Recent advances in targeted therapy of human myelogenous leukaemia. Expert Opinion on Therapeutic Targets 9:6, 1147-1163
CrossRef452
Paul G. Richardson, Constantine S. Mitsiades, Teru Hideshima, Kenneth C. Anderson. (2005) Novel biological therapies for the treatment of multiple myeloma. Best Practice & Research Clinical Haematology 18:4, 619-634
CrossRef453
Patrick Micke, Arne Östman. (2005) Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opinion on Therapeutic Targets 9:6, 1217-1233
CrossRef454
Seth J. Corey. (2005) New agents in the treatment of childhood leukemias and myelodysplastic syndromes. Current Oncology Reports 7:6, 399-405
CrossRef455
Suresh Ramalingam, Chandra P Belani. (2005) Molecularly-targeted therapies for non-small cell lung cancer. Expert Opinion on Pharmacotherapy 6:15, 2667-2679
CrossRef456
Falko Fend, Oliver Bock, Markus Kremer, Katja Specht, Leticia Quintanilla-Martinez. (2005) Ancillary techniques in bone marrow pathology: molecular diagnostics on bone marrow trephine biopsies. Virchows Archiv 447:6, 909-919
CrossRef457
Mellinghoff, Ingo K., Wang, Maria Y., Vivanco, Igor, Haas-Kogan, Daphne A., Zhu, Shaojun, Dia, Ederlyn Q., Lu, Kan V., Yoshimoto, Koji, Huang, Julie H.Y., Chute, Dennis J., Riggs, Bridget L., Horvath, Steve, Liau, Linda M., Cavenee, Webster K., Rao, P. Nagesh, Beroukhim, Rameen, Peck, Timothy C., Lee, Jeffrey C., Sellers, William R., Stokoe, David, Prados, Michael, Cloughesy, Timothy F., Sawyers, Charles L., Mischel, Paul S., . (2005) Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. New England Journal of Medicine 353:19, 2012-2024
Full Text458
François-Xavier Mahon. (2005) JAK the trigger. Oncogene 24:48, 7125-7126
CrossRef459
Marina Bousquet, Cathy Quelen, Véronique De Mas, Eliane Duchayne, Blandine Roquefeuil, Georges Delsol, Guy Laurent, Nicole Dastugue, Pierre Brousset. (2005) The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 24:48, 7248-7252
CrossRef460
Sheila E Taube, Jeffrey S Abrams. (2005) Program for the Assessment of Clinical Cancer Tests (PACCT): assisting the development of tailored cancer therapy. Personalized Medicine 2:4, 363-369
CrossRef461
Paul J Mulholland, Christina Thirlwell, Cathryn S Brock, Edward S Newlands. (2005) Emerging targeted treatments for malignant glioma. Expert Opinion on Emerging Drugs 10:4, 845-854
CrossRef462
H Gao, B-N Lee, M Talpaz, N J Donato, J E Cortes, H M Kantarjian, J M Reuben. (2005) Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19:11, 1905-1911
CrossRef463
Chi Tarn, Andrew K. Godwin. (2005) Molecular research directions in the management of gastrointestinal stromal tumors. Current Treatment Options in Oncology 6:6, 473-486
CrossRef464
H-J Shin, J S Chung, G J Cho. (2005) Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplantation 36:10, 917-918
CrossRef465
Joseph A. Ludwig, John N. Weinstein. (2005) Biomarkers in Cancer Staging, Prognosis and Treatment Selection. Nature Reviews Cancer 5:11, 845-856
CrossRef466
Valeria Brazzelli, Francesca Prestinari, Elena Roveda, Tania Barbagallo, Eleonora Bellani, Camilla Vassallo, Ester Orlandi, Francesco Passamonti, Giovanni Borroni. (2005) Pityriasis rosea–like eruption during treatment with imatinib mesylate: Description of 3 cases. Journal of the American Academy of Dermatology 53:5, S240-S243
CrossRef467
Faye M. Johnson, Babita Saigal, Nicholas J. Donato. (2005) Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. Journal of Cellular Physiology 205:2, 218-227
CrossRef468
Alexandre Mathy, Paul Baas, Otilia Dalesio, Nico van Zandwijk. (2005) Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial. Lung Cancer 50:1, 83-86
CrossRef469
Tanja A Gruber, Dianne C Skelton, Donald B Kohn. (2005) Recombinant murine interleukin-12 elicits potent antileukemic immune responses in a murine model of philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Gene Therapy 12:10, 818-824
CrossRef470
Toshiyuki Sakaeda, Noboru Okamura, Akinobu Gotoh, Toshiro Shirakawa, Shuji Terao, Masahi Morioka, Kenji Tokui, Hisato Tanaka, Tsutomu Nakamura, Mariko Yagi, Yoshihiro Nishimura, Mitsuhiro Yokoyama, Katsuhiko Okumura. (2005) EGFR mRNA is Upregulated, but Somatic Mutations of the Gene are Hardly Found in Renal Cell Carcinoma in Japanese Patients. Pharmaceutical Research 22:10, 1757-1761
CrossRef471
JONG WOO LEE, YOUNG HWA SOUNG, SU YOUNG KIM, WON SANG PARK, SUK WOO NAM, SANG HO KIM, JUNG YOUNG LEE, NAM JIN YOO, SUG HYUNG LEE. (2005) ERBB2 kinase domain mutation in a gastric cancer metastasis. APMIS 113:10, 683-687
CrossRef472
A Burchert, Y Wang, D Cai, N von Bubnoff, P Paschka, S Müller-Brüsselbach, O G Ottmann, J Duyster, A Hochhaus, A Neubauer. (2005) Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19:10, 1774-1782
CrossRef473
Mhairi Copland, Heather G. JØrgensen, Tessa L. Holyoake. (2005) Evolving molecular therapy for chronic myeloid leukaemia—are we on target?. Hematology 10:5, 349-359
CrossRef474
H. Jeffrey Wilkins, Martin M. Crane, Kelly Copeland, William V. Williams. (2005) Hypereosinophilic syndrome: An update. American Journal of Hematology 80:2, 148-157
CrossRef475
A. Poveda, J. Maurel, J. Martín, V. Artigas, A. Casado, J. Cervera, A. López-Pousa, F. Ortega, L. Ortega, R. Ramos, A. Ginés, M.J. Safont, J.M. Buesa. (2005) Guía de práctica clínica en los tumores estromales gastrointestinales. Cirugía Española 78, 1-13
CrossRef476
G. Chepko, R. Slack, D. Carbott, S. Khan, L. Steadman, R.B. Dickson. (2005) Differential alteration of stem and other cell populations in ducts and lobules of TGFα and c-Myc transgenic mouse mammary epithelium. Tissue and Cell 37:5, 393-412
CrossRef477
Anna K. Nowak. (2005) Phase II trials in mesothelioma: An increasing challenge. Lung Cancer 50:1, 87-90
CrossRef478
Guang-Biao Zhou, Sai-Juan Chen, Zhu Chen. (2005) Acute promyelocytic leukemia: A model of molecular target based therapy. Hematology 10:4, 270-280
CrossRef479
Silke Appel, Stefan Balabanov, Tim H. Brümmendorf, Peter Brossart. (2005) Effects of Imatinib on Normal Hematopoiesis and Immune Activation. Stem Cells 23:8, 1082-1088
CrossRef480
Rob DeConde, Peter S. Kim, Doron Levy, Peter P. Lee. (2005) Post-transplantation dynamics of the immune response to chronic myelogenous leukemia. Journal of Theoretical Biology 236:1, 39-59
CrossRef481
K-H Lee, J-H Lee, S-J Choi, J-H Lee, M Seol, Y-S Lee, W-K Kim, J-S Lee, E-J Seo, S Jang, C-J Park, H-S Chi. (2005) Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 19:9, 1509-1516
CrossRef482
V. B. Wreesmann, B. Singh. (2005) Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities. Journal of Oral Pathology and Medicine 34:8, 449-459
CrossRef483
Fumiaki Koizumi, Tatsu Shimoyama, Fumiko Taguchi, Nagahiro Saijo, Kazuto Nishio. (2005) Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. International Journal of Cancer 116:1, 36-44
CrossRef484
Sheila A Doggrell. (2005) Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?. Expert Opinion on Investigational Drugs 14:8, 1063-1066
CrossRef485
Xiaoyi Hu, Eric C. Holland. (2005) Applications of mouse glioma models in preclinical trials. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 576:1-2, 54-65
CrossRef486
Rüdiger Hehlmann, Ute Berger, Andreas Hochhaus. (2005) Chronic myeloid leukemia: a model for oncology. Annals of Hematology 84:8, 487-497
CrossRef487
H. C. A. Drexler, M. Euler. (2005) Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis. Apoptosis 10:4, 743-758
CrossRef488
Xavier Thomas. (2005) Emerging drugs for adult acute lymphoblastic leukaemia. Expert Opinion on Emerging Drugs 10:3, 591-617
CrossRef489
Louise K. Jones, Vaskar Saha. (2005) Philadelphia positive acute lymphoblastic leukaemia of childhood. British Journal of Haematology 130:4, 489-500
CrossRef490
Krause, Daniela S., Van Etten, Richard A., . (2005) Tyrosine Kinases as Targets for Cancer Therapy. New England Journal of Medicine 353:2, 172-187
Full Text491
A Radujkovic, M Schad, J Topaly, M R Veldwijk, S Laufs, B S Schultheis, A Jauch, J V Melo, S Fruehauf, W J Zeller. (2005) Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – Inhibition of P-glycoprotein function by 17-AAG. Leukemia 19:7, 1198-1206
CrossRef492
Catherine M. Shachaf, Dean W. Felsher. (2005) Rehabilitation of cancer through oncogene inactivation. Trends in Molecular Medicine 11:7, 316-321
CrossRef493
Daniella Yeheskely-Hayon, Ronit Regev, Gera D. Eytan, Eldad J. Dann. (2005) The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line. Leukemia Research 29:7, 793-802
CrossRef494
Holger Rumpold, Anna M. Wolf, Kurt Gruenewald, Guenther Gastl, Eberhard Gunsilius, Dominik Wolf. (2005) RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Experimental Hematology 33:7, 767-775
CrossRef495
J J W M Janssen, S M Klaver, Q Waisfisz, G Pasterkamp, D P V de Kleijn, G J Schuurhuis, G J Ossenkoppele. (2005) Identification of genes potentially involved in disease transformation of CML. Leukemia 19:6, 998-1004
CrossRef496
Margaret von Mehren, James C. Watson. (2005) Gastrointestinal Stromal Tumors. Hematology/Oncology Clinics of North America 19:3, 547-564
CrossRef497
Jan Cools, Chantal Maertens, Peter Marynen. (2005) Resistance to tyrosine kinase inhibitors: Calling on extra forces. Drug Resistance Updates 8:3, 119-129
CrossRef498
Luciano Vellón, Marcela González-Cid, Marcelo de Campos Nebel, Irene Larripa. (2005) Additive apoptotic effect of STI571 with the cytoprotective agent amifostine in K-562 cell line. Cancer Chemotherapy and Pharmacology 55:6, 602-608
CrossRef499
Richard Carvajal, Paul Meyers. (2005) Ewing's Sarcoma and Primitive Neuroectodermal Family of Tumors. Hematology/Oncology Clinics of North America 19:3, 501-525
CrossRef500
L SIMPSON, X HE, M PINS, X HUANG, S CAMPBELL, X YANG, E PERLMAN, R BERGAN. (2005) RENAL MEDULLARY CARCINOMA AND ABL GENE AMPLIFICATION. The Journal of Urology 173:6, 1883-1888
CrossRef501
M S Holtz, S J Forman, R Bhatia. (2005) Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 19:6, 1034-1041
CrossRef502
Athanasia Katsoulas, Zakaria Rachid, Fouad Brahimi, James McNamee, Bertrand J. Jean-Claude. (2005) Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias. Leukemia Research 29:6, 693-700
CrossRef503
STEFAN BALABANOV, SILKE APPEL, LOTHAR KANZ, PETER BROSSART, TIM H. BRÜMMENDORF. (2005) Effect of Tyrosine Kinase Inhibition Using Imatinib on Normal Lymphohematopoietic Cells. Annals of the New York Academy of Sciences 1044:1, 168-177
CrossRef504
Susanne Diehl, Christopher B. Umbricht, Alan P.B. Dackiw, Martha A. Zeiger. (2005) Modern Approaches to Age-Old Questions About Thyroid Tumors. Thyroid 15:6, 575-582
CrossRef505
Constantine S Mitsiades, Nicholas Mitsiades. (2005) Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. Expert Review of Anticancer Therapy 5:3, 487-499
CrossRef506
Hagop Kantarjian, Moshe Talpaz, Susan O'Brien, Francis Giles, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, Jianqin Shan, Mary Beth Rios, Richard Champlin, Marcos de Lima, Jorge Cortes. (2005) Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia—Comparison with historic experience. Cancer 103:10, 2099-2108
CrossRef507
Efsevia Albanis, Scott L. Friedman. (2005) Antifibrotic targets and therapy in HCV. Current Hepatitis Reports 4:2, 61-67
CrossRef508
Phillip G Febbo, Geoffrey S Ginsburg. (2005) Personalized diagnostic and therapeutic strategies in oncology. Personalized Medicine 2:2, 97-110
CrossRef509
Young Hwa Soung, Jong Woo Lee, Su Young Kim, Si Hyung Seo, Won Sang Park, Suk Woo Nam, Sang Yong Song, Joung Ho Han, Cheol Keun Park, Jung Young Lee, Nam Jin Yoo, Sug Hyung Lee. (2005) Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Archiv 446:5, 483-488
CrossRef510
J Thiele, H M Kvasnicka, A Schmitt-Graeff, S Kriener, K Engels, P Staib, E S Ollig, C Keller, S Fokkema, M Griesshammer, C F Waller, O G Ottmann, M L Hansmann. (2005) Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients. Histopathology 46:5, 540-550
CrossRef511
G. Sauer, R. Kreienberg. (2005) Neue molekulare Therapiekonzepte beim Mammakarzinom. Der Gynäkologe 38:5, 432-438
CrossRef512
Shaoguang Li. (2005) Src kinases as targets for Bcell acute lymphoblastic leukaemia therapy. Expert Opinion on Therapeutic Targets 9:2, 329-341
CrossRef513
M. Copland, A. R. Fraser, S. J. Harrison, T. L. Holyoake. (2005) Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. Cancer Immunology, Immunotherapy 54:4, 297-306
CrossRef514
Ziyad Al Aly, Jennifer M. Philoctête Ashley, Mary E. Gellens, Esther A. González. (2005) Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: True association or mere coincidence?. American Journal of Kidney Diseases 45:4, 762-768
CrossRef515
Katsuro Ito, Kazunori Tominaga, Toshiya Suzuki, Itsuro Jinnai, Masami Bessho. (2005) Successful Treatment with Imatinib Mesylate in a Case of Minor BCR-ABL-Positive Acute Myelogenous Leukemia. International Journal of Hematology 81:3, 242-245
CrossRef516
Ian Judson, Peiming Ma, Bin Peng, Jaap Verweij, Amy Racine, Eugenio Donato Paola, Martine Glabbeke, Sasa Dimitrijevic, Michelle Scurr, Herlinde Dumez, Allan Oosterom. (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemotherapy and Pharmacology 55:4, 379-386
CrossRef517
Anindita Roy, Mike Bradburn, Anthony V. Moorman, Julie Burrett, Sharon Love, Sally E. Kinsey, Chris Mitchell, Ajay Vora, Tim Eden, John S. Lilleyman, Ian Hann, Vaskar Saha, . (2005) Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. British Journal of Haematology 129:1, 35-44
CrossRef518
Holly Dushkin, Russell J. Schilder. (2005) Imatinib mesylate and its potential implications for gynecologic cancers. Current Treatment Options in Oncology 6:2, 115-120
CrossRef519
Robin L Jones, Ian R Judson. (2005) The development and application of imatinib. Expert Opinion on Drug Safety 4:2, 183-191
CrossRef520
Shanu Modi, Andrew D. Seidman, Maura Dickler, Mark Moasser, Gabriella D’Andrea, Mary Ellen Moynahan, Jennifer Menell, Katherine S. Panageas, Lee K. Tan, Larry Norton, Clifford A. Hudis. (2005) A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Research and Treatment 90:2, 157-163
CrossRef521
Grant H. Skrepnek, Erin E. Ballard. (2005) Cost-Efficacy of Imatinib versus Allogeneic Bone Marrow Transplantation with a Matched Unrelated Donor in the Treatment of Chronic Myelogenous Leukemia: A Decision-Analytic Approach. Pharmacotherapy 25:3, 325-334
CrossRef522
A. Tefferi, G. W. Dewald, M. L. Litzow, J. Cortes, M. J. Mauro, M. Talpaz, H. M. Kantarjian. (2005) Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment. Mayo Clinic Proceedings 80:3, 390-402
CrossRef523
LINDSAY M. HAWKINS, AARTHI A. JAYANTHAN, ARU NARENDRAN. (2005) Effects of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) on Pediatric Acute Lymphoblastic Leukemia (ALL) with Respect to Bcr-Abl Status and Imatinib Mesylate Sensitivity. Pediatric Research 57:3, 430-437
CrossRef524
Didier Decaudin, Patricia de Cremoux, Xavier Sastre, Jean-Gabriel Judde, Fariba Nemati, Carine Tran-Perennou, Paul Fréneaux, Alain Livartowski, Pierre Pouillart, Marie-France Poupon. (2005) In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. International Journal of Cancer 113:5, 849-856
CrossRef525
Raoul Tibes, Jonathan Trent, Razelle Kurzrock. (2005) TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS*. Annual Review of Pharmacology and Toxicology 45:1, 357-384
CrossRef526
Hermann Lage. (2005) Potential applications of RNA interference technology in the treatment of cancer. Future Oncology 1:1, 103-113
CrossRef527
Kazuto Takeuchi, Ikuya Sakai, Hirosi Narumi, Masaki Yasukawa, Kensuke Kojima, Yoko Minamoto, Tomoaki Fujisaki, Kazushi Tanimoto, Masamichi Hara, Akihiko Numata, Hisashi Gondo, Masuhiro Takahashi, Nobuharu Fujii, Kozo Masuda, Shigeru Fujita. (2005) Expression of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic response to IFN-α. Leukemia Research 29:2, 173-178
CrossRef528
Kamakshi Rao, Susan Goodin, Michael J. Levitt, Nisha Dave, Weichung J. Shih, Yong Lin, Terry Capanna, Susan Doyle-Lindrud, Parisa Juvidian, Robert S. DiPaola. (2005) A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. The Prostate 62:2, 115-122
CrossRef529
Alessandro Lugli, Monika Ebnoether, Sergio B. Cogliatti, Alois Gratwohl, Jakob Passweg, Urs Hess, Wolfgang Korte, Hanne Hawle, Marianne Tinguely, Bettina Borisch, Sara Mach-Pascual, Silke Von Juergensonn, André Tichelli, Stephan Dirnhofer. (2005) Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia. Human Pathology 36:1, 91-100
CrossRef530
Yong-Hak Sohn, Hyun-Sook Chi, Chan-Jeoung Park, Kyoo-Hyung Lee, Eul-Ju Seo. (2005) Clinical Resistance to the Tyrosine Kinase Inhibitor Imatinib (STI571) and Detection of BCR-ABL Gene Mutations in Korean Patients with Chronic Myeloid Leukemia. The Korean Journal of Hematology 40:2, 82
CrossRef531
Janice Dutcher, Sandra Lee, Robert Gallagher, Adel Makary, John Hines, Harold Londer, John Farnen, John Bennett, Elisabeth Paietta, Jacob Rowe, Olga Goloubeva, Peter Wiernik. (2005) Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: A study of the Eastern Cooperative Oncology Group (E1993). Leukemia & Lymphoma 46:3, 377-385
CrossRef532
R.K. THOMAS, H. GREULICH, Y. YUZA, J.C. LEE, T. TENGS, W. FENG, T.-H. CHEN, E. NICKERSON, J. SIMONS, M. EGHOLM, J.M. ROTHBERG, W.R. SELLERS, M.L. MEYERSON. (2005) Detection of Oncogenic Mutations in the EGFR Gene in Lung Adenocarcinoma with Differential Sensitivity to EGFR Tyrosine Kinase Inhibitors. Cold Spring Harbor Symposia on Quantitative Biology 70:1, 73-81
CrossRef533
Daniel Morgensztern, Manuel Rosado, Luis Raez, Edgardo Santos, Peter Cassileth. (2005) Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia & Lymphoma 46:2, 297-298
CrossRef534
J.-P. Thiery. (2005) De la biologie des tumeurs aux traitements innovants : un vrai parcours du combattant. Annales Pharmaceutiques Françaises 63:1, 7-9
CrossRef535
Sheila A Doggrell. (2005) BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opinion on Investigational Drugs 14:1, 89-91
CrossRef536
Aamer Aleem, Neelam Siddiqui. (2005) Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate. Leukemia & Lymphoma 46:7, 1097-1099
CrossRef537
Brigitte Lankat-Buttgereit, Dieter Hörsch, Peter Barth, Rudolf Arnold, Silke Blöcker, Rüdiger Göke. (2005) Effects of the Tyrosine Kinase Inhibitor Imatinib on Neuroendocrine Tumor Cell Growth. Digestion 71:3, 131-140
CrossRef538
J.-Y. Blay. (2005) Médicaments actuels et optimisation. Annales Pharmaceutiques Françaises 63:1, 17-24
CrossRef539
Klaus Eisendle, Dominik Wolf, Guenther Gastl, Brigitte Kircher-Eibl. (2005) Dendritic cells from patients with chronic myeloid leukemia: Functional and phenotypic features. Leukemia & Lymphoma 46:5, 663-670
CrossRef540
Bin Peng, Peter Lloyd, Horst Schran. (2005) Clinical Pharmacokinetics of Imatinib. Clinical Pharmacokinetics 44:9, 879-894
CrossRef541
Ka-Hee Yi. (2005) Moleculary Targeted Therapy for Thyroid Cancer. Journal of Korean Society of Endocrinology 20:2, 105
CrossRef542
Peilin Zhang, John Rogers. (2005) Targeted lung cancer therapy: what have we learned from gefitinib?. Therapy 2:1, 1-2
CrossRef543
Jennifer Clark, Jan Cools, D. Gary Gilliland. (2005) EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head. PLoS Medicine 2:3, e75
CrossRef544
Xiao-Shan Liu, Jikai Jiang. (2005) Alterations in Tyrosine Protein Phosphorylation Induced by Matrine in Leukemia Cells. Pharmaceutical Biology 43:7, 624-629
CrossRef545
Joseph Menczer, Vladimir Kravtsov, Tally Levy, Esther Berger, Marek Glezerman, Ilana Avinoach. (2005) Expression of c-kit in uterine carcinosarcoma. Gynecologic Oncology 96:1, 210-215
CrossRef546
Yoichi Tani, Yutaka Hatanaka, Kaoru Hashizume. (2005) Development of Precise Pharmocodiagnostic (PharmDx) Tests for Molecular Targeted Therapies. ACTA HISTOCHEMICA ET CYTOCHEMICA 38:3, 209-216
CrossRef547
Hawk Kim, Heung-Moon Chang, Min-Hee Ryu, Tae-Won Kim, Hee-Jung Sohn, So-Eun Kim, Hye-Jin Kang, Sarah Park, Jung-Shin Lee, Yoon-Koo Kang. (2005) Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor. Journal of Korean Medical Science 20:3, 512
CrossRef548
C. London. (2004) Kinase inhibitors in cancer therapy. Veterinary and Comparative Oncology 2:4, 177-193
CrossRef549
Mark A Pearson, Doriano Fabbro. (2004) Targeting protein kinases in cancer therapy: a success?. Expert Review of Anticancer Therapy 4:6, 1113-1124
CrossRef550
Henrik Daub, Katja Specht, Axel Ullrich. (2004) Strategies to overcome resistance to targeted protein kinase inhibitors. Nature Reviews Drug Discovery 3:12, 1001-1010
CrossRef551
Mihnea V. Chiorean, Maria Eugenia Guicciardi, Jung-Hwan Yoon, Steven F. Bronk, Scott H. Kaufmanns, Gregory J. Gores. (2004) Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. Liver International 24:6, 687-695
CrossRef552
Levi J. Beverly, Anthony J. Capobianco. (2004) Targeting promiscuous signaling pathways in cancer: another Notch in the bedpost. Trends in Molecular Medicine 10:12, 591-598
CrossRef553
G. Di Lorenzo, R. Autorino, F.P. D'Armiento, C. Mignogna, M. De Laurentiis, M. De Sio, M. D'Armiento, R. Damiano, G. Vecchio, S. De Placido. (2004) Expression of proto-oncogene c-kit in high risk prostate cancer. European Journal of Surgical Oncology (EJSO) 30:9, 987-992
CrossRef554
J. Thiele, H. M. Kvasnicka, E. Varus, S. Kriener, K. Engels, P. Staib, E. S. Ollig, M. Griesshammer, C. F. Waller, H. Pfeifer, A. Schmitt-Gr
ff. (2004) Regression der Philadelphia-Chromosom (bcr/abl)-positiven Myelo- und Megakaryopoiese unter Imatinib(STI571)-Therapie bei chronischer myeloischer Leuk
CrossRef555
Ch. M. Zwaan, G. J. L. Kaspers. (2004) Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. British Journal of Haematology 127:3, 264-279
CrossRef556
Innocenzo Sammarco, Gabriele Capurso, Luigi Coppola, Antonio Panicci
CrossRef557
Takatsune Shimizu, Yoshitaka Miyakawa, Satoshi Iwata, Akiko Kuribara, Tony Tiganis, Chikao Morimoto, Yasuo Ikeda, Masahiro Kizaki. (2004) A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein. Experimental Hematology 32:11, 1057-1063
CrossRef558
Toyoki Maeda, Toshitaka Mutoh, Hiromi Muta, Masaharu Nakayama, Yasuhiro Nakajima, Takuya Ikuta, Mikihiko Yasuda, Tomoaki Etoh, Kanako Shimizu, Yukoh Nakazaki, Takashi Hiroyama, Shinichi Somada, Ryo Kurita, Kenzaburo Tani, Motoaki Shiratsuchi, Junji Nishimura. (2004) An 85-Year-Old Japanese Woman with Philadelphia ChromosomeâPositive Chronic Myelogenous Leukemia with Del (5q) Successfully Treated by Intermittent Imatinib Therapy. Journal of the American Geriatrics Society 52:10, 1783-1784
CrossRef559
Yasuo Morishima, Michinori Ogura, Miki Nishimura, Fumiharu Yazaki, Masami Bessho, Hideaki Mizoguchi, Shigeru Chiba, Hisamaru Hirai, Tetsuzo Tauchi, Akio Urabe, Masatomo Takahashi, Kazunori Ohnishi, Toshiya Yokozawa, Nobuhiko Emi, Masami Hirano, Chihiro Shimazaki, Shinji Nakao, Yasukazu Kawai, Masahiro Fujimoto, Hirokuni Taguchi, Itsuro Jinnai, Ryuzo Ohno. (2004) Efficacy and Safety of Imatinib Mesylate for Patients in the First Chronic Phase of Chronic Myeloid Leukemia: Results of a Japanese Phase II Clinical Study. International Journal of Hematology 80:3, 261-266
CrossRef560
Nagahiro Saijo. (2004) What are the reasons for negative phase III trials of molecular-target-based drugs?. Cancer Science 95:10, 772-776
CrossRef561
Michael A. Pulsipher. (2004) Treatment of CML in pediatric patients: Should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?. Pediatric Blood & Cancer 43:5, 523-533
CrossRef562
C. Graux, J. Cools, C. Melotte, H. Quentmeier, A. Ferrando, R. Levine, J.R. Vermeesch, M. Stul, B. Dutta, N. Boeckx, A. Bosly, P. Heimann, A. Uyttebroeck, N. Mentens, R. Somers, R.A.F. MacLeod, H.G. Drexler, A.T. Look, D.G. Gilliland, L. Michaux, P. Vandenberghe, I. Wlodarska, Peter Marynen, Anne Hagemeijer. (2004) Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nature Genetics 36:10, 1084-1089
CrossRef563
Rowan Foster, Renate Griffith, Petranel Ferrao, Leonie Ashman. (2004) Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. Journal of Molecular Graphics and Modelling 23:2, 139-152
CrossRef564
G. Chang. (2004) Predictors of 1-Year Survival Assessed at the Time of Bone Marrow Transplantation. Psychosomatics 45:5, 378-385
CrossRef565
D. M Thomas, N. I. Fleming, A. J. Holloway, D. D. L. Bowtell. (2004) Molecular medicine: a clinician's primer on microarrays. Internal Medicine Journal 34:9-10, 565-569
CrossRef566
Henry T. Lynch, Trudy G. Shaw, Jane F. Lynch. (2004) Inherited predisposition to cancer: A historical overview. American Journal of Medical Genetics 129C:1, 5-22
CrossRef567
Christian Lavedan, Gunther Birznieks, Marlene Dressman, Karen McCullough, Rebecca Paczkowski, Rosa Torres, Curt Wolfgang, Mihael Polymeropoulos. (2004) Translating the Genome into individualized therapeutics. Drug Development Research 62:4, 371-382
CrossRef568
José Baselga, Joaquín Arribas. (2004) Treating cancer's kinase 'addiction'. Nature Medicine 10:8, 786-787
CrossRef569
Heiwa Kanamori, Hirotaka Takasaki, Maki Takabayashi, Satoshi Yamaji, Hideyuki Koharazawa, Katsumichi Fujimaki, Jun Taguchi, Yoshiaki Ishigatsubo. (2004) Long-term cytogenetic remission with ubenimex monotherapy in a case of chronic myeloid leukemia. Anti-Cancer Drugs 15:7, 729-731
CrossRef570
Olivier Kretz, H Markus Weiss, Martin M Schumacher, Gerhard Gross. (2004) In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. British Journal of Clinical Pharmacology 58:2, 212-216
CrossRef571
George Z Rassidakis, Georgios V Georgakis, Mauricio Oyarzo, Anas Younes, L Jeffrey Medeiros. (2004) Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Modern Pathology 17:8, 946-953
CrossRef572
S. A. Wells, J. R. Nevins. (2004) Evolving Strategies for Targeted Cancer Therapy--Past, Present, and Future. JNCI Journal of the National Cancer Institute 96:13, 980-981
CrossRef573
Takehiro Higashi, Junichi Tsukada, Chiaki Kato, Atsushi Iwashige, Takamitsu Mizobe, Shinichiro Machida, Hiroaki Morimoto, Ryosuke Ogawa, Yoko Toda, Yoshiya Tanaka. (2004) Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: Report of two cases. American Journal of Hematology 76:3, 275-278
CrossRef574
Toshiaki Yujiri, Yutaka Sato, Yukio Tanizawa. (2004) Sustained Cytogenetic Remission Induced by Imatinib Mesylate in a Chronic Myeloid Leukemia Patient Who Had a Relapse into Lymphoid Crisis after Allogeneic Hematopoietic Stem Cell Transplantation. International Journal of Hematology 80:1, 67-69
CrossRef575
Takaaki Hato, Jun Yamanouchi, Tatsushiro Tamura, Norimasa Hojo, Yasunari Niiya, Masashi Kohno, Shiro Bando, Yoshihiro Yakushijin, Kiyonori Takada, Ikuya Sakai, Masaki Yasukawa, Shigeru Fujita. (2004) Existence of Leukemic Clones Resistant to Both Imatinib Mesylate and Rituximab before Drug Therapies in a Patient with Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia. International Journal of Hematology 80:1, 62-66
CrossRef576
Srinivasan Madhusudan, Trivadi S. Ganesan. (2004) Tyrosine kinase inhibitors in cancer therapy. Clinical Biochemistry 37:7, 618-635
CrossRef577
Mie Uchida, Tomoko Watanabe, Masae Kunitama, Masaki Mori, Satoru Kikuchi, Kozue Yoshida, Keita Kirito, Tadashi Nagai, Keiya Ozawa, Norio Komatsu. (2004) Erythropoietin Overcomes Imatinib-Induced Apoptosis and Induces Erythroid Differentiation in TF-1/bcr-abl Cells. Stem Cells 22:4, 609-616
CrossRef578
Daniela Katz, Amiel Segal, Yossef Alberton, Oded Jurim, Petachia Reissman, Raphael Catane, Nathan I. Cherny. (2004) Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anti-Cancer Drugs 15:6, 599-602
CrossRef579
Masahide Yamamoto, Tetsuya Kurosu, Kazuhiko Kakihana, Daisuke Mizuchi, Osamu Miura. (2004) The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. Biochemical and Biophysical Research Communications 319:4, 1272-1275
CrossRef580
Jing Chen, Nathan R. Wall, Kerry Kocher, Nicole Duclos, Doriano Fabbro, Donna Neuberg, James D. Griffin, Yang Shi, D. Gary Gilliland. (2004) Stable expression of small interfering RNA sensitizes TEL-PDGFβR to inhibition with imatinib or rapamycin. Journal of Clinical Investigation 113:12, 1784-1791
CrossRef581
Yi Zeng, Michael W. Graner, Hanping Feng, Gang Li, Emmanuel Katsanis. (2004) Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treatbcr-abl+ murine leukemia. International Journal of Cancer 110:2, 251-259
CrossRef582
Robert L Ilaria. (2004) Animal models of chronic myelogenous leukemia. Hematology/Oncology Clinics of North America 18:3, 525-543
CrossRef583
Francesco Piazza, Gianpietro Semenzato. (2004) Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction. Expert Review of Anticancer Therapy 4:3, 387-400
CrossRef584
Krzysztof Mrózek, Nyla A Heerema, Clara D Bloomfield. (2004) Cytogenetics in acute leukemia. Blood Reviews 18:2, 115-136
CrossRef585
Jorge Cortes, Susan O'Brien, Alfonso Quintas, Francis Giles, Jianquin Shan, Mary Beth Rios, Moshe Talpaz, Hagop Kantarjian. (2004) Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 100:11, 2396-2402
CrossRef586
Andreas Hochhaus, Timothy Hughes. (2004) Clinical resistance to imatinib: mechanisms and implications. Hematology/Oncology Clinics of North America 18:3, 641-656
CrossRef587
Lucy C Crossman, Stephen G O'Brien. (2004) Imatinib therapy in chronic myeloid leukemia. Hematology/Oncology Clinics of North America 18:3, 605-617
CrossRef588
Takeshi Kawano, Junko Horiguchi-Yamada, Shinobu Saito, Satsuki Iwase, Yusuke Furukawa, Yasuhiko Kano, Hisashi Yamada. (2004) Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells. Leukemia Research 28:6, 623-629
CrossRef589
Michel Vulfovich, Nabil Saba. (2004) Molecular biological design of novel antineoplastic therapies. Expert Opinion on Investigational Drugs 13:6, 577-607
CrossRef590
Yi-Kong Keung, Michael Beaty, Bayard L Powell, Istvan Molnar, David Buss, Mark Pettenati. (2004) Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia—retrospective study and review of literature. Leukemia Research 28:6, 579-586
CrossRef591
Ayalew Tefferi, Animesh Pardanani. (2004) Imatinib Therapy in Clonal Eosinophilic Disorders, Including Systemic Mastocytosis. International Journal of Hematology 79:5, 441-447
CrossRef592
Francis J Giles, Jorge E Cortes, Hagop M Kantarjian, Susan M O'Brien. (2004) Accelerated and blastic phases of chronic myelogenous leukemia. Hematology/Oncology Clinics of North America 18:3, 753-774
CrossRef593
Carlos L. Arteaga, Jose Baselga. (2004) Tyrosine kinase inhibitors. Cancer Cell 5:6, 525-531
CrossRef594
Renato Bassan, Gemma Gatta, Carlo Tondini, Roel Willemze. (2004) Adult acute lymphoblastic leukaemia. Critical Reviews in Oncology/Hematology 50:3, 223-261
CrossRef595
Chikashi Yoshida, Junia V. Melo. (2004) Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease. International Journal of Hematology 79:5, 420-433
CrossRef596
Lucy C Crossman, Stephen O’Brien. (2004) Clinical results with imatinib in chronic myeloid leukaemia. Leukemia Research 28, 3-9
CrossRef597
Cynthia A. Prows, Daniel R. Prows. (2004) Medication Selection by Genotype. AJN, American Journal of Nursing 104:5, 60-70
CrossRef598
Nicholas B Lydon, Brian J Druker. (2004) Lessons learned from the development of imatinib. Leukemia Research 28, 29-38
CrossRef599
Brenda Wittman, John Horan, Joanna Baxter, John Goldberg, Raymond Felgar, Erin Baylor, Bean Cromwell, Nicholas Cross, John M Bennett. (2004) A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. Leukemia Research 28, 65-69
CrossRef600
E. Nadal, E. Olavarria. (2004) Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies. International Journal of Clinical Practice 58:5, 511-516
CrossRef601
Jonathan Kell. (2004) Emerging treatments in acute myeloid leukaemia. Expert Opinion on Emerging Drugs 9:1, 55-71
CrossRef602
Animesh Pardanani, Ayalew Tefferi. (2004) Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leukemia Research 28, 47-52
CrossRef603
R. J. Jones, W. H. Matsui, B. D. Smith. (2004) Cancer Stem Cells: Are We Missing the Target?. JNCI Journal of the National Cancer Institute 96:8, 583-585
CrossRef604
Pui, Ching-Hon, Relling, Mary V., Downing, James R., . (2004) Acute Lymphoblastic Leukemia. New England Journal of Medicine 350:15, 1535-1548
Full Text605
Pier Paolo Piccaluga, Michele Malagola, Michela Rondoni, Marilina Amabile, Stefania Paolini, Simona Soverini, Stavroula Gaitani, Giuseppe Visani, Michele Baccarani, Giovanni Martinelli. (2004) Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia. European Journal of Haematology 72:4, 302-303
CrossRef606
Stephane Wong, Owen N. Witte. (2004) The BCR-ABL Story: Bench to Bedside and Back. Annual Review of Immunology 22:1, 247-306
CrossRef607
Takahisa Tarumoto, Tadashi Nagai, Ken Ohmine, Takuji Miyoshi, Makiko Nakamura, Takahito Kondo, Kenji Mitsugi, Syuji Nakano, Kazuo Muroi, Norio Komatsu, Keiya Ozawa. (2004) Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. Experimental Hematology 32:4, 375-381
CrossRef608
Jana Moravcová, Václava Zmeková, Hana Klamová, Jaroslava Voglová, Edgar Faber, Kyra Michalová, Jana Rabasová, Marie Jarošová. (2004) Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase. Leukemia Research 28:4, 415-419
CrossRef609
Barbara Scappini, Simona Gatto, Francesco Onida, Clara Ricci, Vladimir Divoky, William G. Wierda, Michael Andreeff, Li Dong, Kimberly Hayes, Srdan Verstovsek, Hagop M. Kantarjian, Miloslav Beran. (2004) Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer 100:7, 1459-1471
CrossRef610
Constantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, Vassiliki Poulaki, Reshma Shringarpure, Masaharu Akiyama, Teru Hideshima, Dharminder Chauhan, Marie Joseph, Towia A Libermann, Carlos Garcı́a-Echeverrı́a, Mark A Pearson, Francesco Hofmann, Kenneth C Anderson, Andrew L Kung. (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5:3, 221-230
CrossRef611
Nada Orsolic, Francis J. Giles, Henriette Gourdeau, Mirna Golemovic, Miloslav Beran, Jorge Cortes, Emil J Freireich, Hagop Kantarjian, Srdan Verstovsek. (2004) Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. British Journal of Haematology 124:6, 727-738
CrossRef612
Greg R Angstreich, B Douglas Smith, Richard J Jones. (2004) Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant. Current Opinion in Oncology 16:2, 95-99
CrossRef613
Kanoko Kohmura, Yoshitaka Miyakawa, Yoko Kawai, Yasuo Ikeda, Masahiro Kizaki. (2004) Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells. Journal of Cellular Physiology 198:3, 370-376
CrossRef614
Mark R Litzow. (2004) The therapy of relapsed acute leukaemia in adults. Blood Reviews 18:1, 39-63
CrossRef615
Alberto Redaelli, Christopher Bell, Jodie Casagrande, Jennifer Stephens, Marc Botteman, Benjamin Laskin, Chris Pashos. (2004) Clinical and epidemiologic burden of chronic myelogenous leukemia. Expert Review of Anticancer Therapy 4:1, 85-96
CrossRef616
Bruno Buecher, Hervé M. Blottière. (2004) Nouvelles approches pharmacologiques de traitement des cancers. Gastroentérologie Clinique et Biologique 28:2, 167-180
CrossRef617
Steven Coutré, Jason Gotlib. (2004) Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Seminars in Cancer Biology 14:1, 23-31
CrossRef618
Jin Seok Kim, Hoi Kyung Jeung, June-Won Cheong, Hoyoung Maeng, Seung Tae Lee, Jee Sook Hahn, Yun Woong Ko, Yoo Hong Min. (2004) Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. British Journal of Haematology 124:2, 166-178
CrossRef619
Henry T. Lynch, Bronson D. Riley, Scott Weismann, Stephanie M. Coronel, Yulia Kinarsky, Jane F. Lynch, Trudy G. Shaw, Wendy S. Rubinstein. (2004) Hereditary nonpolyposis colorectal carcinoma (HNPCC) and HNPCC-like families: Problems in diagnosis, surveillance, and management. Cancer 100:1, 53-64
CrossRef620
Tadeusz Robak. (2004) Acute Lymphoblastic Leukaemia in Elderly Patients. Drugs & Aging 21:12, 779-791
CrossRef621
Jose F Leis, Daniel E Stepan, Peter T Curtin, John M Ford, Bin Peng, Susan Schubach, Brian J Druker, Richard T Maziarz. (2004) Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with Imatinib (STI-571). Leukemia & Lymphoma 45:4, 695-698
CrossRef622
KW Song, J Rifkind, B Al-Beirouti, K Yee, J McCrae, HA Messner, A Keating, JH Lipton. (2004) Subdural Hematomas during CML Therapy with Imatinib Mesylate. Leukemia & Lymphoma 45:8, 1633-1636
CrossRef623
Mark W Drummond, Anne Lennard, Tim H Brûmmendorf, Tessa L Holyoake. (2004) Telomere Shortening Correlates with Prognostic Score at Diagnosis and Proceeds Rapidly during Progression of Chronic Myeloid Leukemia. Leukemia & Lymphoma 45:9, 1775-1781
CrossRef624
John M Goldman. (2004) Chronic myeloid leukemia—still a few questions. Experimental Hematology 32:1, 2-10
CrossRef625
MELISSA S HOLTZ, RAVI BHATIA. (2004) Effect of Imatinib Mesylate on Chronic Myelogenous Leukemia Hematopoietic Progenitor Cells. Leukemia & Lymphoma 45:2, 237-245
CrossRef626
Dax Kurbegov, Hagop M Kantarjian, Moshe Talpaz. (2004) The Role of Imatinib in the Treatment of Chronic Myelogenous Leukemia. American Journal of Cancer 3:6, 337-348
CrossRef627
Ian M Adcock, Gaetano Caramori. (2004) Kinase Targets and Inhibitors for the Treatment of Airway Inflammatory Diseases. BioDrugs 18:3, 167-180
CrossRef628
Atsuji Matsuyama, Shingo Kamoshida, Yoshikazu Mizoguchi, Ryoichi Shimomura, Yutaka Hirasawa, Ken-ichi Inada, Yutaka Tsutsumi. (2004) Appropriate Epitope Retrieval for c-kit Protein Immunostaining in Routinely Prepared Specimens of Gastrointestinal Stromal Tumor. ACTA HISTOCHEMICA ET CYTOCHEMICA 37:2, 87-93
CrossRef629
Hermine Agis, Christine Mannhalter, Wolfgang R Sperr, Felix Keil, Peter Kalhs, Hendrati Pirc-Danoewinata, Maria-Theresa Krauth, Oskar A Haas, Klaus Geissler, Klaus Lechner, Peter Valent. (2004) Detection of Trisomy 8 in Donor-Derived Ph − Cells in a Patient with Ph + Chronic Myeloid Leukemia Successfully Treated with Imatinib (STI571) in Relapse after Allogeneic Transplantation. Leukemia & Lymphoma 45:7, 1453-1458
CrossRef630
Henry T Lynch, Carolyn A Deters, Jane F Lynch, Randall E Brand. (2004) Familial pancreatic carcinoma in Jews. Familial Cancer 3:3-4, 233-240
CrossRef631
Shinya Kimura, Junya Kuroda, Taira Maekawa. (2004) The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Ensho Saisei 24:2, 113-117
CrossRef632
Pellegrino Musto, Antonietta Falcone, Grazia Sanpaolo, Carlo Bodenizza, Gianni Perla, Maria Marta Minervini, Nicola Cascavilla, Matteo Dell'olio, Antonio La Sala, Saverio Mantuano, Lorella Melillo, Michele Nobile, Potito Rosario Scalzulli, Michele Bisceglia, Angelo Michele Carella. (2004) Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis. Leukemia & Lymphoma 45:6, 1219-1222
CrossRef633
Carl-Henrik Heldin. (2004) Development and possible clinical use of antagonists for PDGF and TGF-β. Upsala Journal of Medical Sciences 109:3, 165-178
CrossRef634
Tomohiro MYOJO, Norihiko HINO. (2004) Complete Remission from Chronic Myelogenous Leukemia-Blastic Crisis Caused by Reduced Intensity Stem Cell Transplantation Following Partial Remission Due to Imatinib. Internal Medicine 43:2, 126-130
CrossRef635
Shinya Kimura, Junya Kuroda, Hidekazu Segawa, Kiyoshi Sato, Masaki Nogawa, Takeshi Yuasa, Oliver G. Ottmann, Taira Maekawa. (2004) Antiproliferative Efficacy of the Third-Generation Bisphosphonate, Zoledronic Acid, Combined with Other Anticancer Drugs in Leukemic Cell Lines. International Journal of Hematology 79:1, 37-43
CrossRef636
E. Anders Kolb, Qiulu Pan, Marc Ladanyi, Peter G. Steinherz. (2003) Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. Cancer 98:12, 2643-2650
CrossRef637
Hagop M. Kantarjian, Susan O'Brien, Jorge Cortes, Francis J. Giles, Mary Beth Rios, Jianqin Shan, Stefan Faderl, Guillermo Garcia-Manero, Alessandra Ferrajoli, Srdan Verstovsek, William Wierda, Michael Keating, Moshe Talpaz. (2003) Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase. Cancer 98:12, 2636-2642
CrossRef638
Hans Carl Hasselbalch, Ole Weiss Bjerrum, Bjarne Anker Jensen, Nielsaage T
CrossRef639
Tomasz Sacha, Andreas Hochhaus, Benjamin Hanfstein, Martin C. Müller, Zbigniew Rudzki, Jacek Czopek, Teresa Wolska-Smoleń, Sylwia Czekalska, Zoriana Salamanchuk, Małgorzata Jakóbczyk, Aleksander B. Skotnicki. (2003) ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. Leukemia Research 27:12, 1163-1166
CrossRef640
W. MARSTON LINEHAN, McCLELLAN M. WALTHER, BERTON ZBAR. (2003) The Genetic Basis of Cancer of the Kidney. The Journal of Urology 170:6, 2163-2172
CrossRef641
Floris A de Jong, Jaap Verweij. (2003) Role of imatinib mesylate (Gleevec®/Glivec®) in gastrointestinal stromal tumors. Expert Review of Anticancer Therapy 3:6, 757-766
CrossRef642
Mark Levis, Donald Small. (2003) Novel FLT3 tyrosine kinase inhibitors. Expert Opinion on Investigational Drugs 12:12, 1951-1962
CrossRef643
Mariko Eguchi, Minenori Eguchi-Ishimae, Mel Greaves. (2003) The Role of theMLL Gene in Infant Leukemia. International Journal of Hematology 78:5, 390-401
CrossRef644
Hugh J. M. Brady. (2003) Apoptosis and leukaemia. British Journal of Haematology 123:4, 577-585
CrossRef645
Chirayu Udomsakdi-Auewarakul, Orathai Promsuwicha, Chintana Tocharoentanaphol, Chanya Munhketvit, Kovit Pattanapanyasat, Surapol Issaragrisil. (2003) Immunophenotypes and Outcome of Philadelphia Chromosome-Positive and -Negative Thai Adult Acute Lymphoblastic Leukemia. International Journal of Hematology 78:4, 337-343
CrossRef646
Goldman, John M., Melo, Junia V., . (2003) Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment. New England Journal of Medicine 349:15, 1451-1464
Full Text647
E. M. Connolly, E. Gaffney, J. V. Reynolds. (2003) Gastrointestinal stromal tumours. British Journal of Surgery 90:10, 1178-1186
CrossRef648
Hagop Kantarjian, Susan O'Brien, Jorges Cortes, Jianqin Shan, Francis Giles, Guillermo Garcia-Manero, Srdan Verstovsek, Stefan Faderl, Mary Beth Rios, Moshe Talpaz. (2003) Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-? regimens for early chronic phase. Cancer 98:7, 1430-1437
CrossRef649
Steven S. Shen, Peter S. Zhang, Omar Eton, Victor G. Prieto. (2003) Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. Journal of Cutaneous Pathology 30:9, 539-547
CrossRef650
William E Winter, Jeffrey D Seidman, Thomas C Krivak, Suman Chauhan, Jay W Carlson, G.Scott Rose, Michael J Birrer. (2003) Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecologic Oncology 91:1, 3-8
CrossRef651
Toshio Nishihara, Yasuo Miura, Yumi Tohyama, Chisato Mizutani, Terutoshi Hishita, Satoshi Ichiyama, Takashi Uchiyama, Kaoru Tohyama. (2003) Effects of the Tyrosine Kinase Inhibitor Imatinib Mesylate on a Bcr-Abl-Positive Cell Line: Suppression of Autonomous Cell Growth but No Effect on Decreased Adhesive Property and Morphological Changes. International Journal of Hematology 78:3, 233-240
CrossRef652
Robert Roskoski. (2003) STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochemical and Biophysical Research Communications 309:4, 709-717
CrossRef653
S. Wong, J. McLaughlin, D. Cheng, K. Shannon, L. Robb, O. N. Witte. (2003) IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease. Proceedings of the National Academy of Sciences 100:20, 11630-11635
CrossRef654
Jorge Cortes, Moshe Talpaz, Susan O'Brien, Francis Giles, Mary Beth Rios, Jianquin Shan, Stefan Faderl, Guillermo Garcia-Manero, Alessandra Ferrajoli, William Wierda, Hagop Kantarjian. (2003) Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98:6, 1105-1113
CrossRef655
Oliver Bock, Dunja Reising, Hans Kreipe. (2003) Multiplex RT-PCR for the Detection of Common BCR-ABL Fusion Transcripts in Paraffin-Embedded Tissues From Patients With Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia. Diagnostic Molecular Pathology 12:3, 119-123
CrossRef656
Mel F. Greaves, Joe Wiemels. (2003) Origins of chromosome translocations in childhood leukaemia. Nature Reviews Cancer 3:9, 639-649
CrossRef657
Jeffrey E Lancet, Judith E Karp. (2003) Farnesyl transferase inhibitors in myeloid malignancies. Blood Reviews 17:3, 123-129
CrossRef658
Randall F. Holcombe, Mai Gu, David Imagawa, Tatjana Milovanovic. (2003) Expression of Kit and platelet-derived growth factor receptors ?? and ?? in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571). Anti-Cancer Drugs 14:8, 651-657
CrossRef659
Mitsuko Kotaki, Toshiko Motoji, Minoko Takanashi, Yan-Hua Wang, Hideaki Mizoguchi. (2003) Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line. Cancer Letters 199:1, 61-68
CrossRef660
Xue-mei Sun, Ben Brady. (2003) New drug targeting treatment — Glivec. Chinese Journal of Cancer Research 15:3, 235-239
CrossRef661
D. Nicolella, P. Maione, C. Gridelli. (2003) Targeted therapies: focus on a new strategy for gastrointestinal tumors. Critical Reviews in Oncology/Hematology 47:3, 261-271
CrossRef662
Susan O'Brien, Francis Giles, Moshe Talpaz, Jorge Cortes, Mary Beth Rios, Jianqin Shan, Deborah Thomas, Michael Andreeff, Steven Kornblau, Stefan Faderl, Guillermo Garcia-Manero, Kevin White, Susie Mallard, Emil Freireich, Hagop M. Kantarjian. (2003) Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98:5, 888-893
CrossRef663
Lois M Ramondetta, Thomas W Burke, Anuja Jhingran, Rosemarie Schmandt, Michael W Bevers, Judith K Wolf, Charles F Levenback, Russell Broaddus. (2003) A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. Gynecologic Oncology 90:3, 529-536
CrossRef664
Oliver M Fischer, Sylvia Streit, Stefan Hart, Axel Ullrich. (2003) Beyond Herceptin and Gleevec. Current Opinion in Chemical Biology 7:4, 490-495
CrossRef665
Margaret E. McLaughlin, Caroline D. Robson, Mark W. Kieran, Tyler Jacks, Scott L. Pomeroy, Scott Cameron. (2003) Marked Regression of Metastatic Pilocytic Astrocytoma During Treatment With Imatinib Mesylate (STI-571, Gleevec): A Case Report and Laboratory Investigation. Journal of Pediatric Hematology/Oncology 25:8, 644-648
CrossRef666
Rony Abou-Jawde, Toni Choueiri, Carlos Alemany, Tarek Mekhail. (2003) An overview of targeted treatments in cancer. Clinical Therapeutics 25:8, 2121-2137
CrossRef667
Christian Sillaber, Matthias Mayerhofer, Hermine Agis, Verena Sagaster, Christine Mannhalter, Wolfgang R. Sperr, Klaus Geissler, Peter Valent. (2003) Chronic myeloid leukemia: Pathophysiology, diagnostic parameters, and current treatment concepts. Wiener Klinische Wochenschrift 115:13-14, 485-504
CrossRef668
Frederick W. Fraunfelder, Jonathan Solomon, Brian J. Druker, Bita Esmaeli, Jennifer Kuyl. (2003) Ocular Side-Effects Associated with Imatinib Mesylate (Gleevec ® ). Journal of Ocular Pharmacology and Therapeutics 19:4, 371-375
CrossRef669
Philipp le Coutre, Karl-Anton Kreuzer, Il-Kang Na, Michaela Schwarz, Joachim Lupberger, Matthias Holdhoff, G
CrossRef670
Guillermo Garcia-Manero, Stefan Faderl, Susan O'Brien, Jorge Cortes, Moshe Talpaz, Hagop M. Kantarjian. (2003) Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer 98:3, 437-457
CrossRef671
Cem Akin, Knut Brockow, Claudio D'Ambrosio, Arnold S Kirshenbaum, Yongsheng Ma, B.Jack Longley, Dean D Metcalfe. (2003) Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Experimental Hematology 31:8, 686-692
CrossRef672
Aikaterini Barbouti, Tomas Ahlgren, Bertil Johansson, Mattias H
CrossRef673
Jeremy Sugarman, W. Gillies McKenna. (2003) Ethical Hurdles for Translational Research. Radiation Research 160:1, 1-4
CrossRef674
Takatsune Shimizu, Yoshitaka Miyakawa, Atsushi Oda, Masahiro Kizaki, Yasuo Ikeda. (2003) STI571-resistant KT-1 cells are sensitive to interferon-α accompanied by the loss of T-cell protein tyrosine phosphatase and prolonged phosphorylation of Stat1. Experimental Hematology 31:7, 601-608
CrossRef675
FW Fraunfelder. (2003) Ocular adverse drug reactions. Expert Opinion on Drug Safety 2:4, 411-420
CrossRef676
Brian J Druker. (2003) Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opinion on Pharmacotherapy 4:6, 963-971
CrossRef677
Jorge Cortes, Francis Giles, Susan O'Brien, Deborah Thomas, Maher Albitar, Mary Beth Rios, Moshe Talpaz, Guillermo Garcia-Manero, Stefan Faderl, Laurie Letvak, August Salvado, Hagop Kantarjian. (2003) Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 97:11, 2760-2766
CrossRef678
László Gopcsa, Anikó Barta, Anikó Bányai, János Dolgos, Gabriella Halm, Katalin Pálóczi. (2003) Salvage chemotherapy with donor lymphocyte infusion and STI 571 in a patient relapsing with B-lymphoblastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation. Pathology & Oncology Research 9:2, 131-133
CrossRef679
Aaron D. Schimmer, Irene Munk-Pedersen, Mark D. Minden, John C. Reed. (2003) Bcl-2 and apoptosis in chronic lymphocytic leukemia. Current Treatment Options in Oncology 4:3, 211-218
CrossRef680
Edward P. Gelmann. (2003) Searching for the gatekeeper oncogene of prostate cancer. Critical Reviews in Oncology/Hematology 46, 11-20
CrossRef681
John L. Frater, Martin S. Tallman, Daina Variakojis, Brian J. Druker, Debra Resta, Mary Beth Riley, Mary Ann Hrisinko, LoAnn C. Peterson. (2003) Chronic Myeloid Leukemia Following Therapy With Imatinib Mesylate (Gleevec): Bone Marrow Histopathology and Correlation With Genetic Status. American Journal of Clinical Pathology 119:6, 833-841
CrossRef682
Alberto Redaelli, Jennifer M Stephens, Benjamin L Laskin, Chris L Pashos, Marc F Botteman. (2003) The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML. Expert Review of Anticancer Therapy 3:3, 311-329
CrossRef683
Burton L Eisenberg, Margaret von Mehren. (2003) Pharmacotherapy of gastrointestinal stromal tumours. Expert Opinion on Pharmacotherapy 4:6, 869-874
CrossRef684
Motoi Mukai, Xiao-Fang Che, Tatsuhiko Furukawa, Tomoyuki Sumizawa, Shunji Aoki, Xiao-Qin Ren, Misako Haraguchi, Yoshikazu Sugimoto, Motomasa Kobayashi, Hideo Takamatsu, Shin-ichi Akiyama. (2003) Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Science 94:6, 557-563
CrossRef685
Gurpreet S. Kapoor, Donald M. O’Rourke. (2003) Mitogenic Signaling Cascades in Glial Tumors. Neurosurgery 52:6, 1425-1435
CrossRef686
Carlos Rodriguez-Galindo, Sheri L. Spunt, Alberto S. Pappo. (2003) Treatment of Ewing sarcoma family of tumors: Current status and outlook for the future. Medical and Pediatric Oncology 40:5, 276-287
CrossRef687
Hagop Kantarjian, Moshe Talpaz, Susan O'Brien, Francis Giles, Mary Beth Rios, Kevin White, Guillermo Garcia-Manero, Alessandra Ferrajoli, Srdan Verstovsek, William Wierda, Steven Kornblau, Jorge Cortes. (2003) Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 97:9, 2225-2228
CrossRef688
Beate Gleissner, Eckhard Thiel. (2003) Molecular genetic events in adult acute lymphoblastic leukemia. Expert Review of Molecular Diagnostics 3:3, 339-355
CrossRef689
Sang Kyun Sohn, Jong Gwang Kim, Dong Hwan Kim, Kyu Bo Lee. (2003) Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration. British Journal of Haematology 121:3, 469-472
CrossRef690
Ken Ohmine, Tadashi Nagai, Takahisa Tarumoto, Takuji Miyoshi, Kazuo Muroi, Hiroyuki Mano, Norio Komatsu, Fumimaro Takaku, Keiya Ozawa. (2003) Analysis of Gene Expression Profiles in an Imatinib-Resistant Cell Line, KCL22/SR. Stem Cells 21:3, 315-321
CrossRef691
Paola Dal Cin. 2003. Metaphase Harvest and Cytogenetic Analysis of Malignant Hematological Specimens. .
CrossRef692
Janice V. Scobie, Geza Acs, Christina A. Bandera, Stephanie V. Blank, James E. Wheeler, Teresa L. Pasha, Marilyn Salscheider, Paul J. Zhang. (2003) C-Kit Immunoreactivity in Endometrial Adenocarcinomas and Its Clinicopathologic Significance. International Journal of Gynecological Pathology 22:2, 149-155
CrossRef693
Alex J. Tipping, Junia V. Melo. (2003) Imatinib mesylate in combination with other chemotherapeutic drugs: In vitro studies. Seminars in Hematology 40:2, 83-91
CrossRef694
Edward A Sausville. (2003) Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard?. The Lancet 361:9367, 1400-1401
CrossRef695
Aloysius Y. L. Ho, Allan Deacon, Genevieve Osborne, Ghulam J. Mufti. (2003) Precipitation of porphyria cutanea tarda by imatinib mesylate?. British Journal of Haematology 121:2, 375-375
CrossRef696
Edward A. Sausville, Yusri Elsayed, Manish Monga, George Kim. (2003) S
IGNAL TRANSDUCTION –DIRECTED CANCER TREATMENTS *. Annual Review of Pharmacology and Toxicology 43:1, 199-231
CrossRef697
Frederic Morel, Marie-Josee Le Bris, Angele Herry, Genevieve Le Calvez, Veronique Marion, Jean-Francois Abgrall, Christian Berthou, Marc De Braekeleer. (2003) Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. European Journal of Haematology 70:4, 235-239
CrossRef698
John M. Goldman, David Marin, Eduardo Olavarria, Jane F. Apperley. (2003) Clinical decisions for chronic myeloid leukemia in the imatinib era. Seminars in Hematology 40, 98-103
CrossRef699
Alex J. Tipping, Junia V. Melo. (2003) Imatinib mesylate in combination with other chemotherapeutic drugs: In vitro studies. Seminars in Hematology 40, 83-91
CrossRef700
Catherine Roche-Lestienne, Claude Preudhomme. (2003) Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Seminars in Hematology 40, 80-82
CrossRef701
H. Burger, M.A. den Bakker, G. Stoter, J. Verweij, K. Nooter. (2003) Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. European Journal of Cancer 39:6, 793-799
CrossRef702
George Q. Daley. (2003) Towards combination target-directed chemotherapy for chronic myeloid leukemia: Role of farnesyl transferase inhibitors. Seminars in Hematology 40, 11-14
CrossRef703
Renaud Capdeville, Sandra Silberman. (2003) Imatinib: A targeted clinical drug development. Seminars in Hematology 40, 15-20
CrossRef704
Martee L. Hensley, John M. Ford. (2003) Imatinib treatment: Specific issues related to safety, fertility, and pregnancy. Seminars in Hematology 40:2, 21-25
CrossRef705
Stephen G. O'Brien, Michael W.N. Deininger. (2003) Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Seminars in Hematology 40, 26-30
CrossRef706
George Q. Daley. (2003) Towards combination target-directed chemotherapy for chronic myeloid leukemia: Role of farnesyl transferase inhibitors. Seminars in Hematology 40:2, 11-14
CrossRef707
Benjamin E Rich. (2003) IL-20: a new target for the treatment of inflammatory skin disease. Expert Opinion on Therapeutic Targets 7:2, 165-174
CrossRef708
Andreas Hochhaus. (2003) Cytogenetic and molecular mechanisms of resistance to imatinib. Seminars in Hematology 40:2, 69-79
CrossRef709
Stephen G. O'Brien, Michael W.N. Deininger. (2003) Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Seminars in Hematology 40:2, 26-30
CrossRef710
Catherine Roche-Lestienne, Claude Preudhomme. (2003) Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Seminars in Hematology 40:2, 80-82
CrossRef711
Andreas Hochhaus. (2003) Cytogenetic and molecular mechanisms of resistance to imatinib. Seminars in Hematology 40, 69-79
CrossRef712
C. McNamara, A. Grigg, J. Szer, A. Roberts, L. Campbell, R. Hoyt, K. Lynch, S. Juneja. (2003) Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. Clinical and Laboratory Haematology 25:2, 119-125
CrossRef713
John M. Goldman, David Marin, Eduardo Olavarria, Jane F. Apperley. (2003) Clinical decisions for chronic myeloid leukemia in the imatinib era. Seminars in Hematology 40:2, 98-103
CrossRef714
Renaud Capdeville, Sandra Silberman. (2003) Imatinib: A targeted clinical drug development. Seminars in Hematology 40:2, 15-20
CrossRef715
Martee L. Hensley, John M. Ford. (2003) Imatinib treatment: Specific issues related to safety, fertility, and pregnancy. Seminars in Hematology 40, 21-25
CrossRef716
Christopher A. French, Erik K. Alexander, Edmund S. Cibas, Vania Nose, Julia Laguette, William Faquin, Jeff Garber, Francis Moore, Jonathan A. Fletcher, P. Reed Larsen, Todd G. Kroll. (2003) Genetic and Biological Subgroups of Low-Stage Follicular Thyroid Cancer. The American Journal of Pathology 162:4, 1053-1060
CrossRef717
Cools, Jan, DeAngelo, Daniel J., Gotlib, Jason, Stover, Elizabeth H., Legare, Robert D., Cortes, Jorges, Kutok, Jeffrey, Clark, Jennifer, Galinsky, Ilene, Griffin, James D., Cross, Nicholas C.P., Tefferi, Ayalew, Malone, James, Alam, Rafeul, Schrier, Stanley L., Schmid, Janet, Rose, Michal, Vandenberghe, Peter, Verhoef, Gregor, Boogaerts, Marc, Wlodarska, Iwona, Kantarjian, Hagop, Marynen, Peter, Coutre, Steven E., Stone, Richard, Gilliland, D. Gary, . (2003) A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome. New England Journal of Medicine 348:13, 1201-1214
Full Text718
Peggs, Karl, Mackinnon, Stephen, . (2003) Imatinib Mesylate — The New Gold Standard for Treatment of Chronic Myeloid Leukemia. New England Journal of Medicine 348:11, 1048-1050
Full Text719
Guttmacher, Alan E., Collins, Francis S., , Lynch, Henry T., de la Chapelle, Albert, . (2003) Hereditary Colorectal Cancer. New England Journal of Medicine 348:10, 919-932
Full Text720
Alasdair Breckenridge. (2003) For the good of the patient: risks and benefits of medicines. Pharmacoepidemiology and Drug Safety 12:2, 145-150
CrossRef721
Mohammad Azam, Robert R. Latek, George Q. Daley. (2003) Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL. Cell 112:6, 831-843
CrossRef722
Derek L Stirewalt, Soheil Meshinchi, Jerald P Radich. (2003) Molecular targets in acute myelogenous leukemia. Blood Reviews 17:1, 15-23
CrossRef723
Lihui Wang, Kevin Pearson, Julia E. Ferguson, Richard E. Clark. (2003) The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. British Journal of Haematology 120:6, 990-999
CrossRef724
Muna Sabah, Mary Leader, Elaine Kay. (2003) The Problem With KIT: Clinical Implications and Practical Difficulties With CD117 Immunostaining. Applied Immunohistochemistry & Molecular Morphology 11:1, 56-61
CrossRef725
Muna Sabah, Mary Leader, Elaine Kay. (2003) Applied Immunohistochemistry 11:1, 56-61
CrossRef726
S. M. Ansell, M. J. Ackerman, J. L. Black, L. R. Roberts, A. Tefferi. (2003) Primer on Medical Genomics Part VI: Genomics and Molecular Genetics in Clinical Practice. Mayo Clinic Proceedings 78:3, 307-317
CrossRef727
David P Steensma, Ayalew Tefferi. (2003) The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leukemia Research 27:2, 95-120
CrossRef728
Rachida Inaoui, Barbara Petit, Arnaud Jaccard, Philippe Bertin, Richard Trèves. (2003) Aggressive systemic mastocytosis. Joint Bone Spine 70:1, 64-66
CrossRef729
Mohammad Azam, Tal Raz, Valentina Nardi, Sarah L. Opitz, George Q. Daley. (2003) A screen to identify drug resistant variants to target-directed anti-cancer agents. Biological Procedures Online 5:1, 204-210
CrossRef730
Scott A Armstrong, Andrew L Kung, Meghann E Mabon, Lewis B Silverman, Ronald W Stam, Monique L Den Boer, Rob Pieters, John H Kersey, Stephen E Sallan, Jonathan A Fletcher, Todd R Golub, James D Griffin, Stanley J Korsmeyer. (2003) Inhibition of FLT3 in MLL. Cancer Cell 3:2, 173-183
CrossRef731
Tariq I Mughal, John M Goldman. (2003) Chronic Myeloid Leukemia. American Journal of Cancer 2:5, 305-311
CrossRef732
Motowo NAKAJIMA, Wakako TOGA. (2003) Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor.. Folia Pharmacologica Japonica 122:6, 482-490
CrossRef733
Brian J. Druker. (2003) Imatinib alone and in combination for chronic myeloid leukemia. Seminars in Hematology 40:1, 50-58
CrossRef734
Piotr Smolewski, Zbigniew Darzynkiewicz, Tadeusz Robak. (2003) Caspase-mediated Cell Death in Hematological Malignancies: Theoretical Considerations, Methods of Assessment, and Clinical Implications. Leukemia & Lymphoma 44:7, 1089-1104
CrossRef735
John M. Goldman. (2003) Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase. Seminars in Hematology 40, 10-17
CrossRef736
Efsevia Albanis, Rifaat Safadi, Scott L. Friedman. (2003) Treatment of hepatic fibrosis: Almost there. Current Gastroenterology Reports 5:1, 48-56
CrossRef737
Gordon B. Mills, Xianjun Fang, Yiling Lu, Yutaka Hasegawa, Astrid Eder, Janos Tanyi, Fazad Haq Tabassam, Muling Mao, Hongwei Wang, Kwai Wa Cheng, Yasuhisa Nakayama, Wenlin Kuo, Jim Erickson, David Gershenson, Elise C. Kohn, Robert Jaffe, Robert C. Bast, Joe Gray. (2003) Specific Keynote: Molecular Therapeutics in Ovarian Cancer. Gynecologic Oncology 88:1, S88-S92
CrossRef738
Frédéric Morel, Chandran Ka, Marie-Josée Le Bris, Angèle Herry, Patrick Morice, Pascal Bourquard, Jean François Abgrall, Christian Berthou, Marc De Braekeleer. (2003) Deletion of the 5'ABL Region in Philadelphia Chromosome Positive Chronic Myeloid Leukemia: Frequency, Origin and Prognosis. Leukemia & Lymphoma 44:8, 1333-1338
CrossRef739
Stephan M. Feller, Gabriele Tuchscherer, Jan Voss. (2003) High Affinity Molecules Disrupting GRB2 Protein Complexes as a Therapeutic Strategy for Chronic Myelogenous Leukaemia. Leukemia & Lymphoma 44:3, 411-427
CrossRef740
Jorge Cortes, Hagop Kantarjian. (2003) Advanced-phase chronic myeloid leukemia. Seminars in Hematology 40:1, 79-86
CrossRef741
John M. Goldman, David Marin. (2003) Management decisions in chronic myeloid leukemia. Seminars in Hematology 40:1, 97-103
CrossRef742
Kanoko Sawafuji, Yoshitaka Miyakawa, Ellen Weisberg, James D. Griffin, Yasuo Ikeda, Masahiro Kizaki. (2003) Aminopeptidase Inhibitors Inhibit Proliferation and Induce Apoptosis of K562 and STI571-resistant K562 Cell Lines Through the MAPK and GSK-3ß Pathways. Leukemia & Lymphoma 44:11, 1987-1996
CrossRef743
Partow Kebriaei, John Anastasi, Richard A. Larson. (2002) Acute lymphoblastic leukaemia: diagnosis and classification. Best Practice & Research Clinical Haematology 15:4, 597-621
CrossRef744
Deborah A Thomas, Jorge Cortes, Hagop M Kantarjian. (2002) New agents in the treatment of acute lymphocytic leukaemia. Best Practice & Research Clinical Haematology 15:4, 771-790
CrossRef745
Oliver G Ottmann, Barbara Wassmann. (2002) Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts. Best Practice & Research Clinical Haematology 15:4, 757-769
CrossRef746
Shuji Ueda, Hirokazu Ikeda, Masao Mizuki, Jun Ishiko, Itaru Matsumura, Hirokazu Tanaka, Hirohiko Shibayama, Hiroyuki Sugahara, Emi Takai, Xian Zhang, Takashi Machii, Yuzuru Kanakura. (2002) Constitutive Activation of C-kit by the Juxtamembrane but Not the Catalytic Domain Mutations Is Inhibited Selectively by Tyrosine Kinase Inhibitors STI571 and AG1296. International Journal of Hematology 76:5, 427-435
CrossRef747
John T Lee Jr, James A McCubrey. (2002) Targeting the Raf kinase cascade in cancer therapy – novel molecular targets and therapeutic strategies. Expert Opinion on Therapeutic Targets 6:6, 659-678
CrossRef748
Hendrik W. van Deventer, Melissa D. Hall, Robert Z. Orlowski, Beverly S. Mitchell, Lee R. Berkowitz, Cathe Hogan, Cherie H. Dunphy, Julie Koehler, Thomas C. Shea. (2002) Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia. American Journal of Hematology 71:3, 184-190
CrossRef749
Ronald P. DeMatteo. (2002) The GIST of targeted cancer therapy: A tumor (Gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Annals of Surgical Oncology 9:9, 831-839
CrossRef750
Giovanni Cazzaniga, Marina Lanciotti, Vincenzo Rossi, Daniela Di Martino, Maurizio Arico, Maria Grazia Valsecchi, Giuseppe Basso, Giuseppe Masera, Concetta Micalizzi, Andrea Biondi. (2002) Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. British Journal of Haematology 119:2, 445-453
CrossRef751
Yuka Hirose, Hitoshi Kiyoi, Masanori Iwai, Toshiya Yokozawa, Masafumi Ito, Tomoki Naoe. (2002) Successful Treatment with Imatinib Mesylate of a CML Patient in Megakaryoblastic Crisis with Severe Fibrosis. International Journal of Hematology 76:4, 349-353
CrossRef752
Henry T. Lynch, Dennis D. Weisenburger, Brigid Quinn-Laquer, Patrice Watson, Jane F. Lynch, Warren G. Sanger. (2002) Hereditary chronic lymphocytic leukemia: An extended family study and literature review. American Journal of Medical Genetics 115:3, 113-117
CrossRef753
D. Vidal, L. Puig, A. Sureda, A. Alomar. (2002) Sti571-induced Stevens-Johnson Syndrome. British Journal of Haematology 119:1, 274-275
CrossRef754
Michaela Schwarz, Karl-Anton Kreuzer, Gökben Baskaynak, Bernd Dörken, Philipp le Coutre. (2002) Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. European Journal of Haematology 69:4, 254-256
CrossRef755
Nobuyuki Takayama, Norihide Sato, Stephen G. O'Brien, Yasuo Ikeda, Shin-ichiro Okamoto. (2002) Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. British Journal of Haematology 119:1, 106-108
CrossRef756
Vanita K. Pindolia, Barbara J. Zarowitz. (2002) Imatinib Mesylate, the First Molecularly Targeted Gene Suppressor. Pharmacotherapy 22:10, 1249-1265
CrossRef757
Martin S Tallman. (2002) Advancing the treatment of hematologic malignancies through the development of targeted interventions. Seminars in Hematology 39:4, 1-5
CrossRef758
James C. Barton, Steven C. Jones, Wade C. Lamberth, Michael T. Reymann, Varian C. Scott. (2002) Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia. American Journal of Hematology 71:2, 139-140
CrossRef759
Stephen G. O'Brien, Simon A. J. Rule. (2002) Position paper on imatinib mesylate in chronic myeloid leukaemia*. British Journal of Haematology 119:1, 268-272
CrossRef760
Christophe Barthe, Marie-josee Gharbi, Valerie Lagarde, Claudine Chollet, Pascale Cony-Makhoul, Josy Reiffers, John M. Goldman, Junia V. Melo, Francois Xavier Mahon. (2002) Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. British Journal of Haematology 119:1, 109-111
CrossRef761
J. Topaly, W. J. Zeller, S. Fruehauf. (2002) Combination therapy with imatinib mesylate (sti571): synopsis of in vitro studies. British Journal of Haematology 119:1, 3-14
CrossRef762
Dieter Hoelzer, Nicola Gökbuget, Oliver G Ottmann. (2002) Targeted therapies in the treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia. Seminars in Hematology 39:4, 32-37
CrossRef763
Anne S. Tsao, Hagop Kantarjian, Moshe Talpaz. (2002) Sti-571 in Chronic Myelogenous Leukaemia. British Journal of Haematology 119:1, 15-24
CrossRef764
Mikkael A. Sekeres, Richard Stone. (2002) Older adults with acute myeloid leukemia. Current Oncology Reports 4:5, 403-409
CrossRef765
Louise M. Kelly, D. Gary Gilliland. (2002) G
ENETICS OF MYELOID LEUKEMIAS . Annual Review of Genomics and Human Genetics 3:1, 179-198
CrossRef766
Patricia Ault, Jorge Cortes, Charles Koller, Elizabeth S Kaled, Hagop Kantarjian. (2002) Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leukemia Research 26:9, 881-884
CrossRef767
Lihui Wang, Kevin Pearson, Lynne Pillitteri, Julia E. Ferguson, Richard E. Clark. (2002) Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. British Journal of Haematology 118:3, 771-777
CrossRef768
Daniel J George. (2002) Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology 60:3, 115-121
CrossRef769
Ingo K Mellinghoff, Charles L Sawyers. (2002) The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics 3:5, 603-623
CrossRef770
Ulla Axdorph, Leif Stenke, Gunnar Grimfors, Jan Carneskog, Jan Hansen, Olle Linder, Per Ljungman, Eva Lofvenberg, Claes Malm, Bengt Simonsson, Ingemar Turesson, Lars Vilen, Anne-Marie Uden, Magnus Bjorkholm, . (2002) Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase - a report from the Swedish CML Group. British Journal of Haematology 118:4, 1048-1054
CrossRef771
Marina E Chicurel, Dennise D Dalma-Weiszhausz. (2002) Microarrays in pharmacogenomics – advances and future promise. Pharmacogenomics 3:5, 589-601
CrossRef772
Barbany, Gisela, Höglund, Martin, Simonsson, Bengt, . (2002) Complete Molecular Remission in Chronic Myelogenous Leukemia after Imatinib Therapy. New England Journal of Medicine 347:7, 539-540
Full Text773
Apperley, Jane F., Gardembas, Martine, Melo, Junia V., Russell-Jones, Robin, Bain, Barbara J., Baxter, E. Joanna, Chase, Andrew, Chessells, Judith M., Colombat, Marie, Dearden, Claire E., Dimitrijevic, Sasa, Mahon, François-X., Marin, David, Nikolova, Zariana, Olavarria, Eduardo, Silberman, Sandra, Schultheis, Beate, Cross, Nicholas C.P., Goldman, John M., . (2002) Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta. New England Journal of Medicine 347:7, 481-487
Full Text774
Demetri, George D., von Mehren, Margaret, Blanke, Charles D., Van den Abbeele, Annick D., Eisenberg, Burton, Roberts, Peter J., Heinrich, Michael C., Tuveson, David A., Singer, Samuel, Janicek, Milos, Fletcher, Jonathan A., Silverman, Stuart G., Silberman, Sandra L., Capdeville, Renaud, Kiese, Beate, Peng, Bin, Dimitrijevic, Sasa, Druker, Brian J., Corless, Christopher, Fletcher, Christopher D.M., Joensuu, Heikki, . (2002) Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. New England Journal of Medicine 347:7, 472-480
Full Text775
Lyndon D. Su, Douglas R. Fullen, Lori Lowe, Patricia Uherova, Bertram Schnitzer, Riccardo Valdez. (2002) CD117 (KIT Receptor) Expression in Merkel Cell Carcinoma. The American Journal of Dermatopathology 24:4, 289-293
CrossRef776
Kathryn Senior. (2002) Pharmacogenomics suggests new treatment approach for leukaemia. Drug Discovery Today 7:15, 791-792
CrossRef777
Hooman Ganjavi, David Malkin. (2002) Genetics of Childhood Cancer. Clinical Orthopaedics and Related Research 401, 75-87
CrossRef778
Neil P. Shah, John M. Nicoll, Bhushan Nagar, Mercedes E. Gorre, Ronald L. Paquette, John Kuriyan, Charles L. Sawyers. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:2, 117-125
CrossRef779
Jeannette L. Bennicelli, Frederic G. Barr. (2002) Chromosomal translocations and sarcomas. Current Opinion in Oncology 14:4, 412-419
CrossRef780
Armand Keating. (2002) Chronic myeloid leukemia: Current therapies and the potential role of farnesyltransferase inhibitors. Seminars in Hematology 39:3, 11-17
CrossRef781
Paul La Rosée, Kara Johnson, Michael E O'Dwyer, Brian J Druker. (2002) In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Experimental Hematology 30:7, 729-737
CrossRef782
Philippe Lewalle, Nathalie Meuleman, Alain Verhest, Dominique Bron, Philippe Martiat. (2002) Infusion of peripheral blood stem cells collected at diagnosis, with maintenance of the treatment, resulted in Ph-negative recovery in a chronic myeloid leukaemia patient in persisting aplasia on STI-571 therapy. British Journal of Haematology 118:1, 144-146
CrossRef783
D. Gary Gilliland, James D. Griffin. (2002) Role of FLT3 in leukemia. Current Opinion in Hematology 9:4, 274-281
CrossRef784
Mercedes E. Gorre, Charles L. Sawyers. (2002) Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Current Opinion in Hematology 9:4, 303-307
CrossRef785
Stefan Faderl, Guillermo Garcia-Manero, Deborah A. Thomas, Hagop M. Kantarjian. (2002) Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives. Reviews in Clinical and Experimental Hematology 6:2, 142-160
CrossRef786
Ehab Atallah, Moshe Talpaz, Susan O'brien, Mary Beth Rios, Jie Qiang Guo, Ralph Arlinghaus, Sofia Fernandes-Reese, Hagop Kantarjian. (2002) Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. Cancer 94:11, 2996-2999
CrossRef787
Itaru Kataoka, Katsuji Shinagawa, Yoshihiko Shiro, Shinichiro Okamoto, Reiko Watanabe, Takehiko Mori, Daisuke Ito, Mine Harada. (2002) Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia. American Journal of Hematology 70:2, 149-153
CrossRef788
Robert S. Negm, Mukesh Verma, Sudhir Srivastava. (2002) The promise of biomarkers in cancer screening and detection. Trends in Molecular Medicine 8:6, 288-293
CrossRef789
DANIELA CILLONI, ANGELO GUERRASIO, EMILIA GIUGLIANO, PATRIZIA SCARAVAGLIO, GISELLA VOLPE, GIOVANNA REGE-CAMBRIN, GIUSEPPE SAGLIO. (2002) From Genes to Therapy: The Case of Philadelphia Chromosome-Positive Leukemias. Annals of the New York Academy of Sciences 963:1, 306-312
CrossRef790
R. Bakhtiar, L. Khemani, M. Hayes, T. Bedman, F. Tse. (2002) Quantification of the anti-leukemia drug STI571 (Gleevec™) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 28:6, 1183-1194
CrossRef791
Charles L Sawyers. (2002) Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 1:5, 413-415
CrossRef792
Bob Bennett, Lynn Bennett. (2002) New Wine in Old Bottles. Cancer Biotherapy & Radiopharmaceuticals 17:3, 249-253
CrossRef793
Andreas L. Petzer, Eberhard Gunsilius, Michael Hayes, Guenther Stockhammer, Hans CH. Duba, Folker Schneller, Kurt Grunewald, Werner Poewe, Guenther Gastl. (2002) Low concentrations of STI571 in the cerebrospinal fluid: a case report. British Journal of Haematology 117:3, 623-625
CrossRef794
Rajeev Gupta, Caroline L. Knight, Barbara J. Bain. (2002) Receptor tyrosine kinase mutations in myeloid neoplasms. British Journal of Haematology 117:3, 489-508
CrossRef795
Louise M Kelly, Jin-Chen Yu, Christina L Boulton, Mutiah Apatira, Jason Li, Carol M Sullivan, Ifor Williams, Sonia M Amaral, David P Curley, Nicole Duclos, Donna Neuberg, Robert M Scarborough, Anjali Pandey, Stanley Hollenbach, Keith Abe, Nathalie A Lokker, D.Gary Gilliland, Neill A Giese. (2002) CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 1:5, 421-432
CrossRef796
Andrew G Hall, Julie Irving. (2002) New drugs, new drug resistance mechanisms. Expert Review of Anticancer Therapy 2:3, 239-340
CrossRef797
Manish A. Shah. (2002) Recent developments in the treatment of gastric carcinoma. Current Oncology Reports 4:3, 193-201
CrossRef798
Ching-Hon Pui, Mary V. Relling, Dario Campana, William E. Evans. (2002) Childhood acute lymphoblastic leukemia. Reviews in Clinical and Experimental Hematology 6:2, 161-180
CrossRef799
Liang-Tsai Hsiao, Hung-Ming Chung, Jen-Tsun Lin, Tzeon-Jye Chiou, Jin-Hwang Liu, Frank S. Fan, Wei-Shu Wang, Chueh-Chuan Yen, Po-Min Chen. (2002) Stevens-Johnson syndrome after treatment with STI571: a case report. British Journal of Haematology 117:3, 620-622
CrossRef800
W M Liu, L A Stimson, S P Joel. (2002) The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR–ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. British Journal of Cancer 86:9, 1472-1478
CrossRef801
J Topaly, S Fruehauf, A D Ho, W J Zeller. (2002) Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. British Journal of Cancer 86:9, 1487-1493
CrossRef802
Carlo B. Gambacorti-Passerini, Francesca Rossi, Magda Verga, Holger Ruchatz, Rosalind Gunby, Roberta Frapolli, Massimo Zucchetti, Leonardo Scapozza, Silvia Bungaro, Lucia Tornaghi, Fabio Rossi, Pietro Pioltelli, Enrico Pogliani, Maurizio D'Incalci, Gianmarco Corneo. (2002) Differences between in Vivo and in Vitro Sensitivity to Imatinib of Bcr/Abl+ Cells Obtained from Leukemic Patients. Blood Cells, Molecules, and Diseases 28:3, 361-372
CrossRef803
Robert J. Haas, James M. Malone, Roger A. Warnke, Yasodha Natkunam. (2002) Chronic Myelogenous Leukemia Presenting as Extramedullary Lymphoid Blast Crisis. Pathology Case Reviews 7:3, 117-123
CrossRef804
Keiji Sugimoto, Michiaki Mikoshiba, Kazuteru Ohashi, Hideki Akiyama, Hisashi Sakamaki. (2002) Imatinib Mesylate (Gleevec) in the Treatment of 2 Patients with Philadelphia-Positive ALL Relapsing after Allogeneic Stem Cell Transplantation. International Journal of Hematology 75:4, 440-442
CrossRef805
Athena Countouriotis, Theodore B. Moore, Kathleen M. Sakamoto. (2002) Cell Surface Antigen and Molecular Targeting in the Treatment of Hematologic Malignancies. Stem Cells 20:3, 215-229
CrossRef806
M Ebnöether, J Stentoft, J Ford, L Buhl, A Gratwohl. (2002) Cerebral oedema as a possible complication of treatment with imatinib. The Lancet 359:9319, 1751-1752
CrossRef807
Jennifer T. Loud, June A. Peters, Mary Fraser, Jean Jenkins. (2002) Applications of Advances in Molecular Biology and Genomics to Clinical Cancer Care. Cancer Nursing 25:2, 110-122
CrossRef808
Michael E O'Dwyer, Paul La Rosée, Ramedivi Nimmanapalli, Kapil N Bhalla, Brian J Druker. (2002) Recent advances in Philadelphia chromosome–positive malignancies: The potential role of arsenic trioxide. Seminars in Hematology 39:2, 18-21
CrossRef809
F. Baron, Y. Beguin. (2002) Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 11:2, 243-263
CrossRef810
Helen K Chew. (2002) Medical Management of Breast Cancer: Today and Tomorrow. Cancer Biotherapy & Radiopharmaceuticals 17:2, 137-149
CrossRef811
Andreas Reik, Philip D Gregory, Fyodor D Urnov. (2002) Biotechnologies and therapeutics: chromatin as a target. Current Opinion in Genetics & Development 12:2, 233-242
CrossRef812
Brandon E. Smithey, Alberto S. Pappo, D. Ashley Hill. (2002) c-kit Expression in Pediatric Solid Tumors. The American Journal of Surgical Pathology 26:4, 486-492
CrossRef813
Brian J. Druker. (2002) STI571 (Gleevec™) as a paradigm for cancer therapy. Trends in Molecular Medicine 8:4, S14-S18
CrossRef814
Jerald P. Radich. (2002) Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia. Best Practice & Research Clinical Haematology 15:1, 91-103
CrossRef815
Kristin Henry, Sally Parker, Jane F. Apperley, Robert P. Hasserjian, Federica Boecklin, Eduardo Olavarria, Andy Chase, Andy Chase, Irvin Lampert, Andy Chase, Sunanda Dhar, Andy Chase. (2002) STI571 (Imatinib Mesylate) Reduces Bone Marrow Cellularity and Normalizes Morphologic Features Irrespective of Cytogenetic Response. American Journal of Clinical Pathology 117:3, 360-367
CrossRef816
R Bakhtiar, J Lohne, L Ramos, L Khemani, M Hayes, F Tse. (2002) High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography–tandem mass spectrometry. Journal of Chromatography B 768:2, 325-340
CrossRef817
Monte S. Willis, MD, PhD, Kathleen S. Wilson, MD. (2002) Chronic Myelogenous Leukemia. Laboratory Medicine 33:3, 203-207
CrossRef818
Wood, Alastair J.J., , Savage, David G., Antman, Karen H., . (2002) Imatinib Mesylate — A New Oral Targeted Therapy. New England Journal of Medicine 346:9, 683-693
Full Text819
Kantarjian, Hagop, Sawyers, Charles, Hochhaus, Andreas, Guilhot, Francois, Schiffer, Charles, Gambacorti-Passerini, Carlo, Niederwieser, Dietger, Resta, Debra, Capdeville, Renaud, Zoellner, Ulrike, Talpaz, Moshe, Druker, Brian, . (2002) Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. New England Journal of Medicine 346:9, 645-652
Full Text820
Michael M. Gottesman. (2002) M
ECHANISMS OF CANCER DRUG RESISTANCE . Annual Review of Medicine 53:1, 615-627
CrossRef821
Sanjay Goel, Sridhar Mani, Roman Perez-Soler. (2002) Tyrosine kinase inhibitors: A clinical perspective. Current Oncology Reports 4:1, 9-19
CrossRef822
Doriano Fabbro, Stephan Ruetz, Elisabeth Buchdunger, Sandra W Cowan-Jacob, Gabriele Fendrich, Janis Liebetanz, Jürgen Mestan, Terence O'Reilly, Peter Traxler, Bhabatosh Chaudhuri, Heinz Fretz, Jürg Zimmermann, Thomas Meyer, Giorgio Caravatti, Pascal Furet, Paul W Manley. (2002) Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacology & Therapeutics 93:2-3, 79-98
CrossRef823
Wolf-K Hofmann, Sven de Vos, David Elashoff, Harald Gschaidmeier, Dieter Hoelzer, H Phillip Koeffler, Oliver G Ottmann. (2002) Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. The Lancet 359:9305, 481-486
CrossRef824
Michael E. O'Dwyer, Michael J. Mauro, Brian J. Druker. (2002) R
ECENT ADVANCEMENTS IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA . Annual Review of Medicine 53:1, 369-381
CrossRef825
Brian J Druker. (2002) Perspectives on the development of a molecularly targeted agent. Cancer Cell 1:1, 31-36
CrossRef826
Nikolas von Bubnoff, Folker Schneller, Christian Peschel, Justus Duyster. (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. The Lancet 359:9305, 487-491
CrossRef827
Guy Makin. (2002) Targeting apoptosis in cancer chemotherapy. Expert Opinion on Therapeutic Targets 6:1, 73-84
CrossRef828
James D Griffin. (2002) Resistance to targeted therapy in leukaemia. The Lancet 359:9305, 458-459
CrossRef829
Robert A Wolff. (2002) Exploiting molecular targets in pancreatic cancer. Hematology/Oncology Clinics of North America 16:1, 139-157
CrossRef830
Paul Thambi, Edward A Sausville. (2002) STI571 (imatinib mesylate): the tale of a targeted therapy. Anti-Cancer Drugs 13:2, 111-114
CrossRef831
Charles L Sawyers. (2002) Disabling Abl—Perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell 1:1, 13-15
CrossRef832
F. M. Balis. (2002) Evolution of Anticancer Drug Discovery and the Role of Cell-Based Screening. CancerSpectrum Knowledge Environment 94:2, 78-79
CrossRef833
Louise Kelly, Jennifer Clark, D. Gary Gilliland. (2002) Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications. Current Opinion in Oncology 14:1, 10-18
CrossRef834
Henry T Lynch, Jane F Lynch. (2002) Hereditary cancer: family history, diagnosis, molecular genetics, ecogenetics, and management strategies. Biochimie 84:1, 3-17
CrossRef835
Philipp le Coutre, Karl-Anton Kreuzer, Il-Kang Na, Joachim Lupberger, Matthias Holdhoff, Christine Appelt, Michaela Schwarz, Christian Müller, Carlo Gambacorti-Passerini, Uwe Platzbecker, Ragnhild Bonnet, Gerhard Ehninger, Christian A Schmidt. (2002) Determination of α-1 Acid Glycoprotein in Patients with Ph+ Chronic Myeloid Leukemia during the First 13 Weeks of Therapy with STI571. Blood Cells, Molecules, and Diseases 28:1, 75-85
CrossRef836
Farhad Ravandi, Moshe Talpaz, Hagop Kantarjian, Zeev Estrov. (2002) CELLULAR SIGNALLING PATHWAYS: NEW TARGETS IN LEUKAEMIA THERAPY. British Journal of Haematology 116:1, 57-77
CrossRef837
Amit Verma, Leonidas C. Platanias. (2002) Signaling Via the Interferon-α Receptor in Chronic Myelogenous Leukemia Cells. Leukemia & Lymphoma 43:4, 703-709
CrossRef838
Paul G. Corn, Wafik S. El-Deiry. (2002) Derangement of growth and differentiation control in oncogenesis. BioEssays 24:1, 83-90
CrossRef839
N. C. Gorin. (2002) Autologous Stem Cell Transplantation in Acute Lymphocytic Leukemia. Stem Cells 20:1, 3-10
CrossRef840
Alois Gratwohl. (2002) The role of the EBMT activity survey in the management of hematopoietic stem cell transplantation. International Journal of Hematology 76:S1, 386-392
CrossRef841
Tadeusz Robak, Agata Wrzesień-Kuś. (2002) The Search for Optimal Treatment in Relapsed and Refractory Acute Myeloid Leukemia. Leukemia & Lymphoma 43:2, 281-291
CrossRef842
Francis J. Giles. (2002) Novel agents for the therapy of acute leukemia. Current Opinion in Oncology 14:1, 3-9
CrossRef843
Catherine J. Wu, Donna Neuberg, Antoinette Chillemi, Stephen McLaughlin, Ephraim P. Hochberg, Ilene Galinsky, Daniel DeAngelo, Robert J. Soiffer, Edwin P. Alyea, Renaud Capdeville, Richard M. Stone, Jerome Ritz. (2002) Quantitative Monitoring of BCR / ABL Transcript During STI-571 Therapy. Leukemia & Lymphoma 43:12, 2281-2289
CrossRef844
Martin Begemann, Gregory N. Fuller, Eric C. Holland. (2002) Genetic Modeling of Glioma Formation in Mice. Brain Pathology 12:1, 117-132
CrossRef845
Anna Butturini, Ralph B. Arlinghaus, Robert Peter Gale. 2002. BCR/ABL. , 199-204.
CrossRef846
Nina Shih Liu, Susan O'Brien. (2002) Spontaneous Reversion from Blast to Chronic Phase after Withdrawal of Imatinib Mesylate in a Patient with Chronic Myelogenous Leukemia. Leukemia & Lymphoma 43:12, 2413-2415
CrossRef847
Charles A. Schiffer. 2002. Acute Lymphoblastic Leukemia in Adults. , 1-10.
CrossRef848
Esther Zwick, Johannes Bange, Axel Ullrich. (2002) Receptor tyrosine kinases as targets for anticancer drugs. Trends in Molecular Medicine 8:1, 17-23
CrossRef849
Stefania Mariani, Sabrina Basciani, Mario Arizzi, Giovanni Spera, Lucio Gnessi. (2002) PDGF and the testis. Trends in Endocrinology & Metabolism 13:1, 11-17
CrossRef850
(2001) Current Awareness in Hematological Oncology. Hematological Oncology 19:4, 159-166
CrossRef851
F.A Scappaticci, N Marina. (2001) New molecular targets and biological therapies in sarcomas. Cancer Treatment Reviews 27:6, 317-326
CrossRef852
Giri Rajaratnam, John Edwards. (2001) Imatinib for chronic myeloid leukaemia: a NICE mess. The Lancet 358:9296, 1902
CrossRef853
Roseanne M. Hofmann, Graham J. Cotton, Emmanuel J. Chang, Ephraim Vidal, Darren Veach, William Bornmann, Tom W. Muir. (2001) Fluorescent monitoring of kinase activity in real time: development of a robust fluorescence-based assay for Abl tyrosine kinase activity. Bioorganic & Medicinal Chemistry Letters 11:24, 3091-3094
CrossRef854
Hagop M. Kantarjian, Jianqin Shan, Terry Smith, Moshe Talpaz, Peter Kozuch, Mary Beth Rios, Jorge Cortes, Francis J. Giles, Susan O'Brien. (2001) Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer 92:10, 2501-2507
CrossRef855
Jesper Stentoft, Niels Pallisgaard, Eigil Kjeldsen, Mette Skov Holm, Johan Lanng Nielsen, Peter Hokland. (2001) Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. European Journal of Haematology 67:5-6, 302-308
CrossRef856
Virginia Barbour. (2001) Imatinib for chronic myeloid leukaemia: a NICE mess. The Lancet 358:9292, 1478
CrossRef857
Ching-Hon Pui, Dario Campana, William E Evans. (2001) Childhood acute lymphoblastic leukaemia – current status and future perspectives. The Lancet Oncology 2:10, 597-607
CrossRef858
C. Patrick Reynolds, Richard S. Lemons. (2001) RETINOID THERAPY OF CHILDHOOD CANCER. Hematology/Oncology Clinics of North America 15:5, 867-910
CrossRef859
C Chandra Kumar, Vincent Madison. (2001) Drugs targeted against protein kinases. Expert Opinion on Emerging Drugs 6:2, 303-315
CrossRef860
Fernando Marco, Encarna Bureo, Arancha Bermúdez, Elena Fernández-Fontecha, Alberto Zubizarreta. (2001) Treatment of acute leukemia in children: recent advances and future challenges. Expert Review of Anticancer Therapy 1:3, 479-486
CrossRef861
J. Szer, G. J. Lieschke. (2001) Small molecule: large hopes. Internal Medicine Journal 31:7, 382-383
CrossRef862
F.X Mahon. (2001) Leucémie myéloïde chronique et inhibiteurs de tyrosine kinase. La Revue de Médecine Interne 22:9, 894-899
CrossRef863
Kavita K. Parmar, Reginald S. King. (2001) Imatinib Mesylate: . A New Pill for Chronic Myelogenous Leukemia. Cancer Practice 9:5, 263-265
CrossRef864
Kavita K. Parmar, Reginald S. King. (2001) Imatinib Mesylate: . Cancer Practice 9:5, 263-265
CrossRef865
David Grimwade. (2001) The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Practice & Research Clinical Haematology 14:3, 497-529
CrossRef866
Brouard, Michel, Saurat, Jean-Hilaire, . (2001) Cutaneous Reactions to STI571. New England Journal of Medicine 345:8, 618-619
Full Text867
John P. Perentesis, Eric L. Sievers. (2001) Targeted Therapies for High-Risk Acute Myeloid Leukemia. Hematology/Oncology Clinics of North America 15:4, 677-701
CrossRef868
Brian Druker. (2001) Signal transduction inhibition: Results from phase I clinical trials in chronic myeloid leukemia. Seminars in Hematology 38, 9-14
CrossRef869
Charles L Sawyers. (2001) Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Seminars in Hematology 38, 15-21
CrossRef870
Carolyn Buser, Tohru Takaki, Laura Sepp-Lorenzino. (2001) 92nd Annual Meeting of the American Association for Cancer Research. Expert Opinion on Investigational Drugs 10:6, 1173-1193
CrossRef871
Goldman, John M., Melo, Junia V., . (2001) Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. New England Journal of Medicine 344:14, 1084-1086
Full Text872
Druker, Brian J., Talpaz, Moshe, Resta, Debra J., Peng, Bin, Buchdunger, Elisabeth, Ford, John M., Lydon, Nicholas B., Kantarjian, Hagop, Capdeville, Renaud, Ohno-Jones, Sayuri, Sawyers, Charles L., . (2001) Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. New England Journal of Medicine 344:14, 1031-1037
Full Text873
&NA;. (2001) STI-571 active and well tolerated in CML and ALL. Inpharma Weekly &NA;:1283, 7
CrossRef874
Heikki Joensuu, Sasa Dimitrijevic. (2001) Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumours. Annals of Medicine 33:7, 451-455
CrossRef
